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ABSTRACT
Osteoarthritis (OA) is a common group of disabling joint disorders for 
which there are limited pharmacological therapies to alter disease progression. 
Zoledronate, one of several bisphosphonates found to modulate joint changes 
in animal OA models, may have a disease-modifying role, and potential 
mechanisms of action include effects on cartilage and/or subchondral bone. In 
OA cartilage, loss of aggrecan, the main glycosaminoglycan-bearing 
proteoglycan, and degradation of type II collagen are major biochemical 
changes arising from imbalances in matrix synthesis and degradation. 
Zoledronate, in common with other bisphosphonates, is capable of inhibiting 
matrix metallo-proteinases, enzymes implicated in OA cartilage matrix 
catabolism, providing a biochemical basis for cartilage effects but it is not known 
whether direct effects occur at the cell/tissue level.
Studies described in this thesis have explored the hypothesis that 
zoledronate modifies cartilage metabolism to reduce cartilage 
glycosaminoglycan loss in OA. Short-term treatment effects on proteoglycan 
synthesis and degradation were examined in vitro in models of cartilage and 
chondrocyte metabolism, with IL-1a used to stimulate “OA-like” tissue 
glycosaminoglycan release.
Zoledronate lO^M adversely affected cell viability, proliferation and 
proteoglycan synthesis in bovine articular chondrocytes and, thus, was the 
upper limit of the concentration range investigated. No enhancing effects were 
observed with zoledronate 10'10M to lO^M on proteoglycan synthesis in bovine 
articular chondrocytes. No effects on glycosaminoglycan release were seen 
with zoledronate 10'10M to 10‘5M in bovine articular cartilage or with zoledronate 
10*8M to lO^M in alginate bead constructs containing bovine articular 
chondrocytes and matrix.
Thus, a direct effect on cartilage proteoglycan metabolism following 
short-term treatment does not appear to be a mechanism of action for 
zoledronate as a disease-modifying treatment in OA. However, preventative or 
delayed treatment effects remain unaddressed and other potential targets for
3
zoledronate in the OA joint include cartilage type II collagen metabolism and 
subchondral bone metabolism.
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ABBREVIATIONS AND CONVENTIONS
Conventions: International system (SI) units or units consistent with the 
recommendations of the International Committee for Weights and Measures are 
used throughout except that M is used to represent mol/l for expressing amount 
concentration.
List of abbreviations used in text:
ADAMTS ^  disintegrin and metalloproteinase with thrombospondin
motifs
ACL Anterior cruciate ligament
bFGF Basic fibroblast growth factor
BMD Bone mineral density
CDN Canadian
CILP Cartilage intermediary layer protein
COMP Cartilage oligomeric protein
CV Coefficient of variation
IC50 Concentration producing 50% inhibition
CTX-I C-telopeptide of type I collagen
CTX-II C-telopeptide of type II collagen
ECM Extracellular matrix
Exp Experiment
GAG Glycosaminoglycan
IGF-1 Insulin-like growth factor- 1
IGD Interglobular domain
MMP Matrix metalloproteinase
MT-MMP Membrane-type MMP
OA Osteoarthritis
rOA Radiographic OA
SD Standard deviation
srOA Symptomatic and radiographic OA
SYSADOA Symptomatic slow acting drugs for OA
TIMP Tissue inhibitor of metalloproteinase
TGF-p Transforming growth factor-p
UK United Kingdom
US United States
WOMAC Western Ontario and McMaster Universities
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Chapter 1. Introduction
This chapter is arranged in three parts. The first part focuses on defining 
osteoarthritis and the relevance of the condition. Next, changes to synovial 
joints that are seen during the OA disease process are considered, along with 
underlying pathogenic mechanisms. In particular, alterations to articular 
cartilage and subchondral bone are covered, setting the scene for investigating 
treatments that might modify the course of the condition by targeting the 
metabolic processes in these two tissues. The last part reviews studies relevant 
to the concept of zoledronate as a disease-modifying treatment for osteoarthritis 
and ends with the direction for investigation.
1.1 Osteoarthritis: what is it and how is it relevant?
Osteoarthritis, which is also known as degenerative joint disease and 
osteoarthrosis, is the commonest disorder to affect joints and a major cause for 
locomotor disability. Though a fair amount of attention has been directed 
towards understanding OA, defining OA precisely has been problematic.
1.1.1 Definitions
Several definitions for OA have been put forward. In 1986, the Subcommittee 
on Osteoarthritis of the American College of Rheumatology Diagnostic and 
Therapeutic Criteria Committee proposed the following:
“OA is defined as a heterogeneous group of conditions that lead to joint symptoms and 
signs which are associated with defective integrity of articular cartilage, in addition to 
related changes in the underlying bone and at the joint margins.” (Altman et al. 1986)
In that same year another definition was developed at a conference on the 
“Etiopathogenesis of Osteoarthritis” which summarised OA according to clinical, 
pathological, histological, biomechanical and biochemical characteristics:
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“OA is a degenerative disease of the cartilage of joints. It is of diverse etiology and 
obscure pathogenesis. Clinically, the disease is characterized by joint pain, tenderness, 
limitation of movement, crepitus, occasional effusion, and variable degrees of local 
inflammation, but without systemic effects. Pathologically, the disease is characterized by 
irregularly distributed loss of cartilage more frequently in areas of increased load, 
sclerosis of subchondral bone, subchondral cysts, marginal osteophytes, increased 
metaphyseal blood flow, and variable synovial inflammation. Histologically, the disease is 
characterized early by fragmentation of the cartilage surface, cloning of chondrocytes, 
vertical clefts in the cartilage, variable crystal deposition, remodelling, and eventual 
violation of the tidemark by blood vessels. It is also characterized by evidence of repair, 
particularly in osteophytes, and later by total loss of cartilage, sclerosis, and focal 
osteonecrosis of the subchondral bone. Biomechanically, the disease is characterized by 
alteration of the tensile, compressive, and shear properties and hydraulic permeability of 
the cartilage, increased water, and excessive swelling. These cartilage changes are 
accompanied by increased stiffness of the subchondral bone. Biochemically, the disease 
is characterized by reduction in the proteoglycan concentration, possible alterations in the 
size and aggregation of proteoglycans, alteration in collagen fibril size and weave, and 
increased synthesis and degradation of matrix macromolecules. Therapeutically, the 
disease is characterized by a lack of a specific healing agent” (Mankin et al. 1986).
More recently in 1995 a further definition arose out of a workshop entitled “New 
Horizons in Osteoarthritis”:
“Osteoarthritis is a group of overlapping distinct diseases, which may have different 
etiologies but with similar biologic, morphologic, and clinical outcomes. The disease 
processes not only affect the articular cartilage, but involve the entire joint, including the 
subchondral bone, ligaments, capsule, synovial membrane, and periarticular muscles. 
Ultimately, the articular cartilage degenerates with fibrillation, fissure, ulceration, and full
thickness loss of the joint surface OA diseases are a result of both mechanical and
biologic events that destabilize the normal coupling of degradation and synthesis of 
articular cartilage chondrocytes and extracellular matrix, and subchondral bone. Although 
they may be initiated by multiple factors, including genetic, developmental, metabolic, and 
traumatic, OA diseases involve all of the tissues of the diarthrodial joint. Ultimately, OA 
diseases are manifested by morphologic, biochemical, molecular, and biomechanical 
changes of both cells and matrix which lead to a softening, fibrillation, ulceration, loss of 
articular cartilage, sclerosis and eburnation of subchondral bone, osteophytes, and 
subchondral cysts. When clinically evident, OA diseases are characterized by joint pain,
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tenderness, limitation of movement, crepitus, occasional effusion, and variable degrees of 
inflammation without systemic effects.” (Kuettner and Goldberg 1995)
In terms of understanding OA, the strength of these definitions lies in their 
description of the pathological outcomes of the OA disease process. Clearly OA 
leads to articular cartilage loss, underlying bone changes and alterations to 
other joint tissues. However, it is evident from these definitions that the links 
from aetiology to pathology to clinical outcome remain poorly understood, and it 
is not clear how different joint tissues interact during disease pathogenesis. 
Furthermore, because OA is a heterogeneous group of disorders, it is apparent 
that an all-encompassing definition of OA will either be a non-specific one or a 
lengthy one, more representative of a description.
Several investigators have advocated classifying the condition into subtypes, for 
example according to (i) the localisation of disease (inter- as well as intra- 
articular) and the current balance of degradation and repair in the joint (Dieppe 
1995); or (ii) an initial division into idiopathic and secondary OA, and then sub­
classification of idiopathic OA according to site(s) of involvement and secondary 
OA by cause (Altman et al. 1986; Altman et al. 1990; Altman et al. 1991). The 
use of such classifications in research is likely to be a fruitful way of furthering 
understanding of OA. Investigation of subsets of OA may reveal distinct 
aetiological factors, pathogenic pathways, outcomes and responses to 
treatment (Dieppe 1995). Furthermore, because each subset should 
demonstrate more homogeneity than the collective group of OA conditions, the 
classification approach should allow clearer delineation of the path from 
aetiology to clinical outcome.
As more information becomes available about OA, and along with further 
analyses of the knowledge base, definitions will continue to evolve. Ultimately, 
in order to be clinically useful, a definition of OA should also provide insight into 
prognosis and likelihood of response to intervention.
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1.1.2 Risk factors for OA
OA aetiology is multi-factorial with often complex links to pathological change in 
the tissues of the joint. In a comprehensive review by Felson, OA risk factors 
are grouped into those that are systemic, intrinsic, or extrinsic to the joint 
(Table 1.1) (Felson 2003).
Table 1.1. Risk factors for OA. Adapted from (Felson 2003).
Systemic factors Intrinsic joint factors Extrinsic factors acting on 
joints
Ageing
Female gender 
Oestrogen deficiency in 
women
Genetic susceptibility 
Obesity
Nutritional factors 
Bone mineral density*
Joint site 
Previous damage 
Malalignment/ deformity 
Laxity/ instability 
Muscle weakness 
Proprioceptive deficiency
Obesity
Injurious activity
*The relationship between bone mineral density (BMD) and OA is complex; high BMD is associated with new onset OA 
but low BMD is associated with OA disease progression (Hart et al. 2002; Zhang et al. 2000)
In some cases a single over-riding risk factor can be identified, as in the case of 
anterior cruciate ligament instability and the development of knee OA (Sherman 
et al. 1988). More commonly there is interplay between risk factors such as the 
interaction of age and trauma: older age in subjects who sustain a knee injury 
with meniscal damage is associated with more rapid development of OA 
change (Roos et al. 1995). Complexity is additionally compounded by the fact 
that OA has a gradual onset during which several risk factors may act at 
different time periods. Furthermore the role played by a particular risk factor 
may vary according to the stage of the disease (Doherty 2001; Felson 2003) to 
the extent that, paradoxically, roles can be opposing at different times. In the 
case of bone mineral density (BMD) and OA, high BMD is associated with new 
onset OA whereas low BMD appears to be a risk factor for disease progression 
in patients that already have OA (Hart et al. 2002; Zhang et al. 2000).
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1.1.3 Public health relevance
The importance of OA worldwide is reflected by global burden of disease 
estimates from the World Health Organization which indicate that in 2002 the 
condition was the eighth leading cause of non-fatal disability, with a disease 
burden similar to that for schizophrenia or age-related vision disorders 
(Beaglehole et al. 2004). In the future disease burden is likely to increase for a 
number of reasons. Firstly, the projected increases in the population aged 65 
years and older (to approximately double by 2020 compared to 1990) (Murray 
and Lopez 1997) will lead to more cases of OA because of high disease 
prevalence in the elderly. Secondly, increasing rates of obesity, an important 
risk factor for developing OA, in societies such as the UK will elevate the 
disease burden. Furthermore, socio-economic drives to promote independence 
among older people will mean additional resources are needed in order to 
reduce the disability profile of OA.
1.1.3.1 Prevalence
OA has a predilection to target certain joints whilst sparing others. Commonly 
affected joints are the small joints of the hand (distal interphalangeal, proximal 
interphalangeal and the first carpometacarpal joints), the hip joint, the knee 
joint, the cervical spine and the lumbrosacral spine (Felson 2003). The basis for 
this distribution is not well understood, though it has been suggested that new 
biomechanical demands that have been placed on particular joints as humans 
have evolved are significant (Felson 2003). For example, full weight-bearing on 
the legs will have altered the load distribution through hip and knee joints which 
may predispose these joints to OA.
OA is an extremely common condition and is particularly prevalent for the hand 
and knee (Table 1.2). When interpreting reported OA prevalence rates it is 
important to bear in mind which method was used for case identification. 
Classically OA has been diagnosed by the presence of radiographic change, 
frequently according to the grading system described by Kellgren and Lawrence
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in 1957 which is based on the severity of joint space narrowing (as an indirect 
measure of cartilage loss) and various bony changes (subchondral and 
marginal) (Kellgren and Lawrence 1957). Other classification methods combine 
patient-reported pain and/or other clinical criteria with radiographic features to 
diagnose OA, such as those proposed by the American College of 
Rheumatology Subcommittee on Osteoarthritis for hip OA (Altman et al. 1991) 
and knee OA (Altman et al. 1986). Though radiographic evidence for OA is 
clearly associated with joint pain (Davis et al. 1992; Felson et al. 1997; 
Lethbridge-Cejku et al. 1995; Spector et al. 1993) there is also a lack of overlap 
in many cases (Creamer and Hochberg 1997) and symptoms can be absent in 
about 90% of subjects with radiographic hand OA (Lawrence et al. 1966; 
Lawrence et al. 1998; Zhang et al. 2003) and up to about half of patients with 
radiographic knee OA (Dillon et al. 2006; Du et al. 2005; Felson et al. 1987; 
Jordan et al. 2007; Lawrence et al. 1966). Thus it follows that, for each 
particular joint region, application of combined clinical/radiographic 
classifications to a population will find substantially lower prevalence rates than 
the use of a classification based solely on the radiographic features. 
Furthermore, relying on patient-reported pain within a purely clinical diagnosis 
will miss asymptomatic cases with radiographic OA.
Based on the presence of clinical symptoms and radiographic criteria for OA, 
knee OA affects about 10% of the adult or elderly population (Table 1.2). Hand 
OA is generally less prevalent though reported rates are quite variable, ranging 
from 1.7% for adult men (Lawrence et al. 1998) to 26.2% for elderly women 
(Zhang et al. 2002), and the hip is the least commonly affected joint of the three 
with prevalence rates of less than 1% (Lawrence et al. 1998). Other 
generalisations that are apparent are that OA is more common in the elderly
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Table 1.2. OA prevalence: estimated rates of hand OA, hip OA and knee OA for several countries
Joint
region
Study population
% prevalence
Reference
Radiographic OA with or 
without symptoms
Radiographic OA with 
symptoms
Country Age range 
(years)
Total Female Male Total Female Male
Hand US 25-74 29.5 30.1 28.9 2.4 2.9 1.7 (Lawrence et al. 1998)
US £40 69 31 (Wilder et al. 2006)
us 71-100 26.2 13.4 (Zhang et al. 2002)
UK £15 24.4 18.2 5.9 2 (Lawrence et al. 1966)
China £60 47 44.5 5.8 3 (Zhang et al. 2003)
Finland £30 44.8 (Haara et al. 2003)
Hip US 55-74 3.2 2.8 3.5 0.7 0.7 0.7 (Lawrence et al. 1998)
China 60-89 0.9 1.1 (Nevitt et al. 2002)
Denmark £60 4.4-5.3 (Jacobsen et al. 2004)
Knee US £45 16 8 (Jordan et al. 2007)
US £60 37.4 42.1 31.2 12.1 (Dillon et al. 2006)
US 63-94 33 34.4 30.9 9.5 11.4 6.8 (Felson et al. 1987)
UK £35 18.4 22.6 14.2 9.4 12.4 6.4 (Lawrence et al. 1966)
China £40 37.4 7.2 (Du et al. 2005)
US, United States; UK, Jnited Kingdom
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and, for the hand and knee, the condition more frequently affects women than 
men (Table 1.2).
1.1.3.2 Economic cost
Another way to consider public health relevance is according to the economic 
cost of OA. For individual patients, the direct cost of illness is the expenditure 
for medical care and the indirect cost arises from the impact of the illness on 
function, usually measured by wages lost but also can include implied losses 
from reduced home and leisure activities (Yelin 1998). The monetary cost felt by 
society is the total of these costs per disease case multiplied by the disease 
prevalence.
In a US community-based cohort, average direct costs over a one-year period 
for patients with a diagnosis of OA were found to be US$2 654.51 compared to 
US$1 387.83 in patients without arthritis after adjusting for age and sex (Gabriel 
et al. 1997). Another estimate of annual direct costs due to OA, through 
analysis of insurance claims, gave per patient costs of US$5 294 and US$5 704 
for OA patients aged <65 and > 65 years, respectively, and corresponding 
figures of US$2 467 and US$3 741 for age and sex matched controls (MacLean 
et al. 1998).
The total annual costs among Canadian individuals with disabling hip and knee 
OA were found to be US$9 882 per patient with indirect costs accounting for 
80% of the total (Gupta et al. 2005). For the US, total yearly costs for each case 
of OA have been estimated to range between US$13 000 to US$15 000 (Yelin 
2003). Again indirect costs were more significant, at around US$12 000.
In terms of regional population costs, a French study found evidence for the 
increasing impact of OA in financial terms (Le Pen et al. 2005). Direct medical 
costs attributable to OA in 2002 exceeded 1.6 billion Euros (US$1.4 billion), 
making up 1.7% of the French health insurance system expense, and
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represented a 156% increase compared to costs in 1993 (though adjustments 
for the effects of inflation were not specified in the study methodology). The 
increment was chiefly ascribed to 54% more OA patients with costs per OA 
patient only increasing at 2.5% per year.
An estimate of the total costs of OA for the US population has been derived 
from the analysis of the data from four studies published between 1984 and 
1997 after adjusting amounts to 1999 US dollars (Yelin 2003). Based on the 
assumption that the population prevalence of OA was 4.2% for males and 9% 
for females, total costs for OA were calculated at US$178.9 billion.
Costs bearable by society are also significant in the UK. Data from studies 
commissioned by the Arthritis Research Campaign indicate that in Great Britain 
36 million working days were lost because of OA in 1999-2000 representing 
£3.2 billion (US$2 billion) lost production (Arthritis Research Campaign 2002). 
Further more, OA accounted for 3 million GP consultations in 2000 and 114,628 
hospital admissions in 1999-2000.
Overall the economic impact of OA on society appears to be substantial, 
whether per patient or for whole populations, with indirect costs being more 
significant than direct costs.
1.1.4 Clinical relevance
The primary clinical manifestations of OA are confined to the musculoskeletal 
system and, reflecting the heterogeneity of OA aetiology and pathogenesis, 
these features vary from case to case. Generally the clinical features are slow 
to evolve, lack an inflammatory aspect and usually only involve one or a few 
joints (although polyarticular OA is also common) (O'Reilly and Doherty 2003). 
The patient’s perspective of OA can be considered in terms of problematic 
symptoms and functional disturbance.
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Symptoms
The main symptoms that OA patients experience are pain and stiffness, with 
deformity being another complaint. The pain is usually aching in nature, related 
to joint use and alleviated by rest (O'Reilly and Doherty 2003). With progressive 
disease, the pain may become persistent, occurring at rest and at night. For 
individual patients, the overall perception of pain from OA joints is influenced by 
non-physical factors and studies of patients with knee or hip OA have found 
significant associations between measures of depressive and anxiety states 
and pain (Salaffi et al. 1991; Summers et al. 1988). Additionally, social 
circumstances and coping strategies are considered to be important 
determinants for pain (Creamer 2004; Hadler 2003).
As a symptom, “stiffness” of a joint can vary in meaning between patients, being 
used to describe difficulty or pain with joint movement. Early morning stiffness is 
generally short-lived compared to the prolonged stiffness that characterises 
inflammatory arthritis. Many OA patients complain of stiffness or “gelling” of 
joints after a period of inactivity to describe a transient difficulty in initiating 
movement of their affected joints.
How pathological changes to the joint structure in OA can lead to the pain 
experienced by the patient is not clear. As noted above, joint pain and 
radiographic evidence for OA are often discordant (Table 1.2). However, there 
is clearly an association between OA structural change seen on the X-ray and 
joint pain (Davis et al. 1992; Felson et al. 1997; Lethbridge-Cejku et al. 1995; 
Spector et al. 1993) and this relationship is more commonly observed in 
patients with a longer history and more persistent symptoms (Duncan et al. 
2007).
No single specific articular source for pain in OA has been shown, though joint 
line tenderness elicited on clinical examination suggests a capsular or 
intracapsular origin (O'Reilly and Doherty 2003). Furthermore, transient 
abolishment of pain has been achieved in 60% of patients following an intra-
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articular injection of local anaesthetic into their OA knees (Creamer et al. 1996) 
and clear improvements in pain are seen after replacement of the diseased joint 
for knee or hip OA (Bachmeier et al. 2001; Escobar et al. 2007; Kirwan and 
Silman 1987).
Bone and surrounding periosteum, which are richly innervated with sensory 
nerve fibres (Mach et al. 2002), may be particular sources for pain. A cross- 
sectional observational study of patients with radiographic knee OA found that 
bone marrow lesions, seen on magnetic resonance imaging and thought to 
represent oedema, were more prevalent in subjects with knee pain (77.5%) 
compared to those with no knee pain (30%) (Felson et al. 2001). Because 
cartilage is aneural, it cannot be the originator for nociception, but an indirect 
role is suggested by the finding that chondral defects scored on MRI imaging 
were associated with knee pain in a dose dependent fashion (Zhai et al. 2007). 
Potentially, pain may arise from other joint tissues that are innervated such as 
synovium, capsule or soft tissue. Mechanisms beyond specific joint tissues may 
be also important and it has been proposed that alterations to peripheral and 
central nociceptive pathways in OA subjects increase the sensitivity of the joint 
to usually non-noxious stimuli (e.g. standing and walking), thereby contributing 
to the experience of pain (Kidd 2003).
Other clinical features of OA are more readily explained by structural change. 
Deformity and instability can arise from cartilage loss, bony deformity (through 
subchondral bone remodelling and osteophyte formation), ligament damage or 
laxity and muscle weakness. Reduced range of movement in a joint principally 
results from bone deformity and capsular thickening and is accentuated by 
effusion and soft tissue swelling (O'Reilly and Doherty 2003).
Functional impairment
Disabilities arising from OA include impaired mobility, problems with the 
activities of daily living, other restrictions in usual physical function and social 
difficulties such as lost work opportunities. Restrictions in mobility appear to
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have particularly significant implications for the elderly, as illustrated by the 
finding in a Swedish cohort that walking speed at age 70 years predicted 
independence at age 76 (Sonn 1996). The mechanism for disability in OA is not 
always clear but painful joints, muscle weakness and reduced range of joint 
movement have been considered as contributors (O'Reilly and Doherty 2003). 
Other extra-articular factors also appear important in determining disability 
outcomes. For individuals with knee OA, age and body mass index were the 
non-local factors that were found to increase the risk of a poor functional 
outcome whereas mental health, self-efficacy, social support and aerobic 
exercise protected against disability (Sharma et al. 2003).
1.1.5 Management and disease modification
Because the clinical manifestations of OA have a heterogeneous and 
multifactorial nature, the management of patients with OA requires tailoring for 
the individual according to local joint features and, in addition, psycho-social 
factors. The aims of management are to educate the patient, control pain, 
optimise function, reduce handicap and beneficially modify the OA process 
(Brandt et al. 2003b).
The American College of Rheumatology, the European League Against 
Rheumatism and the National Institute of Clinical Excellence (UK) have 
published guidelines covering the management of hand, hip or knee OA which 
have recommended therapies based on the analyses of published evidence 
combined with expert opinion (2000; Jordan et al. 2003; National Collaborating 
Centre for Chronic Conditions 2008; Pendleton et al. 2000; Zhang et al. 2005; 
Zhang et al. 2007). Interventions that were identified as being beneficial for 
improving symptoms or functional outcome included non-pharmacological 
treatments (e.g. education, exercise, appliances and weight reduction), oral and 
topical analgesics, symptomatic slow acting drugs for OA (SYSADOA; e.g. 
glucosamine sulphate, chondroitin sulphate, diacerhein, avocado soybean
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unsaponifiable and hyaluronic acid), intra-articular steroids and surgery (e.g. 
osteotomy and joint replacement).
Recently, attention has been directed towards the concept of structure- or 
disease-modifying drug treatments that might be able to slow the progression of 
OA and/or promote reparative processes (Abramson et al. 2006; Altman 2005; 
Sun et al. 2007). Findings from clinical trials have suggested disease modifying 
properties for doxycycline (Brandt et al. 2005), diacerhein (Dougados et al.
2001) and glucosamine sulphate (Bruyere et al. 2004; Pavelka et al. 2002; 
Reginster et al. 2001). In addition, there is some evidence for OA disease 
modification with intra-articular hyaluronic acid therapy (Goldberg and 
Buckwalter 2005). Proposed mechanisms of action vary between these agents 
and include effects on cartilage that may reduce matrix degradation or promote 
tissue repair (Table 1.3). However, despite the promising findings for these 
agents, drug treatments with indications for altering the OA disease process 
have yet to become established in clinical management guidelines and, 
currently, this overall approach remains largely conceptual.
Table 1.3. Possible OA disease-modifying agents and their mechanisms of action.
Possible OA disease- 
modifying agent
Possible mechanisms of action References
Doxycycline Inhibition of collagenase-mediated 
degradation of cartilage collagen
(Smith, Jr. et al. 1996; Yu, Jr. 
et al. 1991)
Diacerhein Inhibition of IL-1 or MMP-mediated 
cartilage degradation
(Boittin et al. 1993; Martel- 
Pelletier et al. 1998; Moore et 
al. 1998)
Glucosamine sulphate Stimulation of cartilage proteoglycan 
synthesis or inhibition of 
aggrecanase-mediated degradation 
of cartilage aggrecan
(Bassleer et al. 1998; Sandy 
et al. 1998)
Hyaluronic acid Viscosupplementation of synovial 
fluid, promotion of cartilage repair, or 
inhibition of cartilage degradation
Reviewed in (Goldberg and 
Buckwalter 2005)
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1.2 Osteoarthritis pathogenesis: targets for disease modification
Delineation of OA pathogenic pathways will aid identification of targets for 
disease modification. In the following sections, a conceptual framework for 
considering OA aetio-pathogenesis is described before turning to compositional 
and structural changes that affect articular cartilage and subchondral bone, two 
tissues that undergo characteristic changes in OA. In particular, the 
mechanisms driving these changes are explored, and considered as potential 
targets for modifying the OA disease process. Throughout these sections, a 
recurring theme is the intimate relationship between composition, structure and 
physical function.
1.2.1 The synovial joint: composition and function
The synovial joint is the commonest type of articulation in the human body and, 
like any joint, forms a junction between two or more bones of the skeleton. As 
integral parts of the musculoskeletal system, synovial joints participate in 
providing stable support structures that are able to distribute load and allow 
purposeful movement of different parts of the body relative to each other. Seven 
tissues make up synovial joints: articular cartilage, subchondral bone, 
synovium, synovial fluid, fibrous capsule/ ligament, tendon and muscle (Fig.
1.1). Each tissue has individual properties and together they complement each 
other to fulfil joint function.
1.2.2 OA pathogenesis: a dynamic process involving the whole joint
Views of OA pathogenesis have evolved. Previously OA has been seen as a 
passive degenerative “wear and tear” process leading to articular cartilage loss 
and subchondral bone change. More recent concepts recognise that OA is a 
process involving the entire joint during which important interactions occur 
between the different joint tissues (Brandt et al. 2003a), though there are 
competing theories as to which joint tissue change is of primary importance 
(Brandt et al. 2006).
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Muscle Bursa
Capsule
Synovium
Tendon
Subchondral bone Synovial cavity 
filled with 
synovial fluid
Articular cartilage
Fig. 1.1. Schematic representation of a synovial joint.
Articular cartilage: thin firm visco-elastic layer of connective tissue that 
forms a smooth articulating surface covering the articulating ends of bones. 
Subchondral bone: cortical and cancellous bone layer that physically 
protects and supports the overlying cartilage.
Synovium: thin non-adherent soft connective tissue layer lining the cavity 
not covered by cartilage that secretes hyaluronan, a large molecular weight 
carbohydrate, into the joint cavity.
Synovial fluid: Hyaluronan-rich fluid filling the synovial cavity that acts as 
a lubricant for cartilage surfaces.
Capsule: basket work of strong dense connective tissue (ligament and 
tendon) around a joint that provides stability to the structure. Ligaments 
also hold bones together and restrain movement in particular directions. 
Tendons also connect muscles to bone.
Muscles: force-generating tissue attaching to bone via a tendon that is 
responsible for producing movement of joint structures relative to one 
another. They and also assists in providing stability.
Bursa: structure lined with synovium and filled with synovial fluid that 
facilitates movement between different tissue planes.
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Furthermore, the development of OA is viewed to involve metabolically- 
mediated tissue destruction, repair and remodelling (Brandt et al. 2003a).
A conceptual framework for considering OA aetio-pathogenesis is shown in 
Fig. 1.2. The way that each joint tissue responds to one or more risk factors 
depends on the prevailing joint constitution. This response, called the OA 
process can include acute and destructive structural changes caused by 
physical forces sustained by the joint, such as fibrillation of cartilage (Pritzker
2003) and microcracking or microfracture of subchondral bone (Burr 2003). 
Alternatively, joint tissues can respond with altered metabolism, and in cartilage 
catabolic events at the molecular level appear to be particularly important for 
tissue degradation in the early stages of the OA process (Sandy 2003). On the 
other hand remodelling and attempts at repair are also seen.
Risk factors
act on
V
may
modify*
Synovial joint
OA
process modifies
V
Altered joint 
composition ± 
mechanics
Fig. 1.2. OA aetio-pathogenesis as a dynamic process.
‘ Altered joint mechanics may modify bio-mechanical risk factors
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The cells resident in cartilage proliferate (Mankin et al. 1971; Mankin and 
Lippiello 1970) and increase their synthetic activity (Adams and Brandt 1991; 
Mankin and Lippiello 1970; Nelson et al. 1998). In addition, new cartilage forms 
at joint margins where it ossifies into osteophytes (Brandt et al. 2003a; 
Moskowitz and Goldberg 1987) and subchondral bone undergoes remodelling 
(Burr 2003; Moskowitz 1999).
Changes to other joint tissues include joint effusions (with variable synovitis that 
is usually not intense), capsular thickening, ligament laxity or instability and 
muscle weakness (O'Reilly and Doherty 2003). The sum effect is a joint with 
altered composition, structure and attendant mechanical properties (Fig. 1.2).
As changes develop, the new joint constitution then becomes the substrate for 
the influence of on-going or new risk factors. The effects of the risk factor older 
age illustrate this dynamic and continuous nature to the OA process. Older age 
is associated with a reduction in the tensile properties of human articular 
cartilage from the femoral head (Kempson 1991). This constitutional change 
exposes the aged cartilage to increased susceptibility to damage and, thus, 
trauma to the joint (another risk factor) that might normally have been 
innocuous may perpetuate the OA process. Interestingly, such a process 
provides an explanation for the observation noted above, that the risk factors 
older age and knee injury can interact during the development of knee OA 
(Roos et al. 1995).
Changes that alter joint biomechanics will modify biomechanical risk factors felt 
by the joint, and thus can influence OA pathogenesis. In addition, changes in 
one joint tissue may have direct effects on another tissue. In particular, cartilage 
and subchondral bone may physically or biochemically interact, and this 
concept is discussed further below (section 1.2.4).
At any particular point in time, the structural outcome of the OA process 
depends on the balance between the destructive/ degradative events and the 
effects of the repair response. The process can be slow and, depending on the
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outcome measure, structural changes may take many years before they are 
evident. In patients who sustain anterior cruciate ligament or meniscal damage, 
the first signs of radiographic joint space narrowing appear, on average, ten 
years after injury (Roos et al. 1995).
Changes in articular cartilage and subchondral bone as targets for 
disease modification
Despite the under-explained link between OA structural change and symptoms, 
preventing or reversing structural change presents one approach to disease 
modification. Because OA aetio-pathogenesis is multi-factorial and leads to 
heterogeneous outcomes that can involve all tissues of the joint, the scope for 
selecting targets for disease modification is wide. Broadly, there are two areas 
for investigation: therapies to target risk factors or to modify the pathogenic 
response in joint tissues. It is the latter area that is subsequently further 
considered in relation to cartilage and bone, two tissues of the joint that undergo 
characteristic structural and compositional change during the OA process. The 
following two sections will outline these changes and the underlying metabolic 
mechanisms and it is these mechanisms that are considered to present 
pharmaceutical targets for disease modification.
1.2.3 Articular cartilage changes in OA
1.2.3.1 Articular cartilage composition and function 
Anatomical location and physiological function
Adult articular cartilage is a relatively thin layer of tissue that covers the 
articulating ends of bones in the synovial joint (Fig. 1.1). This layer of cartilage, 
usually of the hyaline type, is a firm but compliant viscoelastic connective tissue. 
The functions of articular cartilage are (i) to provide an interface between 
subchondral bone and the synovial space; (ii) to manage, transmit and 
withstand repetitive physical forces, particularly during joint loading; and (iii) to
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form a smooth articulating surface with the opposite articulating surface, 
assisted by synovial fluid.
Histological architecture
Cartilage is composed of cells embedded in an extracellular matrix (ECM). On 
light microscopy, normal articular cartilage can be distinguished into several 
zones arranged in layers parallel to the joint surface. Differences in cells and 
ECM composition occur between these zones. Moving from the surface 
downwards, these zones are the superficial zone, the middle zone, the deep 
zone then the distinct tide mark that separates the deep zone from the calcified 
zone (Thonar et al. 1999). In addition, domains of ECM are described according 
to their proximity to the cell, namely pericellular, territorial and inter-territorial 
compartments (Kuettner and Thonar 1998).
Chondrocytes
Chondrocytes are the sole cellular elements of cartilage. They are sparsely 
distributed, making up 2-3% of the total tissue volume, and assume flattened 
disc shapes in the superficial zone with their long axes parallel to the articular 
surface, becoming ellipsoid or spherical in shape through middle and deep 
zones (Thonar et al. 1999). Chondrocytes are responsible for synthesising and 
regulating the ECM, processes that are regulated by biochemical and 
mechanical factors (subsequently discussed in section 1.2.3.6). Progenitor-like 
characteristics have been identified in a subpopulation of superficial zone 
chondrocytes (Dowthwaite et al. 2004) suggesting that cells in this zone are 
particularly important for cartilage growth and, possibly, repair.
Matrix composition
The physical properties of cartilage, vital for the management of the physical 
stresses and strains of the tissue, are intimately dependent on the biochemical 
composition and structural integrity of the ECM. Articular cartilage is a highly 
hydrated tissue, with water making up over two-thirds of the tissue weight 
(Bollet and Nance 1966; Venn and Maroudas 1977). The main structural
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component of the matrix is type II collagen which is present as a three- 
dimensional network of fibrils that binds and enmeshes large aggregates of 
negatively charged proteoglycans (Heinegard et al. 2003). Other collagens and 
non-collagenous proteins are found in smaller amounts. The composition of 
normal articular cartilage is not static but undergoes continuous turnover. In 
adult cartilage, the half-lives of collagen and intact aggrecan are estimated to be 
in the order of 100 years and less than 5 years respectively (Maroudas et al. 
1992; Maroudas et al. 1998).
Type II collagen
Ninety percent of collagen in adult cartilage is of the type II variety (Thonar et al.
1999). Type II collagen molecules are fibril forming and have the typical 
collagen structure of a long, stiff, triple stranded helix (Alberts et al. 2002). 
Synthesis occurs in chondrocytes with each collagen molecule being made up 
of three a polypeptide chains tightly wound around one another. The structure is 
stabilised by inter-chain hydrogen bonding between hydroxyproline and 
hydroxylysine and the triple helix is protected from proteolysis by the side chain 
constituents of their amino acid residues. Collagen molecules assemble with 
one another into fibrils where covalent cross-linking between lysine residues of 
the molecules is important for fibril stability and tensile strength. A small amount 
of type XI collagen is present within the fibril which may have a role in 
determining fibril thickness. Another collagen, type IX, is bound on the fibril 
surface and is thought to be involved in regulating fibril assembly (Heineg&rd et 
al. 2003).
Throughout articular cartilage, the collagen fibrils that make up the network vary 
in thickness. The thinnest fibrils occur in the territorial matrix close to 
chondrocytes within the superficial zone and, in general, fibrils become thicker 
with distance from cells and towards the deep zone. In addition, fibril orientation 
demonstrates anisotropy through articular cartilage in which, relative to the 
articular surface, fibrils are mostly parallel in the superficial layer, perpendicular
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in the deep areas and variable in direction in the intermediate parts (Heinegard 
et al. 2003).
Type II collagen imparts tensile properties to cartilage and when tension is 
generated as cartilage is stretched, the strength and stiffness of the tissue is 
dependent on the integrity of the collagen fibrillar network (Mow and Hung
2003). Disruption of the network, such as by breaking down intermolecular 
cross-linking by treating cartilage with elastase, leads to loss of tissue tensile 
strength and stiffness (Bader et al. 1981).
Matrix composition: aggrecan
The second main extracellular macromolecule is aggrecan. This large 
aggregating proteoglycan has important hydrophilic properties and makes up 
approximately 90% of the mass of proteoglycans in articular cartilage (Thonar et 
al. 1999). It has the typical proteoglycan structure of a central core protein with 
multiple glycosaminoglycan side chains which comprise 90% of the 
macromolecular mass (Thonar et al. 1999). Synthesis occurs in chondrocytes 
prior to secretion into the matrix (Hardingham 2004). The core protein of 
aggrecan has several distinct functional domains:
a) CS1 and CS2 domains that are heavily decorated with approximately 
100 glycosaminoglycan chains, each being composed of repeating 
chondroitin sulphate units. Chondroitin sulphate is a disaccharide with 
two negatively charged groups: a sulphate group on the N-acetyl 
galactosamine moiety; and a carboxylate group on the glucuronic acid. 
As each chondroitin sulphate chain is made up of 40 to 50 disaccharide 
units the CS1 and CS2 domains contribute about 8000 to 10000 
negatively charged groups to a single aggrecan molecule (Heinegard et 
al. 2003).
b) N-terminal G1 domain that, with link protein, binds aggrecan to 
hyaluronan (Heinegard et al. 2003). Linkage of a large number of 
aggrecan molecules to hyaluronan, which is a long-chained
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glycosaminoglycan, forms huge polymeric complexes that can be a big 
as a bacterium (Alberts et al. 2002). The large size of such aggregates 
is believed to aid its retention within cartilage,
c) Other domains with less certain functions- a domain containing keratan 
sulphate glycosaminoglycan chains; a G2 domain that has homology 
with the G1 domain; and a C-terminal G3 domain with sequence 
homology to epidermal growth factor, complement regulatory protein 
and lectin (Heinegard et al. 2003). The G3 domain is important for 
secretion of aggrecan from the cell (Zheng et al. 1998).
Aggrecan that is retained within the collagen network contributes to tissue 
viscoelasticity, a behaviour of cartilage that is largely dependent on the ease of 
interstitial fluid flow through the matrix (Mow et al. 1980). Glycosaminoglycan 
chains of aggrecan form porous hydrated gels (Alberts et al. 2002) and fluid 
movement is governed the pore size of these gels (Mow and Hung 2003). A 
further property of aggrecan that influences fluid flow comes from the negatively 
charged groups of the molecule. These impart a high fixed charge density that 
attracts “mobile” osmotically-active counter ions to balance electroneutrality, 
thereby generating an osmotic pressure that causes cartilage to imbibe and 
retain water. The resulting swelling pressure is met and balanced by tension in 
the restraining collagen network, a process that enables cartilage to reversibly 
deform during loading (Mow and Hung 2003).
Factors contributing to a reduced fixed charge density in cartilage, such as 
increased hydration or a lower glycosaminoglycan content, result in a tissue that 
is more compliant in compression (Mow and Hung 2003). For example, in-vitro 
digestion of proteoglycan in human articular cartilage by treatment with 
cathepsin D and cathepsin B has been shown to reduce viscous damping to 
compressive loads (Bader et al. 1992).
36
Matrix composition: other collagens and non-collagenous proteins
Several other types of molecules are found in small amounts in cartilage matrix. 
Type VI collagen may protect the chondrocyte from compression. Numerous 
non-collagenous proteins with less well understood functions have been also 
identified, such as the family of leucine-rich repeat proteins (COMP, cartilage 
oligomeric matrix protein; CILP, cartilage intermediary layer protein; fibronectin; 
perlecan; and matrilins) (Heinegard et al. 2003).
1.2.3.2 Cartilage metabolism during the OA process
A cardinal pathological feature of OA is articular cartilage loss. Tissue 
degradation occurs more frequently in areas of increased load (Mankin et al. 
1986) and, macroscopically, this is first evident as fibrillation of the cartilage 
surface. Later on cartilage becomes eroded and this process can progress to 
full thickness loss of tissue that exposes subchondral bone (Pritzker 2003). In 
advanced OA joints, such as those that are excised at arthroplasty, though the 
cartilage loss is often extensive, some areas of cartilage can appear 
macroscopically normal (Brocklehurst et al. 1984).
At the molecular level, the loss of cartilage matrix during the OA process is 
driven by cell-mediated metabolic events. The principal ECM constituents, 
aggrecan and type II collagen, are altered both quantitatively and qualitatively 
through degradation and synthesis and ultimately it is the balance of catabolism 
and anabolism that is important for determining matrix composition (Nagase 
and Kashiwagi 2003). Thus, in order to alter compositional outcomes, the 
metabolism of aggrecan or type II collagen during the OA process present 
attractive targets for disease modification.
Other alterations that are seen in OA cartilage include chondrocyte hypertrophy, 
elevations in alkaline phosphatase activity and deposition of type X collagen in 
the matrix. In these respects, the tissue composition resembles immature 
cartilage (such as that found in the growth plate) which suggests that OA
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cartilage is resuming its capability to mineralise (Doherty et al. 2004). Variations 
in the levels of matrix non-collagenous proteins (e.g. COMP, CILP and 
fibronectin) are also observed. Because these macromolecules are thought to 
have roles in matrix assembly, cross-linking networks and providing feedback to 
chondrocytes (Heinegard et al. 2003), these changes may be also important for 
the OA process.
1.2.3.3 Aggrecan metabolism in OA
Some of the initial changes in the OA process involve aggrecan molecules. 
Aggrecan is depleted from cartilage matrix thus removing fixed charge groups 
from the tissue with consequent alterations of physio-chemical properties 
(Heinegard et al. 2003). Though the loss of aggrecan from cartilage is 
considered to be reversible (Martel-Pelletier 2004; Mort and Billington 2001), it 
is thought to initiate the cascade of metabolic events leading to irreversible 
tissue disruption (Sandy 2006).
Early OA- cartilage proteoglycan content
Following joint injury and during the development of OA the degradation of 
aggrecan is evidenced by increased levels of fragments of this proteoglycan in 
the synovial fluid of human knee joints (Lohmander et al. 1999). Furthermore, 
with worsening arthroscopic and radiographic severity of OA there is an 
associated rise in the aggrecan fragment concentration of synovial fluid. In the 
cartilage tissue itself, aggrecan loss is reflected in pronounced reductions in 
proteoglycan staining (Heinegard et al. 2003). In addition, in dogs with knee 
joint instability following surgical transection of the cruciate ligament, the extent 
of this proteoglycan depletion increases with the degree of cartilage surface 
disruption (Visco et al. 1993).
Though these observations of reduced staining indicate a lower proteoglycan 
concentration in the tissue, in animal models of early OA the total proteoglycan 
content appears to increase (Adams et al. 1987; McDevitt and Muir 1976).
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Similar findings are seen in human subjects who have sustained anterior 
cruciate ligament rupture; analyses of their femoral condylar cartilage reveals 
reduced histological staining for proteoglycan in some patients and an increase 
in tissue glycosaminoglycan content up to one year post injury (Nelson et al.
2006). These findings may be explained by cartilage swelling, an event that is 
also observed in early OA (Heinegard et al. 2003), whereby though tissue 
proteoglycan concentration may be reduced, the larger cartilage volume results 
in an overall increase in tissue proteoglycan content.
Late OA- cartilage proteoglycan content
Cartilage proteoglycan content is reduced in late-stage OA. By the time patients 
with OA undergo arthroplasty the disease can be considered to be advanced. 
Cartilage samples obtained from the knee or hip joints of such patients shows a 
decreased GAG content (Brocklehurst et al. 1984; Byers et al. 1977; Mankin 
and Lippiello 1970). In addition, the proteoglycan content of late-stage OA 
cartilage has been found to inversely correlate with OA severity at the hip joint 
as assessed histologically (Mankin et al. 1971).
Qualitative changes to aggrecan in OA
Apart from quantitative changes to proteoglycan in OA cartilage, qualitative 
alterations to aggrecan molecules are also seen. In OA cartilage, the 
chondroitin-4 sulphate: chondroitin-6 sulphate and chondroitin sulphate-rich 
proteoglycan: keratan sulphate-rich proteoglycan ratios have been observed to 
be higher than normal, resembling patterns seen in immature cartilage (Adams 
et al. 1987; Doherty et al. 2004). In addition, human OA cartilage from the 
femoral condyle has been found to bear elevated levels of a chondroitin 
sulphate epitope that is usually present in foetal aggrecan (Rizkalla et al. 1992). 
The implications of these biochemical changes are unknown, though some of 
the alterations may modify the binding of growth factors in matrix (Doherty et al.
2004). Another qualitative change is the presence of aggrecan fragments with 
shortened core proteins in OA cartilage (Sandy and Verscharen 2001). This 
finding indicates proteolytic cleavage activity, an important mechanism for the
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release of GAG from the tissue that provides an explanation for the reduced 
GAG content in OA cartilage.
Mechanisms leading to the reduced GAG content in OA cartilage
Overall the findings in synovial fluid and cartilage in early OA indicate an 
increase in proteoglycan turnover, with increases in degradation and release 
from the tissue being accompanied by adequate synthesis to prevent any 
overall reduction in proteoglycan content. However, as the disease becomes 
more advanced the balance shifts and there appears to be a net loss of GAG 
from the tissue.
Mechanisms responsible for GAG release
a) Aggrecan core protein cleavage.
Aggrecan is present in cartilage matrix from normal, acutely injured and 
OA joints in various forms: the full-length species and a series of 
products generated by varying degrees of proteolytic truncation from the 
C-terminal end of the core protein (Sandy and Verscharen 2001). 
Cleavage within the IGD releases the complete GAG-rich region from 
hyaluronan-bound aggrecan molecules leading to loss of GAG from the 
tissue. Thus, the IGD of the aggrecan core protein has been a major 
focus of investigation. Nine different cleavages within the IGD have been 
demonstrated to occur in incubations of aggrecan with purified 
proteinases but only two cleavages of the IGD appear to occur in human 
tissues in vivo: at the matrix metalloproteinase site and aggrecanase site 
(named after the principal enzyme families with activity at those sites) 
(Sandy 2006). Cleavage at these sites generates novel terminals (called 
neoepitopes) with specific N- or C- amino acid sequences that can be 
identified using antibody techniques (Caterson et al. 2000).
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Are matrix metalloproteinases or aggrecanases responsible for 
aggrecanolysis in OA?
Matrix metalloproteinases (MMPs) and aggrecanases are thought to be 
the main proteinases involved in aggrecan degradation though the their 
relative contributions to aggrecanolysis in OA have recently been the 
subject of debate (Sandy 2006; Struglics et al. 2006). Both families of 
enzymes are present OA cartilage (Billinghurst et al. 1997; Curtis et al.
2002). In humans, both MMP and aggrecanase-generated cleavage 
products, identified either as neoepitopes or by protein sequencing, have 
been found in normal cartilage (Flannery et al. 1992; Lark et al. 1997),
OA cartilage (Lark et al. 1997) and synovial fluid from OA joints (Fosang 
et al. 1996; Lohmander et al. 1993b; Sandy et al. 1992). One working 
model, based on analyses of human cartilage and synovial fluid from 
normal, injured and late-stage OA joints (Sandy and Verscharen 2001), 
proposes that aggrecanase activity is responsible for cleaving full length 
aggrecan and the loss of osmotically-active GAG. In this model, 
aggrecanase activity is thus considered “destructive” to the tissue. In 
contrast, MMP activity acts on a separate pool of aggrecan that does not 
bear much GAG and is therefore considered not to be “destructive” 
(Sandy 2006). Others have reported that synovial fluid from OA joints 
contains GAG-bearing aggrecan fragments generated by the activities of 
both MMPs and aggrecanases implicating both families of proteinases in 
aggrecan degradation in human OA (Struglics et al. 2006). In vitro 
studies of cartilage degradation find clear evidence for aggrecanase- 
mediated catabolism of aggrecan (Little et al. 1999) but also demonstrate 
that aggrecan cleavage involves MMP activity (Little et al. 2002).
b) Impaired aggrecan aggregation and altered hyaluronic acid 
metabolism.
Defective aggregation of aggrecan is a further possible mechanism for 
GAG release from cartilage in OA. The capacity of chondrocytes from 
ageing subjects to synthesize link protein and to assemble a
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proteoglycan-rich matrix is impaired (Sandy et al. 1987). These 
impairments could lead to poor stabilisation of hyaluronic acid-aggrecan 
aggregates and loss of aggrecan from the tissue.
In addition, link protein-stabilised aggregates in vitro are less susceptible 
to hyaluronic acid degradation by hyaluronidase or free radicals 
(Rodriguez and Roughley 2006) so decreases in link protein synthesis 
with ageing may expose this vulnerability. Other in vitro studies have 
demonstrated the release of link protein and hyaluronic acid from bovine 
and human cartilage cultured in the presence of catabolic stimuli leading 
to the hypothesis that cleavage of hyaluronic acid and the release of 
small hyaluronic acid-aggrecan complexes is another mechanism for 
proteoglycan loss from the tissue (Sztrolovics et al. 2002).
Reversibility of GAG depletion from cartilage
A reparative ability of chondrocytes to respond to decreases in matrix GAG 
content is suggested by the observation that GAG synthesis inversely correlates 
with GAG content in human femoral head cartilage (Mankin and Lippiello 1970). 
Elevated GAG synthesis rates have been directly demonstrated in a rabbit 
model with instability-induced OA (Ehrlich et al. 1975). However, in the late 
stages of OA the synthetic response appears to reverse. Humans studies have 
shown reduced rates of GAG synthesis in cartilage from OA hip joints (Byers et 
al. 1977) and OA knee joints removed at arthroplasty (Brocklehurst et al. 1984). 
In addition, though GAG synthesis was shown to positively correlate with 
histological severity for cartilage obtained from excised OA hip joints, beyond a 
certain severity grade GAG synthetic rates appeared to decline (Mankin and 
Lippiello 1970).
Recovery from GAG depletion has been demonstrated in bovine articular 
cartilage explants in vitro. Using the catabolic cytokine IL-1 to induce depletion 
of GAG, explants were observed to re-accumulate GAG over a three week 
period if they were allowed to recover in the absence of IL-1 (Williams et al.
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2003). Similarly, in an animal model of OA, the loss of proteoglycans induced by 
an intra-articular injection of IL-1 in rabbits was seen to replace gradually over a 
three to four week period (Page Thomas et al. 1991). Measurements of 
cartilage GAG synthesis showed that after initially depressed rates, there was a 
compensatory increase in GAG synthesis. Interestingly, this restorative 
response was found to be impaired in older animals (Arner 1994), a finding that 
offers some explanation for the association between ageing and OA.
1.2.3.4 Type II collagen metabolism in OA
During the OA process, overt collagen release is thought to follow the onset of 
proteoglycan loss from cartilage matrix (Caterson et al. 2000; Ellis et al. 1994). 
Though collagen is less readily released from matrix, this type of tissue 
disruption is considered to represent the point of irreversible cartilage 
destruction (Cawston et al. 1998; Jubb and Fell 1980). Initial changes to type II 
collagen arising from the OA process are qualitative in nature.
Physical changes to cartilage in OA and their relation to collagen
One early identifiable event in the OA process is oedema and swelling of 
cartilage (Heinegard et al. 2003). These changes are thought to probably reflect 
a loosening of the restraining collagen fibre network resulting in further 
hydration of the enmeshed proteoglycans and consequent swelling of the tissue 
(Venn and Maroudas 1977). In an ovine model of OA, meniscectomy was found 
to lead to areas of thicker more hydrated articular cartilage that demonstrated 
abnormal collagen birefringence intensity suggesting disorganisation of the 
collagen network (Appleyard et al. 2003). Further support for the role of 
collagen disruption in tissue swelling comes from the finding that the swelling of 
OA cartilage from the femoral condyle strongly correlated with the amount of 
damage to collagen molecules (Bank et al. 2000).
Another physical change to OA cartilage is that the superficial tissue layer is 
weaker and less stiff compared to normal cartilage (Kempson et al. 1973). Such
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impaired tensile properties of cartilage have been found to relate to reduced 
tissue collagen content (Kempson et al. 1973) and also to damaged collagen 
fibrils (Bader et al. 1981).
Damage to type II collagen and its loss from cartilage during the OA 
process
Mirroring studies into aggrecan catabolism, many investigators have employed 
antibody techniques to identify neoepitopes revealed on collagen molecules 
when they are degraded. The initial cleavage of type II collagen generates two 
fragments, one approximately one-quarter in length and the other three-quarters 
in length compared to the original molecule (Miller et al. 1976). The resultant 
novel terminals of the molecule can be identified as cleavage neoepitopes 
(Billinghurst et al. 1997). In addition, cleavage of triple helical collagen leads to 
unwinding of the a chains which exposes another identifiable neoepitope, a 
denaturation neoepitope (Dodge and Poole 1989).
Within hours after trauma, higher levels of type II collagen fragments are seen 
in the synovial fluid of acutely-injured knees (Lohmander et al. 2003). In 
addition, the cartilage itself, taken at the time of anterior cruciate ligament (ACL) 
reconstruction surgery from acutely-injured knees, shows increased levels of 
type II collagen denaturation and cleavage though no change to the total 
collagen content (Nelson et al. 2006).
As the OA process progresses, evidence for collagen damage persists. The 
synovial fluid from patients with knee OA demonstrates increased levels of type 
II collagen fragments (Lohmander et al. 2003) and elevated cleavage and 
denaturation neoepitopes have been found in cartilage from OA knee joints 
removed at arthroplasty (Billinghurst et al. 1997; Hollander et al. 1994).
The amounts of cleavage and denaturation of type II collagen correlate with the 
histological severity of OA cartilage (Konttinen et al. 2005) and, within the 
tissue, these neoepitopes are mainly located in the pericellular matrix and in the 
superficial layer of cartilage (Wu et al. 2002).
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In the later stages of the OA process, the collagen content of cartilage tissue is 
reduced (Hollander et al. 1994) and cleavage of collagen molecules appears to 
be an important underlying mechanism. In addition to increased levels of type II 
collagen fragments seen in the synovial fluid of acutely injured and OA knees 
(Lohmander et al. 2003), the amounts of type II collagen cleavage or 
denaturation neoepitopes in cartilage have been found to inversely correlate 
with collagen content (Poole et al. 2003; Squires et al. 2003). Furthermore, OA 
cartilage explants that were cultured in vitro released more type II collagen 
cleavage neoepitopes into culture media than non-arthritic cartilage explants 
(Dahlberg et al. 2000).
Mechanisms of type II collagen cleavage
Proteinases from the MMP family are thought to be responsible for 
collagenolysis in cartilage (Mort and Billington 2001). These degradative 
enzymes are found in the synovial fluid of acutely-injured (Lohmander et al. 
1993a; Walakovits et al. 1992) and OA joints (Clark et al. 1993; Lohmander et 
al. 1993a). They are expressed in OA synovial tissue (Firestein et al. 1991) and 
expressed and secreted by OA chondrocytes at increased levels (Reboul et al. 
1996). Tissue inhibitors of MMPs (TIMPs) are deficient relative to MMPs in OA 
cartilage and this imbalance is also likely to play a role in accelerated matrix 
degradation (Dean et al. 1989). Synthetic inhibitors of MMPs have been found 
to significantly reduce the release of type II collagen cleavage neoepitopes from 
OA cartilage cultured in vitro (Billinghurst et al. 1997; Dahlberg et al. 2000), 
clearly demonstrating the activity of MMPs in OA cartilage.
Synthesis as a repair response
During the OA process, increases in collagen synthesis suggest an attempt at 
repair. Knee joint instability, in a rabbit model of OA, has been found to 
stimulate collagen synthesis (Floman et al. 1980) and surgically-induced ACL 
rupture in canine knee joints increased cartilage type II collagen synthesis as 
measured by incorporation of [3H]proline into new collagen molecules (Eyre et 
al. 1980). Evidence of elevated synthesis of type II collagen is also found in
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human OA cartilage. N- and C-propeptides are removed from type II 
procollagen fibrils as they are synthesised and secreted into ECM (Heinegard et 
al. 2003) and amounts of type II procollagen C-propeptide were found to be 
markedly elevated in human OA femoral condylar cartilage, particularly in the 
mid and deep zones (Nelson et al. 1998). Thus, there may be potential for 
repair of damage to the collagen network, but an effective response in late OA 
when major disruption in the collagen architecture has occurred is thought to be 
less likely (Doherty et al. 2004).
1.2.3.5 Cartilage tissue proteinases
ECM is metabolically degraded by various proteinases. During the OA process 
proteolytic enzymes are produced by chondrocytes and also synovial cells 
(Doherty et al. 2004). Table 1.4 lists proteinases that have been found in 
cartilage (Sandy 2003). Attention has focused on MMPs and aggrecanases as 
the proteinases responsible for the degradation of aggrecan and type II collagen 
in OA cartilage (Poole et al. 2003; Sandy 2006).
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a family of endopeptidases that have 
divalent cations as part of their active structure. They are secreted by cells 
found in joint tissues and are located in the matrix either as soluble proteins or 
bound to the cell membrane. Through their ability to degrade ECM constituents, 
MMPs are considered to play significant roles in normal physiological tissue 
remodelling, turnover and in pathological processes such as OA. In disease 
states, aberrant regulation of MMPs is thought to lead to their hyperactivity with 
consequent ECM degradation (Murphy et al. 2002).
The MMP family includes collagenases, gelatinases, stromelysins, and 
membrane-type MMPs (MT-MMPs). These proteinases have common domains 
in their protein structure with specific functions. The enzymes are secreted in
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Table 1.4. Proteinases present in cartilage. From (Sandy 2003)
Enzyme family Enzyme Other name
MMPs MMP-1 Collagenase 1
MMP-2 Gelatinase A
MMP-3 Stromelysin 1
MMP-8 Collagenase 2
MMP-9 Gelatinase B
MMP-10 Stromelysin 2
MMP-13 Collagenase 3
MMP-14 MT1-MMP
ADAMTSs ADAMTS-1 METH-1
ADAMTS-2 Procollagen-N-proteinase
ADAMTS-3 Procollagen-N-proteinase
ADAMTS-4 Aggrecanase-1
ADAMTS-5 Aggrecanase-2
Others
Metallo-proteinase Procollagen-C-endopeptidase BMP-1
Cysteine proteinases Cathepsin B
Serine proteinases
Calpain
Plasmin
Aspartic proteinases
Plasminogen activator 
Cathepsin D
latent form and are usually activated extracellularly by cleavage of a propeptide 
domain. An N-terminal catalytic domain has a zinc ion bound at the catalytic site 
where hydrolysis is thought to occur by polarisation of a water molecule to act 
as a nucleophile to attack the scissile peptide bond. Further divalent cations, 
zinc and calcium, contained in the catalytic domain also seem significant for 
function. Cleavage of a substrate depends on the depth and structure of the 
catalytic site. Variations in this region between different MMPs are therefore 
important for the substrate specificity. A linker region connects the N-terminal 
catalytic domain to a C-terminal domain that has sequence similarity to the 
serum protein haemopexin. The role of this latter domain seems to vary
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between MMPs but all collagenolytic enzymes appear to require this domain for 
the hydrolysis of triple-helical collagens (Murphy et al. 2002).
MMP-mediated cleavage of triple-helical collagens characteristically and 
specifically occurs at a single locus giving rise to fragments approximately 
three-quarters and one-quarter in length compared to the precursor molecule 
(Miller et al. 1976; Murphy et al. 2002). In articular cartilage, the initial cleavage 
of triple-helical type II collagen is thought to be mediated by MMPs-1, 8, 13 and 
14 (Sandy 2003). The first cleavage then allows further degradation by other 
proteinases (Mort and Billington 2001). Selective inhibition of MMP-13 along 
with MMP-8 blocks the release of collagen from OA cartilage (Dahlberg et al.
2000). In particular, MMP-13 is considered to be important because it 
preferentially cleaves type II collagen (Knauper et al. 1996) and expression of 
human MMP-13 in the joints of transgenic mice was found to lead to OA 
cartilage changes (Neuhold et al. 2001). MMPs are also involved in aggrecan 
degradation as has been outlined above (section 1.2.4.1).
Other roles for MMPs include activation of other MMPs, for example MMP-14 
(MT-1 MMP) is an activator of proMMP-2 on the cell surface (Murphy et al.
2002); release of matrix fragments that have cellular effects, for instance 
fibronectin fragments; release of growth factors or cytokines bound to the matrix 
or cell surface; and proteolytic activation or inactivation of growth factors, 
cytokines and their receptors (Murphy and Lee 2005).
Aggrecanases
The term “aggrecanase” refers to a proteinase that can cleave the aggrecan 
core protein at the glutamyl-X scissile bond which is insensitive to MMP activity 
(Sandy 2003). These glutamyl-X cleavage sites are located in the IGD and CS- 
2 domains of the aggrecan core protein (Caterson et al. 2000). Three members 
of the “A Disintegrin And Metalloproteinase with Thrombospondin motifs” 
(ADAMTS) family of enzymes have been identified as having aggrecanase 
activity: ADAMTS-1, ADAMTS-4 (aggrecanase-1) and ADAMTS-5 
(aggrecanase-2) (Nagase and Kashiwagi 2003). Like MMPs, ADAMTSs also
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have a metallo-proteinase domain that contains a zinc binding motif sequence 
at the catalytic site (Murphy and Lee 2005). Type-1 thrombospondin motifs are 
found in their structure and for aggrecanase-1 this motif is important for binding 
the enzymes to sulphated GAGs in the matrix and, thus, targeting of the 
proteinase to aggrecan molecules (Tortorella et al. 2000).
Other proteinases
Other proteinases implicated cartilage breakdown are the cathepsin lysosomal 
proteinases (Mort and Billington 2001). In an inhibitor study, cathepsin B was 
implicated in IL-1 -stimulated proteoglycan loss from bovine nasal cartilage 
(Buttle et al. 1993). Cathepsins have also been shown to degrade cartilage 
collagens (Maciewicz et al. 1990) and proteoglycans (Roughley 1977). 
However, these enzymes are considered to play a secondary role in cartilage 
degradation with mainly intracellular actions (Mort and Billington 2001). 
Furthermore, because their activity is optimum at acidic pH, it has been 
suggested that cathepsins might only participate in advanced stages of the OA 
process (Nagase and Kashiwagi 2003) when the local pH of cartilage has been 
shown to fall (Konttinen et al. 2002).
Tissue inhibitors metalloproteinases
Four mammalian tissue inhibitors of metalloproteinases (TIMPs) have been 
discovered. TIMP-3 is sequestered in the ECM and the other TIMPs localise to 
the cell surface. TIMPs-1 to 4 all inhibit MMP activity and TIMP-3 inhibits the 
aggrecan-degrading ADAMTSs-1, 4 and 5. Because the TIMPs are thought to 
have significant roles in regulating proteinase activity in ECM (Murphy and Lee
2005), the inhibitors are likely to be important for the maintenance of matrix 
integrity.
The mechanism of MMP inhibition by TIMPs involves the interaction of a 
“wedge-like” part of the TIMP protein and the active site of the MMP. This 
allows the amino and carbonyl groups of Cys1 residue at the N-terminal of the
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TIMP molecule to chelate the catalytic zinc atom of the MMP, and expel the 
zinc-bound water molecule (Nagase et al. 2006).
1.2.3.6 Regulation of aggrecan and type II collagen metabolism
During the OA process, disturbance in the balance of anabolism and catabolism 
results in the net loss of cartilage matrix constituents and, therefore, leads to 
deterioration in the physio-chemical properties of the tissue (Goldring and 
Goldring 2004). Regulation of chondrocyte-mediated synthesis and degradation 
of ECM involves both biochemical and mechanical factors, both of which can 
interact.
Biochemical factors: cytokines
An extensive review on the role of cytokines in regulating cartilage degradation 
in OA has classified cytokines according to their catabolic or anabolic effects on 
chondrocyte-mediated matrix metabolism (Table 1.5) (Goldring and Goldring
2004). In addition, several cytokines have been described as anti-catabolic or 
modulatory based on their ability to inhibit or modulate the activities of other 
cytokines respectively. Within the tissue, cytokines act on cells by paracrine 
(cytokine produced by one cell acts on neighbouring cells) or autocrine 
(cytokine produced by a cell acts on the same cell) mechanisms (Goldring and 
Goldring 2004).
Although synovitis and/or clinical features of inflammation are not prominent in 
OA, proinflammatory cytokines derived from synovial tissues and chondrocytes 
are involved in cartilage destruction (Goldring 2000; Goldring and Goldring
2004). In particular, interleukin-1 (IL-1) and tumour necrosis factor-a (TNF-a) 
are considered to play major roles as catabolic cytokines (Martel-Pelletier et al. 
1999).
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Table 1.5. Classification of chondrocyte-cytokine interactions. From (Goldring and 
Goldring 2004).
Catabolic lnterleukin-1
Tumour necrosis factor-a 
Interleukin-17 
Interleukin-18 
Oncostatin M
Modulatory lnterleukin-6 
lnterleukin-11
Leukaemia inhibitory factor
Anti-catabolic lnterleukin-4
Interleukin-10
Interleukin-13
lnterleukin-1 receptor antagonist 
Interferon-y
Anabolic Insulin-like growth factor-1 
Transforming growth factor-pT.p2.P3 
Fibroblast growth factor (2,4,8)
Bone morphogenetic proteins (2,4,6,7,9,13)
In vitro, IL-1 treatment of articular cartilage or chondrocytes has been shown to 
stimulate aggrecanase activity (Caterson et al. 2000; Little et al. 1999), induce 
matrix degradation (Billinghurst et al. 2000; Caterson et al. 2000; Dodge and 
Poole 1989; Little et al. 1999; Saklatvala et al. 1984; Sandy et al. 1991a; Sandy 
et al. 1991b) and also inhibit proteoglycan synthesis (Chowdhury et al. 2001; 
Hauselmann et al. 1996a; Taskiran et al. 1994). In OA joints this cytokine has 
been found in synovial fluid (Schlaak et al. 1996; Westacott et al. 1990; Wood et 
al. 1983), synovium (Farahat et al. 1993; Pelletier and Martel-Pelletier 1989) 
and cartilage (Pelletier and Martel-Pelletier 1989; Tetlow et al. 2001). Receptors 
for IL-1 have been found on OA chondrocytes at double the normal density in 
association with an increased sensitivity of the cells to the cytokine in terms of 
stimulating metalloproteinase secretion (Martel-Pelletier et al. 1992). Further 
evidence for a role of IL-1 in OA cartilage matrix catabolism comes from studies 
using animal models of OA. Intra-articular injections of IL-1 have been found to 
induce proteoglycan loss (Henderson and Pettipher 1989; O'Byrne et al. 1990; 
Page Thomas et al. 1991) and in two instability models of OA, intra-articular 
administration of IL-1 receptor antagonist therapy (a competitive inhibitor of
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IL-1) has been shown to partially protect against the development of cartilage 
lesions (Caron et al. 1996; Pelletier et al. 1997).
TNF-a has similar in vitro effects to IL-1 on chondrocytes and cartilage, 
including stimulation of proteinase activity (Bunning and Russell 1989), matrix 
degradation (Campbell et al. 1990; Saklatvala 1986) and inhibition of collagen 
and proteoglycan synthesis (Lefebvre et al. 1990) (Saklatvala 1986). In addition, 
TNF-a has been localised in OA joints to the synovial fluid (Schlaak et al. 1996; 
Westacott et al. 1990), synovium (Farahat et al. 1993) and cartilage (Tetlow et 
al. 2001). The potency of TNF-a appears to be 100-fold to 1000-fold less than 
that for IL-1 (Lefebvre et al. 1990; Meyer et al. 1990; Saklatvala 1986) but the 
two cytokines demonstrate synergy to exert cellular effects (Campbell et al. 
1990; Meyer et al. 1990; Saklatvala 1986) and, thus, combinations of IL-1 and 
TNF-a may be important for cartilage destruction (Goldring 2000; Goldring and 
Goldring 2004).
Some cytokines have anabolic effects. Transforming growth factor-p (TGF-P) is 
recognised to stimulate chondrocyte proliferation and proteoglycan synthesis 
(Blumenfeld and Livne 1999; Gueme et al. 1995) and in addition to inhibit IL-1 - 
stimulated proteinase activity (Blumenfeld and Livne 1999), possibly by down- 
regulation of matrix-degrading proteinases and up-regulation of proteinase 
inhibitors such as TIMP-1 (Doherty et al. 2004). Insulin-like growth factor-1 
(IGF-1) is also anabolic for chondrocyte proteoglycan synthesis (van Osch et al. 
1998). It is expressed in fibrillated OA cartilage (Blumenfeld and Livne 1999) 
and so may form part of the repair response.
Cytokines active in cartilage (Table 1.5) are thought to operate within networks 
that also involve other mediators such as nitric oxide and prostaglandin E2 
(Goldring and Goldring 2004) in which the overall balance between the activities 
of catabolic, anti-catabolic, modulatory and anabolic cytokines is important for 
determining the severity of cartilage damage in OA (Goldring 2000).
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Biochemical factors: matrix degradation products
Constituents of matrix that have been degraded also appear to play a part in 
regulating on-going matrix degradation. Fibronectin is a large glycoprotein that 
is involved in organising the matrix and helping cell-matrix attachment (Alberts 
et al. 2002). In vitro, treatment of cartilage explants or chondrocytes with 
fragments of fibronectin has been found to stimulate MMP production, 
proteoglycan degradation (Homandberg and Hui 1996; Stanton et al. 2002) and 
type II collagen degradation (Yasuda and Poole 2002). Depletion of cartilage 
proteoglycan induced by fibronectin fragments was found to be associated with 
enhanced release of IL-1 and TNF-a (Homandberg and Hui 1996), suggesting 
that this catabolic mechanism involves interaction with the cytokine network. 
Moreover, IL-1 was shown to mediate type II collagen cleavage in this pathway 
(Yasuda and Poole 2002).
Type II collagen degradation products may be involved in positive cellular feed­
back mechanisms. Recently, fragments of type II collagen have been found to 
increase mRNA levels of several MMPs in chondrocytes or cartilage explants 
(Fichter et al. 2006) and short synthetic peptides of type II collagen have been 
shown to induce the cleavage of type II collagen and aggrecan in articular 
cartilage (Yasuda et al. 2006).
Mechanical factors
A further regulatory mechanism affecting chondrocyte metabolism involves 
mechanical cues (DiMicco et al. 2003). In vitro, proteoglycan synthesis in 
cartilage explants is inhibited by static compression but stimulated by dynamic 
compression (Sah et al. 1989). This dependence on dynamic stress and strain 
for cartilage health is also demonstrated in vivo. In dogs, immobilisation of their 
joints has been found to cause both reduced synthesis of cartilage proteoglycan 
and its loss from tissue (Behrens et al. 1989).
Mechanical overload can result in direct effects such as collagen network 
disruption and matrix fissuring, but physical stimuli are also be important for
53
modulating cartilage catabolism. Injurious compression of cartilage has been 
shown to cause cell death, increase proteoglycan release (Quinn et al. 1998) 
and up-regulate MMP-3 expression (Patwari et al. 2001) and cutting cartilage 
has been found to induce IL-1 mRNA expression (Gruber et al. 2004). In 
addition, interaction with the cytokine network may be important for cartilage 
loss, as suggested by the finding that mechanical injury and IL-1 or TNF-a can 
act in a synergistic fashion to stimulate proteoglycan degradation (Patwari et al.
2003).
Transduction of mechanical signals to modulate chondrocyte metabolism is 
thought to be highly dependent on the pericellular matrix (Guilak et al. 2006). 
Basic fibroblast growth factor (bFGF) is one proposed mechanotransducer in 
articular cartilage. It has been immuno-localised in the pericellular matrix of 
articular chondrocytes (Vincent and Saklatvala 2006) and cutting to injure 
cartilage has been found to release extracellular stores of bFGF that rapidly 
activated extracellular-signal-regulated kinase (Vincent et al. 2002). Integrins, 
which are transmembrane cell adhesion proteins that tie the matrix to the 
cytoskeleton of the cell (Alberts et al. 2002), have also been found to mediate 
mechanical signals to modify the metabolism of chondrocytes (Chowdhury et al.
2006). Other candidate mechanotransducers include matrilins (Kanbe et al.
2007) and ion channels (Mouw et al. 2007).
1.2.4 Bone changes in OA
Structural and metabolic changes in subchondral bone are clearly evident 
during the OA process (Burr 2003; Westacott 2003) and the BMD status of 
patients is associated with the development or progression of disease (Hart et 
al. 2002; Zhang et al. 2000). Though alterations to subchondral bone often 
relate in a temporal and topographical fashion to articular cartilage loss, there 
has been considerable debate about the exact role of subchondral bone in OA 
pathogenesis (Brandt et al. 2006; Burr 2003). The following sections outline 
subchondral and systemic bone changes seen in OA, as observed by 
radiological, histological and biochemical techniques, and discuss theories on
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mechanical and biochemical mechanisms by which these changes may relate 
to articular cartilage loss and the OA process more generally.
Structure and function of subchondral bone
Subchondral bone refers to the layer of lamellar cortical bone underneath 
articular cartilage and the trabecular cancellous bone buttressing this layer. The 
cortical bone layer and the calcified cartilage above it form the subchondral 
plate that functions (i) to physically protect and support the overlying articular 
cartilage, transmitting forces to the diaphyseal cortex and deforming to increase 
the contact area under load; and (ii) possibly to provide a source of nutrients to 
the deeper layers of hyaline cartilage. Whereas subchondral bone is highly 
vascularised, blood vessels do not normally penetrate through to cartilage (Burr
2003).
Protection of articular cartilage from mechanical damage
Subchondral bone protects the adjacent articular cartilage from damage caused 
by excessive loads in various ways. Together with other periarticular tissues 
(capsule, ligament and muscle), subchondral bone has significant force- 
attenuating properties (Radin and Paul 1970; Radin and Rose 1986). Thus, 
during joint loading these tissues collectively help to manage potentially 
injurious peak forces. Cartilage does have damping properties but its overall 
contribution as a shock absorber is limited by the thinness of the layer (Radin 
and Rose 1986) and synovial fluid plays no significant role (Radin et al. 1970).
Load transfer from the articular surface to the diaphyseal cortex can generate 
damaging shear forces at the bone-cartilage interface. The undulating nature of 
the tide mark at the osteochondral junction transforms these shear forces into 
and tensile compressive stresses that are more easily managed and less 
destructive. Furthermore, the presence of subchondral bone also constrains the 
radial deformation of attached cartilage which imparts some protection against 
load-induced fissuring to cartilage (Burr 2003).
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1.2.4.1 OA subchondral bone: structural changes and possible 
mechanical implications
Subchondral bone sclerosis, thickness and stiffness
Radiographic subchondral bone sclerosis is a characteristic finding in OA. 
Thickening of the subchondral cortical plate and subjacent horizontal trabeculae 
are early changes seen on the radiograph prior to the articular cartilage loss 
that can be detected by joint space narrowing (Buckland-Wright 2004).
Histology also identifies thickened or hypertrophic subchondral bone during the 
OA process in humans and animal models (Dedrick et al. 1993; Grynpas et al. 
1991; Kamibayashi et al. 1995; Li and Aspden 1997; Oettmeier et al. 1992)..
This thickening of subchondral bone is associated with cartilage damage. A 
study of naturally-occurring OA in cynomolgus monkeys found that cartilage 
fibrillation in knee joints was unusual without thickening of the subchondral plate 
and, in addition, the morphological bone changes preceded those found in 
cartilage (Carlson et al. 1994). A subsequent study using the same primate 
model of OA demonstrated further evidence for a relationship between 
subchondral bone and cartilage through the finding that the subchondral plate 
thickness of the medial tibial plateau increased with worsening severity of 
articular cartilage lesions (Carlson et al. 1996).
However, in relation to the temporal association during the OA process, other 
studies have found cartilage changes occurred before bone alterations. Anterior 
cruciate ligament transection of canine knee joints led to increases in 
subchondral plate volume within 18 months but these were preceded by mild 
histological OA changes to articular cartilage that eventually progressed to full 
thickness loss (Burr 2003). In addition, another mechanical model of OA found 
that impacting of the patello-femoral joint through a padded interface induced 
softening of cartilage without underlying subchondral bone thickening (Ewers et 
al. 2000). Overall, these studies indicate that subchondral bone thickening does
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develop during the OA process, but there is conflicting evidence as to whether 
bone or cartilage structural changes come first.
Mechanical mechanisms may be the link between subchondral bone and 
cartilage in OA. Over twenty years ago it was hypothesised that OA 
subchondral bone had areas of increased stiffness that generated destructive 
forces in the attached articular cartilage, thereby initiating and propagating 
cartilage damage (Radin and Rose 1986). A further factor compounding this 
hypothetical destructive process is that load-induced physical forces sustained 
by individual structures of the joint may be elevated in the diseased joint, as 
suggested by the finding that OA knee joints exhibit impaired shock-absorbing 
properties compared to normal knees (Hoshino and Wallace 1987).
Support for the concept of stiffening of subchondral bone in OA has come from 
studies using animal models of OA. These studies involved repeated impulsive 
loading of joints and the bone stiffening was found to occur either before or 
concurrently with cartilage changes (Radin et al. 1978; Simon et al. 1972). On 
the other hand, more recent studies of late-stage OA in humans have found 
evidence against the hypothesis. Instead of increased stiffness, thickened 
subchondral bone from OA femoral heads obtained at arthroplasty has been 
shown to exhibit reduced stiffness (Li and Aspden 1997) along with decreased 
mineralisation and material density (Grynpas et al. 1991). Furthermore, in light 
of the results from an animal study that failed to demonstrate progressive 
cartilage loss secondary to experimental stiffening of the subchondral plate and 
the findings of a finite element model that predicted only moderate increases in 
cartilage stresses secondary to subchondral bone stiffening (Brown et al. 1984), 
the earlier hypothesis has been revised and, though subchondral bone 
stiffening is till considered to occur transiently in some situations, it is not 
thought to be pathophysiologically significant in OA (Burr and Radin 2003).
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Microcracks and subchondral cysts
Structural changes to cartilage and subchondral bone can occur following acute 
trans-articular loading. In vitro structural failure begins with microcracks in the 
zone of calcified cartilage before gross intra-articular fracture of subchondral 
bone and overlying cartilage (Vener et al. 1992). Microcracks are also seen in 
the calcified cartilage of non-diseased human femoral heads (Mori et al. 1993). 
Their physiological significance in OA is unknown but it is thought that 
microcracks may initiate vascular invasion of the calcified cartilage, reactivation 
of the tidemark and enchondral ossification leading to subsequent thinning of 
the overlying articular cartilage (Burr and Radin 2003). In addition microcracks 
involving bone are associated with bone remodelling (Bentolila et al. 1998; Burr 
et al. 1985; Mori and Burr 1993) and may provide physical conduits between 
cartilage and bone (Burr and Radin 2003).
Subarticular cysts are subchondral lesions that are predominantly located 
underneath areas of cartilage thinning or loss. They show features of bone 
necrosis encircled by a rim of reactive new bone and fibrous tissue. These cysts 
are thought to arise secondary to high intra-articular pressure communicated 
through defects of the overlying cortical bone, or from abnormal intra-osseous 
hypertension generated by impaired joint mechanics (Doherty et al. 2004).
Altered joint shape
The bony articular contours can reshape in OA and these alterations are often 
evident radiographically. At the knee, the femoral and tibial articular surfaces 
flatten leading to greater congruity of the articular elements, changes that may 
result from weakened subchondral bone (Buckland-Wright 2004). In advanced 
stages of the OA process, collapse of the subarticular cancellous bone further 
deforms the articular surfaces, altering limb alignment (Buckland-Wright 2004). 
Such changes to the mechanics are likely to lead to the generation of abnormal 
physical forces in the joint.
58
Osteophytes are osseous outgrowths at the margin of the articular surface. 
Though they are considered characteristic manifestations of OA, osteophytes 
are also seen in the absence of cartilage loss (Moskowitz and Goldberg 1987). 
Their formation proceeds through an initial chondrophytic stage followed by 
endochondral calcification and fusion with cortical bone (Hardingham 2004). 
This process can be stimulated by transforming growth factor-p1 (van 
Beuningen et al. 1994) and may also involve basic fibroblast growth factor 
(Uchino et al. 2000).
It is possible that the osteophyte is an adaptive response of the OA process. 
Studies during total knee replacement surgery have found that removal of 
osteophytes increased varus or valgus instability (Pottenger et al. 1990). Thus, 
marginal osteophytes appear to stabilize OA knees, though their presence can 
also cause fixed deformities.
Bone bruises
Structural changes to bone are also seen with magnetic resonance imaging 
(MRI). Early MRI of patients with acute injury and anterior cruciate ligament tear 
has identified an occult osteochondral lesion (also known as a “bone bruise”) in 
over 80% of knees (Rosen et al. 1991; Speer et al. 1992). Though not well 
pathologically characterised, these lesions are thought to represent blood, 
oedema, hyperaemia and, possibly, microfracture of the trabecular subchondral 
bone (Mink and Deutsch 1989). Over time, the bone bruise that follows acute 
anterior cruciate ligament injury can be associated with thinning of adjacent 
cartilage (Faber et al. 1999). Furthermore at arthroscopy the overlying cartilage 
is softened and shows histological evidence of damage including degeneration 
of chondrocytes and loss of proteoglycan (Johnson et al. 1998). Patients with 
established knee OA also have these “bone marrow oedema” lesions which are 
associated with painful symptoms (Felson et al. 2001) and an increased risk of 
progressive disease (Felson et al. 2003).
59
1.2.4.2 OA subchondral bone: changes in metabolism and molecular 
composition
Alterations to subchondral bone metabolism provide explanatory mechanisms 
for some of the observed structural changes described above. In addition, 
abnormal bone metabolism may directly influence cartilage metabolism through 
biochemical mechanisms.
(a) Abnormal bone turnover/ remodelling
Bone scan
Convincing evidence for a role of subchondral bone metabolism in OA 
pathogenesis comes from temporal and topographical associations between 
metabolic changes seen with bone scintigraphy and the OA process. Bone 
scintigraphy is an imaging technique that involves the intra-venous injection 
of a bone-seeking radio-pharmaceutical (usually a technetium-99m-labelled 
bisphosphonate) followed by its localisation with a gamma camera. The 
intensity of isotope uptake seen on the scan reflects the rate of bone 
remodelling (Schauwecker 2003). In patients with generalised nodal OA, 
bone scintigraphy abnormalities predicted the subsequent detection of 
radiographic OA change three to five years later, whereas baseline 
radiographic OA changes on their own had no predictive value (Hutton et al. 
1986). Bone scintigraphy has also been found to identify cases of 
progressive disease in patients with established knee OA. Eighty-eight 
percent of knees that originally demonstrated severe scan abnormalities 
subsequently showed decreasing tibio-femoral joint space after five years. In 
addition, this study found that no knees that scanned normally progressed 
(Dieppe et al. 1993), indicating a high negative predictive value of the test 
for progressive disease.
Overall these findings show that physiological changes to bone that are 
detected by bone scan can precede structural OA changes identified by 
radiograph in specific joints. Later on in the OA process, the bone scan can
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become negative though abnormal structural alterations will persist on the 
radiograph (Schauwecker 2003).
Biomarkers of bone turnover
Markers of total bone turnover that can be measured in serum, urine or 
synovial fluid are being evaluated as indicators of subchondral bone 
formation and resorption (Lohmander and Poole 2003). Several studies 
have demonstrated increased levels of bone turnover markers in patients 
following acute joint injury (Lohmander et al. 1996) or in cases of established 
OA (Astbury et al. 1994; Campion et al. 1989; Seibel et al. 1989; Thompson 
et al. 1992). However, others have found reduced bone turnover markers in 
patients with knee OA (Gamero et al. 2001b) and hand OA (Sowers et al. 
1999). All of these studies were cross-sectional in design and thus the 
differences may have arisen due to variation in the rate of bone turnover at 
different stages of the OA process. A longitudinal study found that bone 
resorption markers were increased in patients with progressive knee OA but 
not elevated in those with non-progressive knee OA (Bettica et al. 2002). 
These findings support the bone scintigraphy data, indicating that bone 
remodelling appears to be a dynamic process in OA.
There is also evidence at the tissue or cell level that subchondral bone 
turnover is elevated in OA. Osteocalcin levels (Hilal et al. 1998) and alkaline 
phosphatase activity (Hilal et al. 1998; Lajeunesse 2004; Mansell et al.
1997; Mansell and Bailey 1998), both markers of bone formation (Westacott 
2003), have been found to be elevated. This increased turnover may relate 
to an altered phenotype of osteoblasts (Hilal et al. 1998) or be driven by 
elevations in osteoblast-stimulating cytokines, such as insulin-like growth 
factor and transforming growth factor-p, which have been observed in OA 
subchondral bone (Hilal et al. 1998; Mansell and Bailey 1998). Transforming 
growth factor-p may be particularly important for osteophyte formation (van 
Beuningen et al. 1994).
H istomorphometry
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Histomorphometric analyses employing tetracycline labelling indicate that 
bone remodelling of subchondral plate is one of the earliest changes seen in 
response to impulsive loading in a rabbit model of OA (Radin et al. 1984). In 
addition, studies of human samples using static histomorphometry indicate 
increased bone turnover in the OA subchondral bone from the femoral 
heads (Grynpas et al. 1991).
Bone remodelling is a well characterised process comprised of coupled 
events (activation, resorption and then formation) that sequentially occur at 
the same location. Activation of osteoclasts leads to their resorption of bone, 
and then during formation, osteoblasts produce an uncalcified matrix, the 
osteoid. Density and stiffness of bone is endowed by mineralisation of 
osteoid, a process that initially occurs rapidly but requires six months to a 
year for full calcification of the matrix (Burr 2004). Thus, during the OA 
process increased remodelling of subchondral plate will replace old matrix 
with a new under-mineralised one. Such a scenario provides an explanatory 
mechanism for the observed decreases in bone density and stiffness in OA 
subchondral bone (Burr 2004).
(b) Abnormal collagen metabolism in OA subchondral bone
Changes in collagen metabolism are a further indication of subchondral bone 
abnormality in OA. In humans, the subchondral bone from OA femoral heads 
shows increases in collagen synthesis and content compared to age-matched 
controls. Furthermore, this collagen was found to be hypomineralised (Mansell 
and Bailey 1998). Subsequent studies, using a similar source of tissue, have 
demonstrated the unusual presence of type I collagen homotrimer (composed 
of three a1 chains) in addition to the normal type I collagen heterotrimer (two a1 
chains and one a2 chain). The significance of this finding is unclear but, drawing 
on the observations relating to abnormal collagen in osteogenesis imperfecta (a 
condition characterised by poorly mineralised and highly brittle bone), it has 
been hypothesised that the presence of type I collagen homotrimer may explain
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the hypomineralisation and reduced strength of OA subchondral bone (Bailey et 
al. 2002).
(c) OA bone cells altering cartilage metabolism
In vitro, bone cells from OA subchondral bone can produce effects on cartilage 
metabolism. One study isolated cells from the subchondral bone of human OA 
knee joints that demonstrated medial joint surface cartilage damage and 
cultured these cells with non-arthritic cartilage (Westacott et al. 1997). Of the 
bone cell cultures derived from the medial, damaged side of the joint, over a 
third increased GAG release from cartilage. Over three quarters of the cell 
cultures established from the lateral side of the same joints altered cartilage 
metabolism, half of them increasing and half decreasing GAG release. Control 
bone cell cultures from non-arthritic joints had no effect on GAG release. All cell 
cultures secreted osteocalcin, indicating osteoblast-like activity and a bone 
origin. Further work using this co-culture system indicates that aggrecanase 
activity may be the mechanism for increased GAG release from cartilage 
caused by the OA bone cells (Diffin et al. 2001).
Recently another in vitro co-culture study found that osteoblasts isolated from 
sclerotic zones of human OA subchondral bone inhibited aggrecan production 
and increased MMP-3 and MMP-13 expression from co-cultured human OA 
chondrocytes (Sanchez et al. 2005). Because osteoblasts from non-sclerotic 
bone of the same joints did not have these effects on chondrocyte metabolism, 
the authors concluded that sclerotic OA subchondral osteoblasts could 
contribute to cartilage degradation by stimulating MMP production and inhibiting 
aggrecan synthesis.
A biochemical interaction between subchondral bone and cartilage will require a 
communication between compartments. In normal adult joints this does not 
appear to exist since vessels do not penetrate the osteochondral junction (Burr
2003) and diffusion through the subchondral plate does not appear to play a 
role in cartilage nutrition (Ogata et al. 1978). However, during the OA process, a
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route for biochemical interaction may be opened up by microcracks in calcified 
cartilage that have been found in ageing and OA joints (Sokoloff 1993). 
Additional support for the existence of a biochemical communication between 
subchondral bone and cartilage in OA comes from the finding that osteocalcin is 
present in synovial fluid of diseased knee joints (Sharif et al. 1995).
1.2.4.3 Bone mineral density alterations in OA
Measurements of bone mineral density (BMD) that reflect bone mass are used 
in the diagnosis osteoporosis (Kanis 1994). This is a skeletal disorder 
characterised by low bone mass and architectural deterioration of bone tissue 
with a consequent decrease in bone strength and increase in fracture risk (NIH 
Consensus Development Panel on Osteoporosis Prevention 2001). The 
possibility of a relationship between OA and osteoporosis has been widely 
studied. A review of the literature between 1972 and 1996 found that 28 out of 
36 publications reported significant increases in bone mass or bone density in 
OA patients compared to age- and sex-matched controls. Furthermore, 
correction for body weight, a possible confounding factor, did not change the 
results in most studies (Dequeker et al. 1996).
More recent longitudinal studies that have further investigated the association 
between OA and BMD indicate a more complex relationship. Consistent with 
previous findings, a study of a population-based female cohort found that 
patients with high BMD or BMD gain at the femoral neck had an increased risk 
of incident (new onset) knee OA. On the other hand, in patients with established 
knee OA, low BMD or BMD loss was associated with an increased the risk of 
radiographic progression (Zhang et al. 2000). Another study confirmed higher 
BMD measurements (at the hip and spine) in women who went on to develop 
incident knee OA and also found that low BMD at the hip was weakly related to 
knee OA progression (Hart et al. 2002).
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Further evidence for the role of bone loss in the OA process comes from studies 
of BMD in the periarticular bone of affected joints (Kannus et al. 1992; Karvonen 
et al. 1998; Leppala et al. 1999). Ten to eleven years following surgical 
treatment for anterior cruciate ligament rupture secondary to acute knee injury, 
BMD measurements have been found to be lower around the injured knee 
(distal femur, patella and proximal tibia) compared to the uninjured knee 
(Kannus et al. 1992). BMD was not different between left and right when 
measured further away from the knee at the femoral neck or calcaneus. This 
type of bone loss is seen as early as 12 months following knee injury (Leppala 
et al. 1999) and appears to occur irrespective of whether subjects have 
osteoporosis based on spine BMD (Karvonen et al. 1998). The findings from 
these three studies are consistent with the reported lower mineralization and 
material density of OA subchondral bone that is seen histologically (Grynpas et 
al. 1991; Li and Aspden 1997).
Overall the findings indicate that high BMD is associated with OA, in particular 
the risk of developing OA. However, once the OA process is established, 
localised bone loss occurs around affected joints and reductions in BMD are 
associated with disease progression.
1.2.5 Limitations to interpreting studies of cartilage and bone change in 
OA
As detailed in sections 1.2.3 and 1.2.4, a great deal of insight has been 
provided into the underlying mechanisms behind the changes to cartilage and 
bone in OA. However, many findings have arisen from in vitro or in vivo studies 
performed under specific circumstances. Collective interpretation of the 
evidence base to draw conclusions about common events or pathways of the 
OA disease process is limited by differences between studies that could have 
led to different active metabolic processes. Those that are likely to be important 
include between-study differences in:
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(a) Dominant aetiological factors. Differences in these factors may be 
difficult to identify, particularly in human studies in which multiple risk 
factors may be involved.
(b) Duration of disease activity prior to assessment of outcome measures. 
OA pathogenesis proceeds slowly and most studies have investigated 
only a small part of the process. Dominant mechanisms that occur in 
early OA may be different to those seen in advanced disease.
(c) Species investigated. Variation in cartilage metabolism is seen between 
species (Cawston et al. 1998; Hughes et al. 1998).
(d) Joint sites investigated. Cartilage metabolism varies not only between 
joints (Eger et al. 2002) but also at different topographical locations 
within a joint (Barakat et al. 2002; Bayliss et al. 1999).
(e) Setting for investigation in terms of in vitro vs. in vivo. During in vitro 
investigation, much of the usual physiological, biochemical and 
biomechanical environment of the joint tissue of interest is often absent. 
These environmental factors are important for regulating tissue 
metabolism in cartilage and the osteochondral unit (discussed in sections 
1.2.3.6 and 1.2.4).
Thus, caution should be exercised when extrapolating findings between studies.
1.3 Is there a role for zoledronate as a disease-modifying treatment in 
osteoarthritis?
Zoledronate and other bisphosphonates are best known clinically as efficacious 
treatments for various metabolic bone conditions. Interestingly, findings from in 
vivo and in vitro studies suggest that certain bisphosphonates may be useful as 
disease-modifying therapies in OA with possible mechanisms of action on 
cartilage or bone or their interactions in the osteochondral unit.
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1.3.1 Zoledronate and other bisphosphonates as therapies for metabolic 
bone diseases
Over the last four decades, bisphosphonates have become established as 
effective inhibitors of bone resorption with therapeutic efficacy in the treatment 
of various metabolic bone disorders such as osteoporosis, Paget’s disease, 
myeloma and bone metastases (Russell 2006).
Chemically, bisphosphonates are stable analogues of inorganic pyrophosphate, 
a naturally occurring inhibitor of hydroxyapatite crystal formation and dissolution 
which is thought to be important for regulation of tissue mineralisation (Francis 
et al. 1969). The phosphonate-carbon-phosphonate structure of 
bisphosphonates (Fig. 1.3) is important for binding to hydroxyapatite of bone 
mineral, enabling these compounds to localise to the skeleton. From there they 
are well placed to exert effects on bone-resorbing osteoclasts (Russell 2006).
The anti-resorptive potency of bisphosphonates has been found to relate to the 
composition of the R2 side chain on the bridging carbon atom (Fig. 1.3). 
Etidronate and clodronate are early generation bisphosphonates that 
respectively have a methyl group or chlorine atom at the R2 position (Fig. 1.4) 
and were the first to enter clinical use. Newer compounds with side chains 
containing nitrogen, such as pamidronate and alendronate (Fig. 1.4) were 
subsequently developed which demonstrated increased anti-resorptive potency. 
The most potent bisphosphonates were found to be those in which the nitrogen 
was contained within a heterocyclic ring, for example risedronate and 
zoledronate (Fig. 1.4) (Russell 2006).
Zoledronate has a R2 side chain with two nitrogen atoms contained within a 
heterocyclic ring and in one in vivo model of bone resorption, its potency was 
observed to be 850 times more than pamidronate and >10000 times more than 
etidronate (Green et al. 1994). Currently in the UK, zoledronate is licensed for 
the treatment of Paget’s disease of bone, the prevention of skeletal-related
67
OH OH
1 I
0 = P - 0 - P s s O  
I I
OH OH
OH m  OH
I I I
0 =  P — C — P = 0
j I I
OH R2 OH
Fig. 1.3. Chemical structures of inorganic pyrophosphate (left) and a 
generic bisphosphonate (right). From (Russell and Rogers 1999).
Both are shown in their acid forms. The R2 side chain composition of bisphosphonates is 
important for determining anti-resorptive potency.
o
II
HO-P-OH
H ^ f o H
MU" P -O H
\lo
Etidronate
HO 
\  OH
Pamidronate
OH 
) P-OHc , w n OH
o "  \
OH
Clodronate
H\ OHp v
 _____ V f/ = \ °  > P X
V   Q OH
Tiludronate
H?  OH
H j N ' ^ V ^ N V  v Ol
hc% A oh
h o  y °
X H
o ^ r
ch- n- s> .
V
0/y X OH
0^P> H  
p-O H
O OH
Alendronate
S / oh
"P,VvOH /N
, ^OHp
IIN oh
'3
Ibandronate
HO
O
I U 0H
’' 'P'"'OH 
\  OH
K h
o
Risedronate Zoledronic acid
Fig. 1.4. The chemical structures of selected bisphosphonates (shown as 
acids). From (Green and Rogers 2002).
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events in advanced bone malignancies and the treatment of tumour-induced 
hypercalcaemia (2007a; 2007b). In addition, the results of a recent clinical trial 
indicate efficacy for zoledronate in the treatment of osteoporosis in post­
menopausal women (Black et al. 2007).
Bisphosphonates: mechanisms of bone anti-resorptive activity
Considerable attention has been directed towards elucidating the mechanisms 
by which bisphosphonates inhibit bone resorption. The principal mechanism is 
thought to be a direct effect on osteoclasts following cellular uptake by 
endocytosis (Russell 2006). Cellular effects that have been seen include 
diminished osteoclast formation, resorptive activity and survival (Benford et al. 
2001; Flanagan and Chambers 1991; Hughes et al. 1989; Hughes et al. 1995; 
Selander et al. 1994; Selander et al. 1996). Results of work to unravel these 
cellular mechanisms at a biochemical level has led to the proposal that 
bisphosphonates can be classified into at least two major groups based on 
modes of intracellular action (Table 1.6) (Russell 2006).
Table 1.6. Classification of bisphosphonates according to mechanism of action. Adapted 
from (Russell 2006).
Non-nitrogen bisphosphonates Nitrogen-containing bisphosphonates
Bisphosphonate Molecular 
mechanism of 
action
Bisphosphonate Molecular 
mechanism of 
action
Etidronate
Clodronate
Tiludronate
Incorporated into 
intracellular 
analogues of ATP
Pamidronate
Alendronate
Risedronate
Ibandronate
Zoledronate
Inhibit the prenylation 
and function of GTP- 
binding proteins 
required for 
osteoclast formation 
and survival
The first group is comprised of non-nitrogen bisphosphonates such as 
etidronate and clodronate which have been shown to be metabolised to
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analogues of adenosine triphosphate (ATP) (Auriola et al. 1997; Frith et al.
1997; Pelorgeas et al. 1992). These metabolites are non-hydrolysable and 
accumulate in the cell cytoplasm, a process that is thought to lead to adverse 
effects on cell metabolism, function and survival (Russell 2006). For example 
clodronate has been shown to increase osteoclast apoptosis via the intracellular 
accumulation of a clodronate metabolite (AppCCI2p) (Frith et al. 2001).
The more potent anti-resorptive bisphosphonates that contain nitrogen form the 
second group (Table 1.6). These compounds do not appear to be metabolised 
to analogues of ATP (Frith et al. 1997; Rogers et al. 1994) and act in a different 
fashion. All nitrogen-containing bisphosphonates have been shown to inhibit the 
mevalonate pathway (Russell 2006). This pathway is responsible for the 
biosynthesis of cholesterol and other sterols, and also isoprenoid lipids (such as 
famesyldiphosphate and geranylgeranyldiphosphate) that are needed for the 
post-translational prenylation of small guanine triphosphate (GTP) binding 
proteins (e.g. Ras, Rab, Rho and Rac). These GTP proteins regulate a variety 
of cellular functions including membrane ruffling, trafficking of vesicles and 
apoptosis (Fukuda et al. 2005; Ridley et al. 1992; Zerial and Stenmark 1993). In 
osteoclasts, Rac1 and Rho have been found to play significant roles in 
facilitating bone resorptive activity (Fukuda et al. 2005; Zhang et al. 1995).
Thus, the mechanism of anti-resorptive activity seen with the nitrogen- 
containing bisphosphonates appears to be through interference of protein 
prenylation and the downstream function of several GTP binding proteins that 
are important for osteoclast function (Russell 2006). Farnesyl diphosphate 
synthase, an enzyme within the mevalonate pathway that catalyses the 
synthesis of isoprenoid lipids, has been identified as the specific target of 
action. Consistent with this mechanism of action, the abilities of different 
nitrogen-containing bisphosphonates to inhibit farnesyl diphosphate synthase 
have been shown to closely correlate to their abilities to inhibit bone resorption 
in vivo (Dunford et al. 2001).
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1.3.2 In vivo evidence for zoledronate and other bisphosphonates as 
disease-modifying treatments in OA
In addition to clinical efficacy in metabolic bone disorders, zoledronate may also 
have a role in OA. Substantial, though not universal, support for this concept 
comes from several studies that report on the effects of zoledronate and other 
bisphosphonates in animal models of OA. Results from clinical trials on the 
effects of risedronate in knee OA patients have also recently become available 
(Bingham, III et al. 2006; Spectoret al. 2005).
1.3.2.1 Effects of zoledronate on chymopapain-induced cartilage damage 
in an animal model of OA
Injections of chymopapain into the knee joints of rabbits have been found to 
cause persistent cartilage and bone changes similar to those seen in OA 
(Muehleman et al. 2002; Uebelhart et al. 1993; Williams et al. 1993). 
Chymopapain is a cysteine endopeptidase of the papain family that has 
aggrecanolytic activity (Dekeyser et al. 1995) but does not cause direct damage 
to collagen fibres (Postacchini et al. 1982).
Cartilage and bone changes have been characterised for the OA model. Two 
days after intra-articular chymopapain injections, pronounced loss of cartilage 
proteoglycan occurs followed by fibrillation of the articular surface and 
chondrocyte loss at three weeks (Uebelhart et al. 1993; Williams et al. 1988). 
Subsequently, at six months, the cartilage becomes eroded in loaded regions 
and marginal osteophytes develop. Associated with these changes there are 
increases in urinary levels of lysyl pyridinoline (LP) and hydroxylysyl pyridinoline 
(HP) crosslinks of collagen (Muehleman et al. 2002; Uebelhart et al. 1993). LP 
cross-links appear to be fairly specific for collagen in bone whereas HP collagen 
cross-links are found in bone and cartilage (Eyre et al. 1988). Thus, the 
elevated urinary levels of LP and HP cross-links are considered to reflect 
increased collagen catabolism in bone and bone or cartilage respectively 
(Uebelhart et al. 1993).
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In a controlled-study that used this model of cartilage damage, zoledronate 
treatment has been found to partially reduce levels of grossly- and 
histologically-detectable cartilage degeneration (Muehleman et al. 2002). 
Commencing 24 hours before intra-articular chymopapain, zoledronate 10 pg/kg 
was administered to rabbits by subcutaneous injection three times a week, 
dosing that approximates to the monthly intravenous zoledronate 4 mg regimen 
that is used clinically in humans (personal communication from Dr. J.R. Green, 
Novartis Pharma AG). Animals were sacrificed for histological and biochemical 
analyses 28 days and 56 days post chymopapain and the results for these two 
time points were reported together. Though all chymopapain-injected knees, 
whether the animals were zoledronate-treated or not, demonstrated cartilage 
damage compared to uninjected control knees, partial reductions for some 
outcome measures were observed with zoledronate treatment.
A gross visual grade was used to measure cartilage fibrillation, fissuring and 
erosion, and also osteophytes in the knee joints (Muehleman et al. 2002). 
Chymopapain injections led to significant increases in joint damage assessed 
by the visual grade and this effect was partly attenuated by zoledronate 
treatment. Articular cartilage was also scored for microscopic histological 
change. On a 15-point scale that assessed surface integrity, cell clone 
formation and cellularity (15 points representing the highest level of 
degenerative change), the mean score for tibial cartilage was lower for 
chymopapain-injected/ zoledronate treated rabbits than chymopapain-injected 
rabbits (mean scores 5.8 and 8.6 respectively; P=0.001 for the difference). In 
addition, for patella cartilage there was a trend for a lower score in the 
chymopapain-injected/ zoledronate treated group compared to the 
chymopapain-injected group (mean scores 6.5 and 7.3 respectively; P=0.07 for 
the difference).
Biochemical analyses revealed a trend for improved cartilage proteoglycan 
retention with zoledronate treatment (Muehleman et al. 2002). Chymopapain-
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injected/ zoledronate-treated animals demonstrated a 21% reduction in cartilage 
proteoglycan content of injected knees compared to 28% for chymopapain- 
injected animals (P=0.12 for difference between groups). However, rises in 
serum levels of keratan sulphate (a proposed measure of cartilage proteoglycan 
degradation (Williams et al. 1988)) with chymopapain injections were not altered 
by zoledronate treatment.
In association with these histological and biochemical findings, the study also 
found indirect evidence for inhibition of bone remodelling with zoledronate 
treatment (Muehleman et al. 2002). Urinary levels of LP cross-links rose with 
chymopapain injections but not with concomitant zoledronate treatment.
Based on the study findings, the authors hypothesised that inhibition of bone 
remodelling by zoledronate in the model might be the mechanism for the 
observed protective effects on cartilage damage (Muehleman et al. 2002). 
However, the pathophysiological relationship between subchondral bone 
remodelling and cartilage degradation in the model is not clear (discussed in 
section 1.2.4). Clearly another possibility is inhibition of chymopapain proteolytic 
activity, though such an ability has not been reported in the MEROPS peptidase 
database (Rawlings et al. 2006). Alternatively, the mechanism could be a direct 
effect by zoledronate on cartilage metabolism (further discussed below).
1.3.2.2 Effects of zoledronate in a cruciate-deficient animal model of OA
Surgical transection of the anterior cruciate ligament of the stifle joint in dogs 
causes joint instability and provides an animal model in which persistent OA-like 
lesions develop (Brandt et al. 1991). A few weeks after ligament transection, the 
articular cartilage begins to swell. Cartilage degeneration subsequently 
develops with fibrillation, loss of surface tissue and chondrocyte cloning.
Marked osteophyte formation is apparent at about three months (Griffiths and 
Schrier 2003) and eventually cartilage ulceration progresses to full thickness 
loss (Brandt et al. 1991). Other changes that have been observed in unstable
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knees in the model include increases in bone turnover (Brandt et al. 1997), 
decreases in periarticular BMD indicative of bone loss (Agnello et al. 2005; 
Behets et al. 2004; Boyd et al. 2000) and mechanical weakening of periarticular 
cancellous bone (Wohl et al. 2001).
The effects of zoledronate treatment have been evaluated in this model of OA 
(Agnello et al. 2005). Though articular cartilage changes were not assessed, 
subcutaneous zoledronate treatment was found to inhibit elevations in serum 
osteocalcin and bone-specific alkaline phosphatase (markers of systemic bone 
remodelling) and to prevent decreases in periarticular BMD that occurred 
following anterior cruciate transection.
1.3.2.3 Other bisphosphonates and in vivo models of OA
Substantial attention has focused on risedronate as a possible disease- 
modifying treatment in OA. The bisphosphonate was initially evaluated in an 
animal OA model (Meyer et al. 2001a; Meyer et al. 2001b). The Duncan-Hartley 
strain guinea pigs that were used in the studies are known to develop 
spontaneous cartilage degeneration (Bendele and Hulman 1988) preceded by 
subchondral bone remodelling (Griffiths and Schrier 2003; Quasnichka et al.
2006). Treatment with risedronate or with bisphosphonates structurally similar 
to risedronate was found to slow progression of macroscopically-evident 
cartilage degeneration and osteophyte formation in Duncan-Hartley guinea pigs 
(Meyer et al. 2001a; Meyer et al. 2001b). Interestingly, alendronate and other 
bisphosphonates structurally dissimilar to risedronate did not demonstrate 
treatment effects in this model. Risedronate has also been found to protect 
against periarticular BMD loss and to partly attenuate the deterioration in some 
of the mechanical properties of bone and ligament in the knee joints of rabbits 
with instability induced by ACL transection (Doschak et al. 2004). These 
favourable results for risedronate have been followed by studies in human OA.
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A British one-year prospective randomised placebo-controlled trial investigated 
the effects of risedronate in 284 patients with OA of the medial compartment of 
the knee (Spector et al. 2005). Patients taking the higher dose of risedronate 
tested (15 mg daily) showed improvement in symptoms and function as 
assessed by the Western Ontario and McMaster Universities (WOMAC) OA 
index, the patient global assessment and the use of walking aids. In addition a 
trend towards attenuation of joint-space narrowing was observed. Though 
numbers were small, 8% of patients receiving placebo (n=7) and 4% of those 
receiving 5 mg risedronate daily (n=4) demonstrated radiographic disease 
progression compared with 1% (n=1) of patients receiving 15 mg risedronate 
(P=0.067). Radiographic disease progression was defined as joint-space 
narrowing of £0.75 mm or loss of joint space of £25%. Associated with these 
observations, risedronate treatment reduced urinary levels of N-terminal cross- 
linking telopeptide of type I collagen (NTX-I) and urinary levels of C-terminal 
cross-linking telopeptide of type II collagen (CTX-II). NTX-I and CTX-II are 
proposed markers of bone resorption (Pagani et al. 2005) and cartilage 
degradation respectively (Christgau et al. 2001; Lohmander and Poole 2003).
However, these encouraging results were not reproduced in a large 2-year trial 
that used a similar protocol involving nearly 2500 patients with medial 
compartment knee OA from North America and the European Union (KOSTAR 
study)(Bingham, III et al. 2006). Risedronate treatment did cause a dose- 
dependent reduction in urinary CTX-II levels but, for the primary outcomes 
investigated, risedronate (5 mg daily, 15 mg daily, 35 mg weekly or 50 mg 
weekly) compared to placebo did not improve symptoms and signs of OA or 
reduce radiographic progression of knee OA.
A more detailed analysis of the patients from the North American arm of the 
KOSTAR study on the effects of risedronate on subchondral bone has been 
reported in a separate study (Buckland-Wright et al. 2007). In patients with 
progressive disease (defined in the study as joint-space narrowing £0.6 mm 
over 2 years in the OA knee), higher doses of risedronate treatment were found
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to inhibit radiographically-measured trabecular bone loss in the subchondral 
region of the diseased medial compartment of the tibia.
Other bisphosphonates have been evaluated using animal models of OA with 
conflicting findings for effects on cartilage degradation. Etidronate given to 
SRT/ORT mice, an inbred strain which commonly develops a severe form of OA 
(Griffiths and Schrier 2003), did not influence the incidence or severity of 
histologically-assessed cartilage degeneration (Walton 1981). The 
bisphosphonate NE-10035 (2-[acetylthio]ethylidene-1, 1-bisphosphonate) has 
been tested in the canine cruciate deficient model of OA (Myers et al. 1999). 
Though NE-10035 effectively reduced subchondral bone turnover, it had no 
effect on osteophyte formation or the severity of OA cartilage changes.
However the authors did note that the cartilage degeneration observed in the 
study was mild and the possibility of an inhibitory effect on cartilage damage in 
a model displaying more severe cartilage degradation remained.
Disease-modifying effects have been demonstrated with alendronate treatment 
in the rat ACL transection model of OA (Hayami et al. 2004). This 
bisphosphonate was found to prevent osteophyte formation, inhibit bone 
turnover (assessed by bone histomorphometry) and partially protect against the 
development of histologically-observed cartilage degeneration. Consistent with 
these structure-modifying effects, alendronate also reduced urinary levels of 
CTX-II and C-terminal telopeptide of type I collagen (CTX-I; a marker of bone 
resorption (Pagani et al. 2005)).
1.3.2.4 Zoledronate and other bisphosphonates in inflammatory arthritis
Following encouraging findings from animal models of inflammatory arthritis, 
there has been recent interest in the use of bisphosphonates to reduce the 
development of bone erosions in inflammatory arthritic conditions such as 
rheumatoid arthritis (Breuil and Euller-Ziegler 2006; Goldring and Gravallese
2004). In addition, zoledronate has been found to partly inhibit cartilage
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degradation along with decreasing focal bone damage in transgenic mice with 
tumour necrosis factor-mediated arthritis (Herrak et al. 2004) and in rabbits with 
carrageenan-induced inflammatory arthritis (Podworny et al. 1999).
However, several clinical trials with bisphosphonates in patients with 
rheumatoid arthritis have found more equivocal results. No evidence for efficacy 
with respect to preventing the progression of focal bone destruction was 
observed for pamidronate in two studies (Lodder et al. 2003; Ralston et al.
1989) and etidronate in one study (Valleala et al. 2003) though another trial 
demonstrated a beneficial effect for pamidronate (Maccagno et al. 1994). In 
addition, a small study of 39 rheumatoid arthritis patients has found that 
zoledronate treatment can prevent the development of new bone erosions 
(Jarrett et al. 2006).
Extrapolation of the findings arising from studies of inflammatory arthritis to OA 
is questionable because the underlying pathogenic mechanisms are different.
By definition there is often intense synovial inflammation driving the pathology in 
inflammatory arthritis. This is not usually present in OA. However, the beneficial 
effect of zoledronate on cartilage damage in the animal models of inflammatory 
arthritis was unlikely to have been due to an anti-inflammatory action since no 
accompanying reductions in synovitis were observed (Herrak et al. 2004; 
Podworny et al. 1999), suggesting an alternative mechanism such as a direct 
effect on cartilage metabolism. In both inflammatory arthritis and OA, MMPs 
and aggrecanases are key mediators of cartilage matrix destruction (Clark and 
Parker 2003; Elliott and Cawston 2001). Thus, the findings from these studies of 
zoledronate in models of inflammatory arthritis (Herrak et al. 2004; Podworny et 
al. 1999) may be relevant for considering a role for the bisphosphonate in OA.
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1.3.3 Exploring potential mechanisms of action of zoledronate as a 
disease-modifying treatment in OA
Understanding the mechanisms by which zoledronate might be able to modify 
the OA disease process will support a role for the bisphosphonate as a 
treatment for OA. In the subsequent discussion the following possible targets for 
zoledronate in the OA joint will be considered:
(a) Inhibition of bone remodelling
(b) A direct effect on cartilage metabolism
Although findings with respect to bisphosphonates other than zoledronate will 
continue to be discussed, it is useful to bear in mind that disease-modifying 
effects seen with bisphosphonate treatment in one animal OA model did not 
relate to bisphosphonate anti-resorptive potency (Meyer et al. 2001a; Meyer et 
al. 2001b). The absence of such an association indicates that a bone effect is a 
less likely mechanism, making an effect on cartilage the more attractive 
underlying mechanism of action.
1.3.3.1 Inhibition of bone turnover by zoledronate: a possible mechanism 
for disease-modification in OA?
Structural and metabolic changes to subchondral bone are clearly evident in the 
OA joint though their pathophysiological relationship to cartilage loss and the 
OA process are not well understood (discussed in section 1.2.4). Furthermore 
BMD appears to relate to OA incidence and progression. Zoledronate and other 
bisphosphonates have well-known effects on bone, and these may beneficially 
modify the OA process. In this section, the effects of bisphosphonate on bone 
and their possible implications for the OA joint are discussed.
Is inhibiting bone remodelling in OA a useful effect?
OA joints that demonstrate increased bone turnover on bone scintigraphy have 
a higher risk of disease progression (Dieppe et al. 1993; Hutton et al. 1986).
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Thus, using a bisphosphonate such as zoledronate to inhibit bone remodelling 
and modify this risk factor may retard OA disease progression.
Support for this concept comes from the numerous in vivo studies that 
evaluated zoledronate and other bisphosphonates in models of OA which found 
favourable treatment effects on OA cartilage and subchondral bone (Agnello et 
al. 2005; Buckland-Wright et al. 2007; Doschak et al. 2004; Hayami et al. 2004; 
Meyer et al. 2001a; Meyer et al. 2001b; Muehleman et al. 2002; Spector et al.
2005). In addition, calcitonin, another bone anti-resorptive agent, has been 
found to reduce the severity of OA cartilage lesions in the canine ACL 
transection OA model (Manicourt et al. 1999) and to attenuate cartilage and 
subchondral bone changes in the rabbit ACL transection OA model 
(Papaioannou et al. 2007)
Ultimately, whether inhibition of bone remodelling is beneficial in OA will depend 
on the role of bone remodelling during OA pathogenesis. This remains an area 
that is not well understood. However, it is interesting to consider how modifying 
bone metabolism might affect the OA process.
Implications of effects on BMD and subchondral bone structure
Zoledronate treatment leads to sustained increases in BMD in post-menopausal 
women with osteoporosis, along with reducing the risk of fracture (Black et al.
2007). It is likely that the bisphosphonate would also increase BMD in OA 
patients. If the BMD status of patients that has been found to be associated with 
OA according to epidemiological data (discussed in section 1.2.4.3) turns out to 
be a causal risk factor for OA, then zoledronate treatment to increase BMD 
could increase the risk of incident OA but, on the other hand, reduce the risk of 
disease progression in established OA.
With regard to local bone loss, subcutaneously-administered zoledronate was 
found to prevent significant BMD decreases in periarticular bone in the canine 
ACL transection model of OA, (Agnello et al. 2005). Additionally, zoledronate
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has been observed to increase the mechanical strength of long bones of 
ovariectomised rats (Hornby et al. 2003) and if such effects also occurred in 
periarticular bone, the subchondral plate might be protected from acute 
structural failure and the development of microcracks. However, the 
pathophysiological significance of such structural changes in OA is not clear. 
Strengthening OA subchondral bone may also prevent articular surface 
deformity and limb malalignment, changes that are thought to arise from 
collapse of weakened subarticular cancellous bone (Buckland-Wright 2004).
Bisphosphonates may also reduce osteophyte formation. In the rat ACL 
transection model of OA, alendronate was found to dose-dependently decrease 
the incidence and area of osteophytes (Hayami et al. 2004). In addition, 
risedronate reduced the size of osteophytes that developed in the Duncan- 
Hartley guinea pig OA model (Meyer et al. 2001b). However, treatment with the 
bisphosphonate NE-10035 in the canine ACL transection OA model (Myers et 
al. 1999) or risedronate in patients with knee OA (Bingham, III et al. 2006) did 
not produce effects on osteophyte formation. Inhibition of osteophyte formation 
will clearly modify one of the characteristic features of OA, but because the 
osteophyte might actually improve joint instability (Pottenger et al. 1990), this 
disease-modifying effect may not be beneficial for the OA process.
Potential effects of zoledronate on a possible biochemical interaction 
between OA subchondral bone and articular cartilage
Osteoblasts from OA subchondral bone can biochemically stimulate GAG 
release or inhibit aggrecan synthesis in cartilage, and so may be important for 
cartilage degradation (Sanchez et al. 2005; Westacott et al. 1997). If this 
abnormal osteoblastic activity occurs as part of bone remodelling, then a potent 
anti-resorptive therapy such as zoledronate could have beneficial effects. 
Another possibility is a direct effect on the OA osteoblasts since zoledronate 
has been found to directly act on osteoblasts to inhibit their proliferation 
(Fromigue and Body 2002; Reinholz et al. 2000).
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1.3.3.2 Does zoledronate have effects on cartilage metabolism?
Can zoledronate localise to cartilage?
Localisation of zoledronate to cartilage has not been reported, but one 
theoretical route for systemically-administered zoledronate to reach cartilage is 
via bone. The bisphosphonate has a high adsorption affinity for hydroxyapatite 
(Nancollas et al. 2006) and is avidly taken up by bone following intravenous 
administration (Green and Rogers 2002). Because bisphosphonates in general 
bind preferentially to areas of bone which have high turnover rates (Lin 1996), 
such as OA subchondral bone (section 1.2.4.2), it is likely that zoledronate can 
localise to the bone underlying articular cartilage in the OA joint. Possible routes 
from subchondral bone to cartilage include the synovial fluid and microcracks in 
OA calcified cartilage (section 1.2.4.2).
Alternatively, the blood circulation could deliver the bisphosphonate directly to 
cartilage in diseased joints. Though blood vessels do not penetrate from 
subchondral bone through to cartilage in normal synovial joints, capillary 
invasion of the tidemark is seen in OA (Sokoloff 1993). Overall, the existence of 
these possible access routes is consistent with the concept that the protective 
effects on cartilage damage with zoledronate treatment observed in an animal 
OA model (Muehleman et al. 2002) could have occurred through a direct action 
on cartilage.
Effects of bisphosphonates on chondrocyte synthetic function and 
survival
In vitro work has demonstrated direct effects of bisphosphonates on cartilage or 
chondrocyte matrix synthesis, though there is some discordance between 
studies. Etidronate and clodronate (at concentrations ranging from 10'6 M to 
5x10*4 M) were shown to produce reversible inhibition of GAG synthesis in 
canine articular cartilage explants (Palmoski and Brandt 1978). However, for 
rabbit articular chondrocytes, clodronate (2.5x1 O'5 M and 2.5x1 O'4 M), but not
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etidronate (2.5x1 O'4 M), was found to increase GAG and collagen synthesis 
(Guenther et al. 1979; Guenther et al. 1981). In addition, mild inhibition of cell 
proliferation was observed for 2.5x1 O'4 M clodronate and 2.5x10‘4 M etidronate 
(Guenther et al. 1979).
Chondrocyte survival appears to be promoted by some bisphosphonates under 
certain conditions. In an in vitro study of bovine articular chondrocytes, 
incubation with glucocorticoid dexamethasone was used to reduce cell viability, 
to increase cell apoptosis and to inhibit cell proliferation in the cultures (Van 
Offel et al. 2002). Each of these detrimental effects on chondrocytes was 
partially prevented by co-treatment with pamidronate (10"6 M) or risedronate 
(1CT8 M or 10'6 M) but not with clodronate (Van Offel et al. 2002). Higher 
concentrations of the bisphosphonates were not protective and, moreover, at 
10 4 M and above, the bisphosphonates were found to reduce cell viability or 
proliferation.
Effects of zoledronate and other bisphosphonates on chondrocyte- 
mediated degradation of cartilage matrix
Evidence from several studies points towards cartilage matrix catabolism as a 
potential target for zoledronate. Reductions in urinary CTX-II levels have been 
observed in patients with Paget’s disease of bone following intravenous 
zoledronate (Garnero et al. 2001a). Though the OA status of the subjects was 
unknown, and so it is not clear whether the effects might relate to normal or OA 
cartilage, the findings do suggest that the bisphosphonate has an ability to 
inhibit type II collagen degradation. Furthermore, the observed reduction in 
urinary CTX-II was rapid (within five days) and transient which points towards a 
direct effect of zoledronate on cartilage rather than on subchondral bone with 
consequent changes to cartilage metabolism. This is because (i) five days is too 
early to see structural alterations to subchondral bone that could have had 
secondary effects on cartilage; and (ii) an effect that arose from inhibition of 
bone remodelling should have been persistent.
82
In agreement with a possible effect of bisphosphonates in general on collagen II 
metabolism, decreases urinary CTX-II have also been observed following 
risedronate treatment in knee OA patients (Bingham, III et al. 2006; Spector et 
al. 2005). One caveat about these studies involving urinary CTX-II assays is 
that there may be unknown factors affecting systemic metabolism of the marker 
prior to its measurement in urine which could complicate interpretation 
(Lohmander and Poole 2003).
Direct evidence for an effect on cartilage matrix catabolism comes from in vitro 
work. Three reported studies employed a similar culture model in which an IL-1- 
like factor (either derived from mononuclear cells, macrophages, or synovial 
tissue) was used to stimulate proteinase production by articular chondrocytes 
(Emonds-Alt et al. 1985; Evequoz et al. 1985; McGuire et al. 1982). Cultures 
were also treated with the bisphosphonates of interest and at the end of the 
culture period proteinase activity was assayed in the chondrocyte-conditioned 
culture medium. Findings indicate that chondrocyte-derived proteinase activity 
can be influenced by bisphosphonates, though the reports are somewhat 
conflicting as to the direction of effect.
Addition of etidronate 2.5x10‘5 M or pamidronate 2.5x1 O'6 M was found to 
enhance the collagenase activity produced by stimulated rabbit chondrocytes, 
though treatment effects were not seen with clodronate (2.5x1 O'5 M or 
2.5x10‘4 M) or etidronate at a higher concentration (2.5x10‘4 M)(Evequoz et al. 
1985). Another study also evaluated etidronate and clodronate but used human 
chondrocytes (McGuire et al. 1982). However, in these experiments, 2.5x10'4 M 
etidronate or 2.5x1 O'4 M clodronate were both found to inhibit stimulated 
collagenase activity. A limitation of both studies is that specific data on possible 
cytotoxic effects of the bisphosphonates were not shown and, thus, cell death 
can not be excluded as the mechanism for any observed inhibitory effects.
From a third study with similar methodology, tiludronate (10'5 M to 5x1 O'4 M) 
was seen to dose-dependently inhibit proteinase activity (against collagen,
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proteoglycan and casein) produced by stimulated rabbit chondrocytes (Emonds- 
Alt et al. 1985). Etidronate (1 O'4 M to 10'3 M) also inhibited these enzyme 
activities but was much less potent. In this study, the bisphosphonates at the 
concentrations tested did not induce chondrocyte toxicity.
In addition, the effects of etidronate and pamidronate on proteoglycan 
degradation in bovine nasal septum cartilage have been examined (Couchman 
and Sheppeard 1986). Following culture of the bisphosphonates with cartilage, 
the amount of GAG released from cartilage into the medium was measured. In 
this culture model, 10'5 M pamidronate increased GAG release, though no 
effect was observed with 10'5 M etidronate.
It is not clear why the results are discrepant between in vitro studies. Factors 
that may have been significant include (i) inter-species differences in 
chondrocyte metabolism (Hughes et al. 1998), (ii) differences in metabolism 
between nasal and articular cartilage (Caterson et al. 2000), (iii) differential 
effects between bisphosphonates and (iv) differing bisphosphonate treatment 
concentrations between studies in conjunction with possible cytotoxic effects at 
high bisphosphonate concentrations (Van Offel et al. 2002). Nonetheless, there 
are findings to suggest that certain bisphosphonates (etidronate, clodronate and 
tiludronate) can favourably inhibit chondrocyte-mediated catabolism of matrix 
(Emonds-Alt et al. 1985; McGuire et al. 1982).
Effects of zoledronate and other bisphosphonates on MMP activity
At the biochemical level, inhibition of the matrix-degrading enzymes, the MMPs 
and the aggrecanases, is an attractive therapeutic strategy to prevent cartilage 
loss in arthritic conditions including OA (Clark and Parker 2003). Several reports 
by a Finnish research group indicate that zoledronate and other 
bisphosphonates can directly reduce MMP activity in vitro (Heikkila et al. 2002; 
Konttinen et al. 1999; Teronen et al. 1997a; Teronen et al. 1997b; Teronen et 
al. 1999). These studies employed cell-free enzyme activity assays using
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various substrates such as casein, pro-urokinase, gelatine and type I collagen, 
though not aggrecan or type II collagen.
Zoledronate (concentration range 2x1 O'5 M to 10‘3 M) was found to inhibit 
human MMPs-3, 8, 13 and 20 in a concentration-dependent fashion with fifty 
percent inhibition (IC50) of MMP-20 activity occurring at zoledronate 
concentrations between 5x1 O'5 M to 10‘4 M (Heikkila et al. 2002). In the same 
study, similar inhibitory effects were seen for clodronate and alendronate 
(against MMPs-1, 2, 3, 8, 9 and 13), and pamidronate (against MMPs-3, 8, 13 
and 20). In addition, increasing the calcium ion concentration in the assay buffer 
attenuated some of the inhibitory abilities of clodronate and alendronate 
suggesting that the mechanism of MMP inhibition involved interaction between 
the bisphosphonate and divalent cations, such as the zinc ion bound at the 
MMP catalytic site.
Separate studies reported by the same group also found inhibitory effects of 
several bisphosphonates on MMP activity. Alendronate reduced MMP-13 
activity (IC50 between 5x1 O'4 M and 7.5x1 O'4 M) (Konttinen et al. 1999), and 
clodronate inhibited the activities of MMP-1 (IC50 1.5x1 O'4 M) (Teronen et al. 
1997b) and MMP-8 (IC50 1.5x10‘4 M) (Teronen et al. 1997a). In addition, 
zoledronate reduced the activities of MMPs-3, 12, 13 and 20 in a concentration- 
dependent fashion with IC50S that ranged from 5x1 O'5 M to 1.5x1 O'4 M (Teronen 
et al. 1999).
Though currently there are no reports on the effects of bisphosphonates on 
aggrecanase activity, metal-chelating chemicals are known to inhibit the 
activities of both MMPs and aggrecanases (Hughes et al. 1998). This is 
understandable since both families of enzymes contain zinc in their metallo- 
proteinase catalytic domain (Murphy and Lee 2005). Thus, in theory, 
bisphosphonates should be able to inhibit aggrecanase activity.
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1.3.4 Summary of evidence. Direction for investigation
In vivo data largely support the concept that there is a role for zoledronate as a 
disease-modifying treatment in OA. Studies that have evaluated zoledronate in 
models of OA and inflammatory arthritis are summarised in Table 1.7. In 
addition, Table 1.8 summarises the in vivo data on other bisphosphonates in 
models of OA. Despite their promising findings, these in vivo studies are not 
able to conclude on underlying mechanisms of action. Exploring potential 
mechanisms of action would provide additional insight towards defining a 
possible role for zoledronate as a disease-modifying treatment in OA.
Clearly zoledronate has well known actions on bone metabolism but an 
alternative target is cartilage metabolism. In cartilage, loss of the principal GAG- 
bearing proteoglycan (aggrecan) from cartilage is a well characterised process
T ab le  1.7. E ffects o f zo ledron ate  in an im al m odels o f osteoarthritis  and  in flam m atory arthritis .
M odel o f O A  o r IA Efficacious
b isphosphonate
dose
Effects observed Reference
Chymopapain- 
induced 
cartilage 
damage in 
rabbits
OA Subcutaneous 
injections; 10 pg/kg 
3x per week
.Partially reduced cartilage damage 
assessed by histology 
•Trend for improved cartilage 
proteoglycan retention 
• Prevented rise in urinary lysyl pyridinoline 
collagen cross-links (marker of bone 
turnover)
(Muehleman 
et al. 2002)
ACL transection 
in dogs
OA Subcutaneous 
injections; 10 pg/kg 
or 25 pg/kg every 
90 days
• Prevented peri-articular BMD decreases
• Inhibited rise in serum osteocalcin 
(marker of osteoblast activity)
(Agnello et 
al. 2005)
Collagen- 
induced arthritis 
in rats
IA Subcutaneous
injections;
>10 ug/kg as a 
single dose
•Reduced bone erosions 
.Reduced juxta-articular trabecular bone 
loss
• Reduced serum type I collagen cross-link 
levels (marker of bone resorption)
(Sims et al. 
2004)
Human tumour 
necrosis factor 
transgenic mice
IA Intra-peritoneal
injections;
100 pg/kg as a 
single dose or 5x 
per week
• Prevented bone erosions
• Partially reduced cartilage damage 
assessed by histology (repeated doses 
only)
. Reduced serum lysyl pyridinoline 
collagen cross-link levels and serum 
osteocalcin levels
(Herrak et 
al. 2004)
Carrageenan- 
induced 
inflammatory 
arthritis in 
rabbits
IA Subcutaneous 
injections; 10 pg/kg 
3x per week
• Preserved subchondral bone integrity 
assessed by histology
• Partially reduced cartilage degradation 
assessed by histology
•Trend for improved cartilage 
proteoglycan retention
(Podworny 
et al. 1999)
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Tab le  1.8. E ffects o f b isphosphonates (o ther than zo ledron ate ) in O A  an im al m odels and OA  
clin ica l trials.
B isphosphonate
evaluated
O A  m odel B isphosphonate
dose
E ffects observed Reference
R isedronate Duncan- 
Hartley 
guinea pigs
Subcutaneous: 
12 pg/kg or 
30 pg/kg 5x per 
week
• Reduced grossly-visible 
cartilage lesion size
• Reduced grossly-visible 
osteophyte size
(Meyer et 
al. 2001b)
ACL
transection
Subcutaneous: 
10 pg/kg daily
• Prevented periarticular BMD 
decreases
(Doschak 
et al.
in rabbits • Partially conserved mechanical 
properties of peri-articular 
bone and the medial collateral 
ligament
2004)
Human 
knee OA 
(clinical trial)
Oral: 5 mg or 
15 mg daily
• Improved symptoms and 
function (15 mg dose)
• Trend for reduced radiographic 
joint space narrowing
• Reduced urinary CTX-II levels 
(marker of cartilage 
degradation)
• Reduced urinary NTX-I levels 
(marker of bone resorption)
(Spector et 
al. 2005)
Human 
knee OA* 
(clinical trial)
Oral: 5 mg/day, 
15 mg/day,
35 mg/week or 
50 mg/week
• No treatment effects 
demonstrated for 
symptoms/signs or 
radiographic joint space 
narrowing
• Reduced levels of urinary 
CTX-II
• Reduced levels of urinary 
NTX-I
(Bingham, 
III et al. 
2006)
Human 
knee OA* 
(clinical trial)
Oral: 5 mg/day, 
15 mg/day, or 
50 mg/week
• In patients with marked 
cartilage loss (radiographic 
joint space narrowing 
> 0.6 mm), conserved 
subchondral bone structure 
(15 mg/day and 50 mg/week 
closing)
(Buckland- 
Wright et 
al. 2007)
E tidronate SRT/ORT
mice
Subcutaneous: 
5 mg/kg or 
50 mg/kg
• No treatment effect on articular 
cartilage degeneration 
assessed by histology
• Reduced levels of bone 
resorption
(Walton
1981)
N E -10035 ACL
transection 
in dogs
Subcutaneous: 
5-10 mg/kg 5x 
per week
• Reduced subchondral bone 
turnover assessed by 
histomorphometry
• No treatment effect on 
osteophyte formation or OA 
cartilage changes assessed by 
histology
(Myers et 
al. 1999)
A lendronate ACL
transection 
in rats
Subcutaneous:
15 pg/kg or
120 pg/kg twice a
week
• Partially reduced cartilage 
damage assessed by histology
• Prevented osteophyte 
formation (120 pg/kg dose)
• Prevented rise in urinary CTX-I 
and CTX-II
(Hayami et 
al. 2004)
‘These two studies involved the same group of patients. OA= osteoarthritis; ACL= anterior cruciate 
ligament; BMD= bone mineral density; CTX-I= C-terminal cross-linking telopeptide of type I collagen; 
CTX-II= C-terminal cross-linking telopeptide of type II collagen; NTX-I= N-terminal cross-linking 
telopeptide of type I collagen
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T ab le  1.9. D irect effects  o f b isphosphonates on cartilage m etabolism
M etabo lic  
p rocess in 
cartilag e
E ffect observed  w ith  various b isphosphonates
B isphosphonate Effect B isphosphonate  
concentra tion  w ith  
activ ity
R eference
C hondrocyte  
surv ival or
Clodronate Reduced 10'4M to 10'3M (Van Offel et al. 2002)
pro liferation Pamidronate Reduced 10‘3M (Van Offel et al. 2002)
Risedronate Reduced 10'3M (Van Offel et al. 2002)
M atrix
synthesis-
G AG
Etidronate Reduced 10'6 M to 5x1 O'4 M (Palmoski and Brandt 1978)
Clodronate Reduced 10'6 M to 5x1 O'4 M (Palmoski and Brandt 1978)
Clodronate Increased 2.5x10"5 M to 2.5x10‘4 M (Guenther et al. 1979)
M atrix
synthesis-
C ollagen
Clodronate Increased 2.5x1 O’5 M to 2.5x10"4 M (Guenther et al. 1981)
C hondrocyte
-m ediated
Increased 2.5x1 O'5 M (Evequoz et al. 1985)
p ro te inase
activ ity
Etidronate Reduced 2.5x1 O'4 M (McGuire et al. 1982)
Reduced 10'4 M to 10'3M (Emonds-Alt et al. 1985)
Increased 2.5x1 O'6 M (Evequoz et al. 1985)
Pamidronate
Increased 10‘5M
(Couchman
and
Sheppeard
1986)
Clodronate Reduced 2.5x1 O'4 M (McGuire et al. 1982)
Tiludronate Reduced 10'5 M to 5x1 O'4 M (Emonds-Alt et al. 1985);
M M P activ ity
Zoledronate
Inhibited activity of 
MMPs-3, 8, 13 and 
20
2.5x1 O’5 M to 10'3M (Heikkila et al. 2002)
Inhibited activity of 
MMPs-3, 12, 13 
and 20
IC50 between 5x10‘5 M 
and 1.5x1 O'4 M
(Teronen et al. 
1999)
Pamidronate Inhibited activity of MMPs-3, 8 and 13 2x1 O'5 M to 10'3M
(Heikkila et al. 
2002)
Alendronate
Inhibited activity of 
MMPs-3, 8 and 13 2x1 O’5 M to 10’3M
(Heikkila et al. 
2002)
Inhibited activity of 
MMP-13
IC50 between 5x10'4 M 
and 7.5x104M
(Konttinen et 
al. 1999)
Clodronate Inhibited activity of MMPs-1 and 8 IC50 1.5x1 O'4 M
(Teronen et al. 
1997a;
Teronen et al. 
1997b)
GAG= glycosaminoglycan; MMP= matrix metalloproteinase; IC5o= concentration producing 50% 
inhibition of activity
in OA that compromises the physio-chemical behaviour of the tissue (Heinegard 
et al. 2003; Mow and Hung 2003). This compositional change is thought to 
initiate a series of events that leads to irreversible tissue degradation (Sandy 
2006). Thus, reducing the loss of cartilage aggrecan should conserve tissue
88
integrity and function, and may represent one way of retarding the OA disease 
process. Since cartilage proteoglycan content is dependent on balance between 
anabolism and catabolism in matrix (Nagase and Kashiwagi 2003), 
interventions to increase proteoglycan synthesis or decrease its degradation 
during the OA process are likely to be beneficial.
At the biochemical level, there is evidence to suggest that zoledronate can 
reduce cartilage matrix degradation. Zoledronate and other bisphosphonates 
have been found to inhibit the activity of various MMPs (summarised in Table 
1.9), one family of proteinases implicated in cartilage matrix degradation. At the 
cell/tissue level, bisphosphonates other than zoledronate have been shown to 
influence chondrocyte viability, matrix synthesis and proteinase production, 
though both beneficial and detrimental effects have been reported (summarised 
in Table 1.9). It is not known whether zoledronate has direct effects on cartilage 
tissue or chondrocytes that alter proteoglycan metabolism.
The following chapters describe studies that have explored hypotheses relating 
to effects of zoledronate on hyaline cartilage at the cell/tissue level. The general 
hypothesis was that zoledronate modifies cartilage metabolism to reduce the 
loss of cartilage glycosaminoglycan during the osteoarthritic process.
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Chapter 2. Hypothesis, experimental design and materials and methods
This chapter describes the experimental approach that was taken. Background 
is provided on the in vitro culture models of OA that were used in the 
experiments. In addition, the basic materials and methods for the models are 
detailed.
2.1 General hypothesis
Zoledronate modifies cartilage metabolism to reduce loss of cartilage 
glycosaminoglycan during the osteoarthritic process
2.2 Experimental design and study objectives
An in vitro approach to investigation was taken to test the general hypothesis 
since cartilage and chondrocyte metabolism can be studied isolated from other 
joint tissues. Information was sought by testing individual specific hypotheses in 
experiments using in vitro models of chondrocyte, chondrocyte-matrix or 
cartilage metabolism. IL-1, a cytokine involved in regulating cartilage catabolism 
(discussed in section 1.2.3.6), was employed to stimulate “OA-like” metabolic 
changes.
Study objectives
i) Define the concentration range of zoledronate to evaluate in the studies.
ii) Evaluate zoledronate for effects on GAG synthesis and degradation 
using culture models of chondrocyte and cartilage metabolism with IL-1 
as an OA stimulus.
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2.2.1 In vitro models of OA cartilage and OA chondrocyte metabolism
In vitro culture models have been widely used to examine metabolic processes 
in OA (Caterson et al. 2000). Two model systems were used in this present 
study. In both, IL-1 was employed as a stimulus of OA metabolic change.
2.2.1.1 Bovine articular cartilage explant culture model
Articular cartilage explants are ex vivo pieces of tissue. When cultured in vitro, 
the chondrocytes within the explants are maintained in their usual three- 
dimensional matrix. Bovine articular cartilage is often used in this culture model 
and the addition of the catabolic cytokine IL-1 stimulates proteoglycan 
degradation that can be measured as released GAG or aggrecan in the culture 
medium (Caterson et al. 2000; Little et al. 1999; Sandy et al. 1991a; Sandy et 
al. 1991b). Western blot analysis of the medium using monoclonal antibodies to 
identify cleavage sites on released aggrecan fragments indicates that 
aggrecanase activity is primarily responsible for aggrecan catabolism in this 
culture system. Furthermore, IL-1 up-regulates aggrecanase-1 and 
aggrecanase-2 mRNA transcription in bovine cartilage explants. Taken 
together, the metabolic events that characterise the model simulate the 
cartilage metabolic processes in vivo which lead to the loss of cartilage GAG 
during OA pathogenesis (discussed in section 1.2.3.3).
2.2.1.2 Chondrocyte/ alginate bead culture model
Chondrocyte and matrix metabolism may also be studied in a three-dimensional 
culture system in which cells that have been isolated from cartilage are cultured 
encapsulated and suspended in alginate gel beads. Alginates, glycuranans 
extracted from brown seaweed algae (Guo et al. 1989), are linear unbranched 
polymers containing D-mannuronic acid and L-guluronic acid residues that form 
gels in the presence of calcium or other multivalent counter ions (Chaplin 2007).
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The morphologic and metabolic features of this culture system have been 
extensively characterised, indicating that cells retain their chondrocyte 
phenotype. The cells are observed (i) to maintain a spherical shape (Guo et al. 
1989); (ii) to synthesise characteristic matrix molecules (aggrecan and type II 
collagen) (Almqvist et al. 2001; Hauselmann et al. 1992; Hauselmann et al. 
1994); and (iii) to express MMPs (Chubinskaya et al. 2001). These 
characteristics appear to persist for some time and even after 8 months of 
culture, the cells remain metabolically active and continue to synthesise type II 
collagen and aggrecan (Hauselmann et al. 1994).
The distribution and composition of elaborated matrix in the culture model also 
demonstrates similarities to that found in articular cartilage. Long-term culture of 
normal adult human chondrocytes in alginate beads establishes matrix that is 
found in two compartments: the cell-associated and further-removed matrix. 
These compartments correspond respectively to the pericellular/territorial and 
interterritorial matrix of articular cartilage (Hauselmann et al. 1996b). By day 30 
of culture, the absolute and relative volumes occupied by these compartments 
and the encapsulated cells were observed to be nearly identical to those found 
in native articular cartilage. Furthermore, other investigators have shown that 
after 4 weeks of culture, collagen types II, IX and XI are seen to accumulate in 
the matrix in relative proportions that are similar to those in found in adult 
cartilage (Petit et al. 1996).
Collectively, these observed cell and matrix characteristics indicate that the 
chondrocyte phenotype is maintained in the chondrocyte/ alginate culture 
system. Thus, as a model for studying chondrocyte metabolism it has 
advantages over the two-dimensional culture of chondrocytes in monolayer, a 
model that suffers from problems with chondrocyte dedifferentiation and loss of 
phenotypic traits (Benya and Shaffer 1982; Holtzer et al. 1960). Additionally, in 
comparison to cartilage explant culture, the chondrocyte/ alginate culture 
technique allows intra-joint topographical variability in metabolism to be 
somewhat minimalised through the removal of native cartilage matrix and the
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pooling of isolated chondrocytes, the benefit being that small-sized treatment 
effects on cell metabolism should be more easily observed.
Effects of IL-1 on cell and matrix metabolism in the chondrocyte/ alginate 
bead culture model
In the alginate bead culture model, IL-1 has been found to have inhibitory 
effects on proteoglycan synthesis by bovine articular chondrocytes (D'Souza et 
al. 2000) and aggrecan production by human OA chondrocytes (Sanchez et al. 
2002). Effects on matrix degradation have also been seen. Following the culture 
of bovine articular chondrocytes in alginate beads for two weeks to establish 
matrix, subsequent treatment with IL-1 induced profound GAG release from the 
beads into the media (Beekman et al. 1998). Though the exact mechanism for 
GAG release induced by IL-1 in the model was not demonstrated specifically, 
MMP activity was not increased implying that other proteolytic enzymes such as 
aggrecanases might have been responsible for GAG catabolism.
Thus, the chondrocyte/ alginate bead culture model has compositional and 
metabolic characteristics that mimic native cartilage and addition of IL-1 to the 
culture system allows aggrecan catabolism to be investigated. Previously, 
several studies have used this model to investigate the effects of agents on 
chondrocyte metabolism to help define therapeutic potential in OA (Henrotin et 
al. 2003; Sanchez et al. 2002; Sanchez et al. 2003).
2.2.1.3 Form and concentration of IL-1 used in the in vitro studies
IL-1 is the prototypic pro-inflammatory cytokine and is found in two forms, IL-1 a 
and IL-1 (3 (Dinarello 1997). In most studies both forms have very similar 
biological activities, however, bovine articular chondrocytes appear more 
sensitive to human recombinant IL-1 a than to IL-1 (3. IL-1 a has been found to 
have a greater inhibitory effect than IL-1 p on proteoglycan synthesis by bovine 
articular chondrocytes cultured in agarose gel and only IL-1 a was capable of 
stimulating proteoglycan degradation (Aydelotte et al. 1992). In addition, IL-1 a is
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the form of the cytokine that has been frequently used as a catabolic stimulus to 
study aggrecan degradation in bovine articular cartilage explants (Little et al. 
1999; Sandy et al. 1991a; Sandy et al. 1991b). Thus, for the culture 
experiments of this present study, IL-1 a was selected as the form of the 
cytokine to be used to stimulate proteoglycan degradation and inhibit 
proteoglycan synthesis.
The concentration of IL-1 a chosen for the majority of experiments was 10 ng/ml, 
based on upon a previously described method for bovine articular cartilage 
explant culture (Little et al. 1999). Though for the purposes of in vitro 
investigation with short culture periods, 10 ng/ml IL-1 a is an effective stimulus of 
cartilage proteoglycan degradation, it is important to note that in vivo the 
synovial fluid concentrations of IL-1 (albeit IL-1 (3 rather than IL-1 a) from patients 
with knee OA are reported to be nearly 100-fold lower (Westacott et al. 1990). 
The difference is striking but might be partly explained by interactions of various 
cytokines in vivo, such as TNFa acting synergistically with IL-1 to drive cartilage 
destruction (Goldring 2000; Goldring and Goldring 2004). Furthermore, another 
difference is that in vitro the cytokine is employed to stimulate cartilage 
degradation over a relatively short time period (e.g. 4 days), whereas in vivo this 
process is much more prolonged.
2.2.2 Use of culture models to fulfil study objectives
Study objective (i). Define the concentration range of zoledronate to evaluate 
in the studies.
Experiments using the bovine chondrocyte/ alginate bead culture model were 
performed to investigate adverse effects of zoledronate on chondrocytes to 
define the upper limit of the concentration range. Specific outcomes measured 
were cell viability, proliferation and GAG synthesis. The results on GAG 
synthesis served partly to deliver study objective (ii).
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Study objective (ii). Evaluate zoledronate for effects on GAG synthesis and 
degradation using culture models of chondrocyte and cartilage metabolism with 
IL-1 as an OA stimulus.
Both the bovine cartilage explant culture model and the bovine chondrocyte/ 
alginate bead culture model were used. The outcome measured was the 
amount of GAG released from the tissue.
2.3 Materials and methods
2.3.1 Basic methods: cell and tissue culture 
Tissue source
Bovine forefeet were obtained on the day of animal slaughter from a local 
abattoir and used within 24 hours. All animals were aged 12-30 months and of 
unknown breed and sex unless otherwise specified.
2.3.1.1 Culture of bovine articular cartilage explants 
Medium and general maintenance conditions
The basic medium used for all explant cultures was Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco, Paisley, UK) supplemented with 50 pg/ml 
gentamicin (Gibco) and 0.5% (v/v) antibiotic/antimycotic solution (100x 
containing 10,000 units penicillin, 10,000 pg streptomycin, and 25 pg 
amphotericin B/ml; Gibco). All explant cultures were maintained at 37°C in a 
humidified atmosphere of 5% C 02 and 95% air.
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Preparation and culture of explants
Bovine articular cartilage explant culture was performed according to previously 
described methods (Little et al. 1999). Only one joint from one foot was used for 
each experiment to exclude inter-animal and inter-joint variation. Fore feet were 
washed and the skin was excised. After exposing metacarpophalangeal (MCP) 
joints under aseptic conditions, full depth articular cartilage slices were excised 
off the metacarpal articular surface with a scalpel (approximately 80 explants 
per articular surface), pooled, washed with DMEM and then pre-cultured in 
DMEM supplemented with 10% (v/v) foetal calf serum (FCS; First Link, West 
Midlands, UK) for 48 hours. Explants were then washed 3 times for 10 minutes 
each in serum-free DMEM before treatment culture. Methods for treatment 
culture are detailed in Chapter 4.
2.3.1.2 Culture of cells isolated from bovine articular cartilage in alginate 
beads
Medium and general maintenance conditions
The basic medium used for all cell cultures was DMEM supplemented with 150 
mg/ml ascorbic acid (Sigma, Poole, UK), 100 unit/ml penicillin (Gibco) and 100 
pg/ml streptomycin. All cell cultures were maintained at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air.
Isolation of cells
Articular cartilage was obtained using the same method as for explant culture. 
Cartilage slices obtained from one to seven MCP joints were pooled, washed 
with Earle’s balanced salt solution (EBSS; Gibco) and cultured overnight in 
DMEM supplemented with 20% FCS. The next day the cartilage was finely 
diced with a scalpel and then, to digest the matrix and release cells, the tissue 
was incubated for 1 hour at 37°C in DMEM + 20% FCS and 10 mg/ml pronase 
E (BDH, Lutterworth, Leics, UK) and then for further 16 hours at 37°C in DMEM 
+ 20% FCS and 100 unit/ml collagenase XI (Sigma). The resulting cell
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suspension was passed through a 70 pm pore size sieve (Falcon, Oxford, UK) 
and washed twice with EBSS. Viability and total cell numbers were determined 
using the trypan blue (Sigma) exclusion method and a cell counting chamber. 
Cell viability ranged from 96% to 100%. Cells were resuspended in DMEM + 
20% FCS to yield a suspension with 2x107 cells/ml.
Forming alginate gel beads containing cells
Alginate Keltone LV (Kelco Nutrasweet, Poole, UK) was dissolved in EBSS and 
autoclaved to give a sterile 4% (w/v) alginate solution which was added to an 
equal volume of the cell suspension to yield a final concentration of 2% alginate 
containing 1x107 cells/ml. The cell/alginate suspension was slowly expressed 
through a 25-gauge needle into a solution containing 100 mM CaCI2 (BDH) in 
phosphate buffered saline (PBS; Sigma) to form alginate beads containing the 
cells. The bead volume and cells per bead were calculated. Beads were 
incubated at room temperature in the CaCI2/PBS solution for 10 mins to induce 
crosslinking of the alginate gel and then washed three times with EBSS 
followed by a final wash with DMEM + 20% FCS. Different methods were used 
for the subsequent culture of the beads and these are detailed in the materials 
and methods section of each experimental chapter.
2.3.2 Basic methods: statistical analyses
Statistical analyses were performed using SPSS 14.0 for Windows software 
(SPSS Inc.). Assumptions about the normal distribution and homogeneity of 
variance in relation to the data were assessed by frequency plots and Levene’s 
test respectively. Because nearly all data sets fulfilled these assumptions, all 
comparisons were carried out using parametric tests to maintain consistency. 
First, data were analysed by ANOVA and if differences of the means between 
groups were found (P<0.05), post-hoc comparisons were then performed. 
Within experiments, comparisons of means between two groups were made 
using the Independent-Samples T Test and comparisons of means between 
multiple groups were made with Dunnett’s t test or the Bonferroni test. When
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experimental hypotheses were tested in a single experiment, the alpha level for 
statistical significance between means was set at 0.05. When multiple 
experiments were performed to test the same hypothesis, a more stringent 
alpha level of 0.01 was used in order to take into account the increased 
likelihood of statistical type 1 error. In the event that data sets showed a non­
normal distribution or exhibited unequal variance, any comparisons with 
significance levels near to the set alpha level were interpreted cautiously.
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Chapter 3. Effects of zoledronate on bovine articular chondrocyte viability, 
proliferation and proteoglycan synthesis. Selection of the zoledronate 
concentration range to evaluate.
There were two aims behind the experiments described in this chapter. In order 
to aid selection of the concentration range to evaluate in further studies, the 
adverse effects of zoledronate on chondrocyte metabolism (cell viability, 
proliferation and proteoglycan synthesis) were investigated. In addition, another 
purpose for examining effects on chondrocyte proteoglycan synthesis was to 
provide information for the general hypothesis.
3.1 Introduction
Three criteria were considered in relation to the concentration range of 
zoledronate to evaluate for effects on cartilage or chondrocyte proteoglycan 
metabolism. Ideally, the range should include zoledronate concentrations that 
were achieved in cartilage in the in vivo studies that found beneficial treatment 
effects with respect to cartilage outcomes. In addition, zoledronate 
concentrations with known in vitro cellular effects or inhibitory MMP activities 
should be covered and, moreover, the upper limit of the range should be 
defined by zoledronate concentrations that have adverse effects on 
chondrocytes.
Reduction in cartilage damage in rabbits was seen with subcutaneous 
zoledronate 10 pg/kg given three times a week (Muehleman et al. 2002), a 
dosing regimen that approximates to intravenous 4 mg zoledronate given 
monthly in humans (personal communication from Dr. J.R. Green, Novartis 
Pharma AG). Patients with Paget’s disease, in whom zoledronate treatment 
reduced a urinary marker of type II collagen degradation (CTX II), received 
either a single 200 pg or 400 pg intravenous dose of zoledronate (Garnero et al. 
2001a).
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It is not possible to make accurate estimates for zoledronate cartilage tissue 
concentrations achieved in either of the above studies since specific 
pharmacokinetic distribution data for cartilage have not been reported.
Available data indicate that in humans receiving a single dose of intravenous 
zoledronate 4 mg, the mean peak plasma concentration was 309 ng/ml (about 
10'6 M) which then declined rapidly to <1% of the peak twenty-four hours post 
infusion (Skerjanec et al. 2003). Extrapolating from these data, the 400 pg dose 
of zoledronate should have lead to an approximate peak plasma concentration 
of 10'7 M in the Paget’s disease patients. Drug distribution data have also been 
reported for systemically-administered zoledronate in rats (Green and Rogers 
2002). In rat bone, zoledronate was found in high concentrations between 
10"4 mol/kg and 10'3 mol/ kg, levels which persisted up to eight months after 
injection. During this period, zoledronate was present also in soft tissue 
(10‘7 mol/kg to 10'6 mol/kg) and blood (10'9 mol/kg to 10'7 mol/kg). Despite the 
lack of reports to indicate that systemically-administered zoledronate can 
distribute to cartilage, there are theoretical mechanisms by which the 
bisphosphonate could reach cartilage, namely via subchondral bone or the 
circulation (discussed in 1.3.3.2).
Numerous in vitro studies have found effects of zoledronate on various enzyme, 
cell and tissue metabolic processes (Table 3.1). These effects were observed at 
zoledronate concentrations between 2x1 O'9 M to 10 3M and, in particular, cell 
toxicity was demonstrated in rabbit osteoclasts (Benford et al. 2001), human 
foetal osteoblasts (Reinholz et al. 2000) and human myeloma cells (Derenne et 
al. 1999) at concentrations 10'5 M and above. In addition, other in vitro studies 
have found that etidronate, clodronate, pamidronate and risedronate have 
detrimental effects on chondrocytes, mostly with bisphosphonate concentrations 
around the 10‘4 M mark (Guenther et al. 1979; Palmoski and Brandt 1978; Van 
Offel et al. 2002). However, it is not known whether zoledronate has adverse 
effects on chondrocyte metabolism.
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Table 3.1. Some reported effects of zoledronate on various metabolic processes that 
have been observed in vitro
Effect on metabolic process Zoledronate concentration 
for observed effect
Reference
Bone-related
Inhibition of protein prenylation in 
rabbit osteoclasts
10‘bM (Coxon et al. 2000)
Inhibition of recombinant human 
farnesyl diphosphate synthase 
activity
3x10‘y M (IC50) (Dunford et al. 2001)
Stimulation of capsase-3-like activity 
in rabbit osteoclasts
lO^M (Benford et al. 2001)
Inhibition of 1,25-dihydroxyvitamin 
D3-induced bone resorption in 
mouse calvaria
2x10 yM (IC50) (Green et al. 1994)
Inhibition of calcium incorporation 
into calvaria
10_1>M to 10'4M (Green and Rogers 
2002)
Inhibition of human foetal osteoblast 
proliferation
10'b M to 10'4 M (Reinholz et al. 2000)
Stimulation of human foetal 
osteoblast mineralisation of matrix
1 0 5M
MMP-related
Inhibition of MMP-20 activity against 
p-casein
5x10_{3 M to 5x104M (Heikkila et al. 2002)
Inhibition of MMP-3, MMP-8 and 
MMP-13 activity against 3-casein
2x10 5 M to 10'3M
Inhibition of MMP-1 production by 
bone marrow stromal cells 
stimulated by IL-1p
10'yM (Derenne et al. 1999)
Stimulation of MMP-2 secretion by 
bone marrow stromal cells
10'9M to 10'6M
Myeloma-related
Inhibition of human myeloma cell 
proliferation
5x10‘b M to 5x104 M (Derenne et al. 1999)
Stimulation of bone marrow stromal 
cell apoptosis
10’4M
Stimulation of human myeloma cell 
apoptosis
10"4 M to 5x1 O'4 M
IC5o= concentration producing 50% in nibitory effect
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On the other hand, zoledronate may have beneficial effects on chondrocyte 
metabolism. In relation to the general hypothesis, one way that zoledronate 
could improve the proteoglycan content in OA cartilage is by increasing 
chondrocyte proteoglycan synthesis. Interestingly, clodronate (2.5x10"5 M and 
2.5x1 O'4 M) has been found to stimulate GAG synthesis in rabbit articular 
chondrocytes (Guenther et al. 1979), though another study found that both 
etidronate and clodronate (10'6 M to 5x1 O'4 M) inhibited GAG synthesis in 
canine articular cartilage explants (Palmoski and Brandt 1978).
It is not known (i) whether zoledronate has adverse effects on chondrocyte 
metabolism and (ii) whether the bisphosphonate can stimulate chondrocyte 
proteoglycan synthesis. The experiments described in this chapter have been 
performed to determine this information using the bovine articular chondrocyte/ 
alginate bead culture model with and without IL-1a co-treatment as an OA 
stimulus (model described in section 2.2.1).
3.2 Experimental hypotheses
Zoledronate at concentrations 10'5 M and above reduces cell viability and 
inhibits cell proliferation and proteoglycan synthesis of bovine articular 
chondrocytes cultured in alginate beads with and without IL-1a 
co-treatment
Zoledronate at concentrations without adverse effects on cell viability or 
proliferation stimulates the proteoglycan synthesis of bovine articular 
chondrocytes cultured in alginate beads with and without IL-1a 
co-treatment
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3.3 Experimental objectives
i) Culture bovine articular chondrocytes in alginate beads with and without 
zoledronate (10'12 M to 10'4 M) and with and without IL-1a (10 ng/ml)
ii) Measure cell viability
iii) Measure rates of cell proliferation by 3H-TdR incorporation
iv) Measure rates of cell proteoglycan synthesis by 35S 04 incorporation
3.4 Materials and methods
3.4.1 Cell culture and treatments
Bovine articular chondrocyte/ alginate bead culture
Alginate beads containing cells isolated from bovine articular cartilage were 
formed as described in section 2.3.1.2. Four experiments assessing cell viability 
(exps. b.a2, b.a4.1, b.a5.1 and b.a6.2) were performed on separate occasions 
using different tissue sources. Another experiment was performed to assess cell 
proliferation and proteoglycan synthesis (exp. b.a6.1) using the same tissue 
source as experiment b.a6.2.
Differences in the culture method and outcome measure between experiments 
are summarised in Table 3.2. Experiment b.a2: treatment commenced on the 
day of bead formation. Experiments b.a4.1, b.a5.1, b.a6.1 and b.a6.2: beads 
were pre-cultured in DMEM + 20% FCS for 3 days in 225 cm2 tissue culture 
flasks (Corning Life Sciences, Schipol-Rijk, The Netherlands) prior to 
commencing treatment culture. This 3-day pre-culture period allows stabilisation 
of the cells in alginate as previously described (van Susante et al. 2000).
Beads were then washed 3 times for 10 minutes each in DMEM. Up to 6 beads 
were placed in individual wells of 24-well tissue culture plates. Into each well 
were added 1 ml of treatment serum-free DMEM (experiments b.a4.1 and 
b.a5.1) or DMEM + 10% FCS (experiments b.a2, b.a6.1 and b.a6.2) with and
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without 10 ng/ml IL-1a and with and without zoledronate treatment 
concentrations. For experiment b.a6.1 treatment DMEM was supplemented also 
with 37 kBq/ml tritiated thymidine (3H-TdR; Amersham Biosciences UK, Bucks, 
UK) and 370 kBq/ml 35SC>4 (Amersham Biosciences UK). Treatment cultures 
were performed in replicates of 6 and maintained in treatment DMEM for 1 or 2 
days. Cell viability was assessed after 1 or 2 days culture. For experiment 
b.a6.1 beads and medium were harvested after 2 days of culture and stored 
separately at -20°C until biochemical analysis.
3.4.2 Cell viability analysis
Beads were washed twice with PBS. Cell viability was assessed using the 
Live/dead viability/cytotoxicity kit (Molecular Probes Inc., Eugene, Oregon,
USA). This technique distinguishes live cells by the presence of ubiquitous 
intracellular esterase activity that enzymatically converts virtually non- 
fluorescent cell-permeant calcein AM to calcein producing intense green 
fluorescence. Dead cells with damaged membranes allow ethidium homodimer- 
1 (Ethd-1) to enter and bind to nucleic acids to produce bright red fluorescence. 
Beads were incubated for 1 hour at 37°C in 0.5 ml of PBS containing 4 pM 
EthD-1 and 1 pM calcein AM. Each bead was sliced, placed on a glass slide, 
covered with a coverslip, viewed by fluorescence microscopy and photographed 
(Fig 3.2). Live cells and dead cells were manually counted within a defined area 
and cell viability was calculated as follows:
% cell viability = number live cells x 100/ (number live cells + number dead 
cells)
Reproducibility of manual cell counting: coefficient of variation (CV) < 1% for 
counts repeated 3 times.
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Table 3.2. Summary of cell source characteristics and culture conditions for experiments evaluating the effects of zoledronate on cell viability, proliferation and 
proteoglycan synthesis in the bovine chondrocyte/ alginate bead culture model.
Exp. Characteristics of cell 
source
Cell viability 
post isolation
Bead volume; cells/ 
bead; beads/well
Pre-culture; medium No. days of 
treatment culture; 
medium
Treatment Outcome
measured
b.a2
1x MCP joint from bovine 
animal aged 12-30 months; 
sex unknown
96.4% 6.8 pi; 67600; 3 Not performed
1 day;
DMEM + 10% FCS
IL-1a 0, 10 ng/ml;
Zol 0 ,1012M to 10'4M
Cell viability
b.a4.1
2x MCP joints from 2 bulls 
each aged 13 months
100% 7.4 pi; 73500; 3 3 days; DMEM + 20% FCS
1,2 days; 
serum-free DMEM
IL-1 a 0,10 ng/ml;
Zol 0, 10‘9 M to 10'6M
Cell viability
b.a5.1
2x MCP joints from 2 
heifers aged 24 and 29 
months
100% N/A; N/A; 6 3 days; DMEM + 20% FCS
2 days;
serum-free DMEM
IL-1 a 0, 10 ng/ml;
Zol 0, 108 M to 10‘4M Cell viability
b.a6.1
7x MCP joints from 4 
heifers each aged 18 
months
99% 7.1 pi; 71400; 6 3 days; DMEM + 20% FCS
2 days;
DMEM + 10% FCS
IL-1 a 0,10 ng/ml;
Zol 0 ,101°M to 104 M
Cell proliferation 
and proteoglycan 
synthesis
b.a6.2
7x MCP joints from 4 
heifers each aged 18 
months
99% 7.1 pi; 71400; 6 3 days; DMEM + 20% FCS
2 days;
DMEM + 10% FCS
IL-1 a 0,10 ng/ml;
Zol 0, 10'1°M to 10'4M Cell viability
Exp= experiment; MCP= metacarpophalangeal; DMEM= Dulbecco’s modified Eagle’s medium; FCS= foetal calf serum; Zol= zoledronate
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3.4.3 Biochemical analyses
Alginate beads were disrupted and digested by incubating at 60°C for 24 h in 
1ml of 55 mM sodium citrate (BDH), 150 mM sodium chloride (Sigma), 5 mM 
cysteine hydrochloride, 5 mM EDTA (BDH) and 0.56 units/ml papain (Sigma) as 
previously described (Enobakhare et al. 1996). All biochemical analyses of 
samples were performed in duplicate.
Quantification of 3H-TdR incorporation
Rates of cell proliferation were assessed by quantifying amounts of 3H-TdR 
incorporated into newly-formed DNA over the two day incubation period using 
the trichloroacetic acid (TCA) precipitation technique and liquid scintillation 
counting. Aliquots (100 pi) of the alginate bead digest were added to individual 
wells of a multiscreen plate (0.65 pm pore size; Millipore, Watford, Herts, UK) 
followed by 100 pi of 20% (w/v) TCA (BDH) and incubated at 4°C for 30 min. 
The multiscreen plate was vacuum aspirated and wells were rinsed twice with 
100 pi 10% TCA, vacuum aspirating each time. The plate was dried and the 
filters were punched out into scintillation vials. Five hundred pi of 0.01 M KOH 
(BDH) was added to each of the vials which were then agitated for 2 h to 
release bound 3H-Tdr from the filter into solution. A 4.5 ml volume of Ultima 
Gold™ MV liquid scintillation cocktail (Perkin Elmer LAS UK, Beaconsfield, 
Bucks, UK) was added to each vial and scintillations were measured using a 
Perkin Elmer Tricarb 2900 TR scintillation counter (Perkin Elmer LAS UK). 
Reproducibility: mean intra-assay CV 1.8%.
Quantification of 35S04 incorporation
Rates of proteoglycan synthesis were assessed by measuring the amounts of 
35S 04 incorporated into newly-synthesised proteoglycans and/or 
glycosaminoglycans over the two day incubation period using an alcian blue 
precipitation method and liquid scintillation counting (Masuda et al. 1994). 
Aliquots (75 pi) of a pH 5.8 solution containing 50 mM sodium acetate (BDH) 
and 0.5% (v/v) triton X-100 (BDH) were added to individual wells of a 
multiscreen plate (0.65 pm pore size) followed by 40 pi aliquots of medium or
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alginate bead digest and 150 |jl of alcian blue solution consisting of 0.2% (w/v) 
alcian blue 8GX (BDH) in 50 mM sodium acetate, 85 mM magnesium chloride, 
pH 5.8. The plate was gently mixed for 1 h at room temperature and vacuum 
aspirated. Wells were washed 3 times with 200 pi volumes of a pH 5.8 solution 
containing 50 mM sodium acetate, 85 mM magnesium chloride and 100 mM 
sodium sulphate, vacuum aspirating on each occasion. The filters were 
punched out into scintillation vials and gently agitated for 1 h in 0.5 ml of 4 M 
guanidine HCI in 33% (v/v) propan-2-ol. Four ml of Ultima Gold™ MV was 
added to each vial and scintillations measured using a Perkin Elmer Tricarb 
2900 TR scintillation counter. Reproducibility: mean intra-assay CV 1.9%.
DNA quantification
Amounts of DNA contained in the beads were determined using the Hoechst 
fluorimetric method (Rao and Otto 1992). Aliquots (100 pi) of standards 
prepared using calf thymus DNA (Sigma) in pH 7.0 saline sodium citrate (SSC; 
150 mM NaCI and 15 mM sodium citrate; both from BDH) or alginate bead 
digests were placed in individual wells of 96-well microtitre plates (Nunc, 
Roskilde, Denmark). Aliquots (100 pi) of 2 pg/ml Hoechst 33258 (Sigma) in 
SSC were added to each well and then the plate was read using a Fluoroskan 
Ascent microtitre fluorimeter (Labsystems Oy, Helsinki, Finland) with excitation 
at 348 nm and emission readings at 460 nm. Values for the DNA content of the 
alginate beads were used to normalise values obtained for sulphate 
incorporation. Reproducibility: mean intra-assay CV 1.8%
3.4.4 Statistical analyses
Statistical analyses were performed as described in section 2.3.2. With respect 
to %  cell viability data, phrases such as “caused a 10% reduction” or 
“decreased by 10 %” are used in relation to absolute differences in values. With 
respect to cell proliferation and proteoglycan synthesis data, these phrases 
indicate the proportional differences between values.
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3.5 Results
3.5.1 Effects of zoledronate on chondrocyte viability with and without 
IL-1 a co-treatment
Four experiments were performed to assess the effects of zoledronate on 
chondrocyte viability with and without IL-1 a co-treatment (experiments b.a2, 
b.a4.1, b.a5.1 and b.a6.2).
Chondrocyte viability in controls and IL-1a-treated controls (Table 3.3)
In controls, with or without IL-1 a 10 ng/ml, cell viabilities after one-day or two- 
day culture ranged from 92.1% to 98.2%. IL-1 a 10 ng/ml did not affect cell 
viability in the one-day cultures, but in cultures for two days caused a 3.1% 
reduction in cell viability compared to no cytokine in one experiment (P<0.001) 
and a trend for a 1.7% reduction in another (P=0.049). Duration of culture also 
had an effect. Comparing two-day culture to one-day culture in the single 
experiment in which both time points were examined (exp. b.a4.1), a trend for a 
1.5% reduction in cell viability was observed in controls (P=0.049) and a 2.7% 
reduction was seen in IL-1a-treated controls (P=0.001).
Table 3.3. Cell viability after one-day or two-day culture of bovine articular chondrocytes 
in alginate beads in controls and IL-1a-treated controls.
Culture
period
Experiment Mean % cell viability P value for difference in 
means between control and 
IL-1a-treated control*
Control IL-1a-treated
control
One day of 
culture
b.a2 94.4 95.2 P=0.413
b.a4.1 98.2 97.7 P=0.118
Two days of 
culture
b.a4.1 96.7 95.0 P=0.049
b.a5.1 92.6 93.1 P=0.555
b.a6.2 95.2 92.1 P=0.000183**
* Since multiple experiments were performed the alpha level to indicate a significant difference 
between means was set at P=0.01 as described in section 2.3.2.
** Statistically significant difference at the P<0.01 level.
108
Effects of zoledronate on chondrocyte viability
In the first experiment (b.a2), one-day treatment cultures were carried out. In 
basal cultures (i.e. without IL-1 a co-treatment), zoledronate 10'6M and 
zoledronate 10'4 M reduced cell viability compared to control by 4.3% (P=0.002) 
and 7.4% (P<0.001) respectively (Fig. 3.1; Table 3.4). Fig. 3.2 shows 
photographs of the cells following treatment for control and zoledronate 10'4 M. 
In IL-1 a co-treated cultures, zoledronate 10'4 M caused a 10.1% reduction in 
cell viability (P<0.001; Fig. 3.1; Table 3.4). Lower concentrations of zoledronate 
down to 10'12 M did not affect cell viability in either basal or IL-1 a co-treated 
cultures.
Fig. 3.1. Experiment b.a2: Effects of zoledronate (1.E-12 M to 1.E-4 M) with and without 
IL-1a co-treatment on the viability of chondrocytes cultured in alginate beads after one- 
day treatment culture.
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IE -12 IE -10 1.E-09 1.E-08 IE-06 1.E-04 X 0 1.E-12 IE -10 1.E-09 1.E-08
zoledronate (M) X zoledronate (M)+IL-1a 10 ng/rrt
Treatment
Bovine articular chondrocytes cultured in alginate beads in the presence of treatments for one day prior to assessment of 
chondrocyte viability. Values for %cell viability shown as means ±  SD (n=6). *P=0.002 or **P<0.001 vs. zoledronate 0M. ***P<0.001 
vs. zoledronate OM + IL -la  10 ng/ml.
As zoledronate 10'6 M and zoledronate 10'4 M had been observed to reduce cell 
viability in experiment b.a2 but concentrations between 10'8 M and 10‘6 M had 
not been explored, an additional experiment (b.a4.1) was performed to 
determine adverse effects of zoledronate 10'9 M to 10'6 M (x10 increments 
between concentrations). However, no zoledronate treatment effects on cell 
viability were seen in one-day or two-day cultures with or without
109
Fig 3.2. Experiment b.a2: Photographs of chondrocytes after live/dead staining.
Examples of photographs taken through a fluorescent microscope after one day of 
treatment culture and subsequent incubation in live/dead stain (live cells appear green 
and dead cells red); cells counted in photographs to measure %cell viability (results 
detailed elsewhere). Left: control culture; right: culture with zoledronate 10 4 M treatment.
IL-1 a co-treatment (Figs 3.3 and 3.4; Table 3.4). Of note, the animal source for 
chondrocytes was different between experiments, and pre-culture of 
chondrocytes and serum supplementation of treatment medium were performed 
in experiment b.a4.1 but not experiment b.a2 (Table 3.2).
Since the results for effects of zoledronate 1CT6 M disagreed between 
experiments b.a2 and b.a4.1, investigations were repeated. In the next 
experiment (b.a5.1), culture conditions were the same as for experiment b.a4.1 
except chondrocytes were sourced from 24- to 29-month old heifers instead of 
13-month old bulls and only two-day culture was performed (Table 3.2). The 
concentration range investigated was extended back up to 10'4 M. Compared to 
control, zoledronate 10'4 M reduced cell viability by 2.6% in basal cultures 
(P=0.003; Fig. 3.5; Table 3.4). No other effects were observed for lower 
zoledronate concentrations in basal cultures or for any concentration (10'8 M to 
10'4 M) in IL-1 a co-treated cultures.
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Fig. 3.3. Experiment b.a4.1: Effects of zoledronate (1.E-9M to 1.E-6 M) 
with and without IL-1a co-treatment on the viability of chondrocytes 
cultured in alginate beads after one-day treatment culture.
0 1.E-09 1.E-08 1.E-07 5.E-07 IE -06 X 0 1.E-09 1.E-08 1.E-07 1 5.E-07 1.E-06
zoledronate (M ) X zoledronate (M)+IL-1a 10 ng/ml
Treatment
Bovine articular chondrocytes cultured in alginate beads in the presence of treatments for one day prior to assessment of 
chondrocyte viability. Values for % cell viability shown as means ± SD (n=6).
Fig. 3.4. Experiment b.a4.1: Bfects of zoledronate (1.E-9 M to 1.E-6 M) 
with and without IL-1ct co-treatment on the viability of chondrocytes 
cultured in alginate beads after two-day treatment culture
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1.E-09 1.E-08 IE -07  , 5.E-07 | tE -06 x
zoledronate (M ) | x
Treatment
1.E-09 | IE -08 | 1.E-07 | 5.E-07 | 1.E-06 
zoledronate (M)+IL-1a 10 ng/ml
Bovine articular chondrocytes cultured in alginate beads in the presence of treatments for two days prior to assessment 
of chondrocyte viability. Values for % cell viability shown as means ± SD (n=6).
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Fig. 3.5. Experiment b.a5.1: Effects of zoledronate (1.E-8 M to 1.E-4 M) 
with and without IL- 1a co-treatm ent on the viability of chondrocytes 
cultured in alginate beads after two-day treatment culture
*
1.E-08 tE -07 tE -06  1.E-05 1.E-04 X 0 1.E-08 tE -07 1.E-06 1.E-05
zoledronate (M ) X zoledronate(M)+IL-1a 10 ng/ml
Treatment
Bovine articular chondrocytes cultured in alginate beads in the presence of treatments for two days prior to assessment 
of chondrocyte viability. Values for % cell viability shown as means ± SD (n=6). *P=0.003 vs. zoledronate OM.
Fig. 3.6. Experiment b.a6.2: Effects of zoledronate (1.E-10 M to 1.E-4 M) with and 
without IL- 1a co-treatment on the viability of chondrocytes cultured in alginate 
beads after two-day treatment culture.
i
f
1.E-10 1.E-09 1.E-08 tE -07 , 1.E-06 | 1.E-05 1.E-04
zoledronate (M ) f  x
Treatment
1.E-10 1.E-09 1.E-08 1.E-07 | 1.E-06 j  1.E-05 | 1.E-04
zoledronate (M )+ IL-1a 10 ng/rri
Bovine articiiar chondrocytes cultured in alginate beads in the presence of treatments for two days prior to assessment of chondrocyte 
viability. Values for%cell viability shown as means ±SD (n=6). *P<0.001 vs. zoledronate OM. **P=£).003 vs. zoledronate OM + IL-1a 10 ng/ml.
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Table 3.4. Results summary from four experiments for effects of zoledronate (1 .E-12 M to 1 .E-4 M) with and without IL-1 a co-treatment on chondrocyte viability after one-day or 
two-day treatment culture
Treatment Mean 
% cell 
viability of 
control
Difference (A) in mean % cell viability between control and treatment and significance level of the difference (P*)
culture IL-1 a 
co-treatment 
(ng/ml)
Zol 10'12 M Zol 10‘10 M Zol 10'9 M Zol 10"8 M Zol 10‘7 M
Exp.
duration
(days) A P A P A P A P A P
b.a2 1 010
94.4
94.8
+0.8
+0.9
.934
.980
-0.2
-0.7
>.999
.995
-0.1
-2.3
>.999
.523
-0.1
-1.9
>.999
.688
b.a4.1
1 010
98.2
97.7
-0.1
-0.4
.992
.904
+0.5
+0.1
.362
.999
-0.2
+0.1
.944
>.999
2 010
96.7
95.0
0
+0.5
>.999
.776
+0.8
+0.3
.695
.975
+0.1
-0.8
>.999
.466
b.a5.1 2 010
92.6
92.9
0
-0.8
>.999
.891
+1.3
-1.5
.253
.373
b.a6.2 2 010
95.2
92.1
+0.5
-0.4
.992
.997
-0.9
-1.8
.895
.254
-0.7
-0.3
.963
>.999
-1.3
-0.4
.630
.999
T reatment Mean
Difference (A) in mean % cell viability between control and treatment and significance level of the
difference (P*)
culture
duration
(days)
IL-1 a 
co-treatment 
(ng/ml)
% cell 
viability of 
control
Zol 5x1 O'7 M Zol 10"8 M Zol 10'6 M Zol 10"4 M
Exp. A P A P A P A P
b.a2 1 010
94.4
94.8
-4.3
-2.4
.002**
.463
-7.4
-10.1
<.001**
<.001**
b.a4.1
1 010
98.2
97.7
+0.7
-0.2
.129
.996
-0.5
-0.4
.277
.847
2 010
96.7
95.0
+0.4
+0.5
.957
.763
-1.1
0
.379
>.999
b.a5.1 2 010
92.6
92.9
+0.2
-1.1
.997
.680
-0.3
-1.5
.987
.384
-2.6
-1.9
.003**
.176
b.a6.2 2 010
95.2
92.1
-1.2
+0.1
.715
>.999
-1.3
+0.3
.571
>.999
-5.7
-3.5
<.001**
.003**
Zol= zoledronate; * As multiple experiments were performed the alpha level to indicate a significant difference between means was set at P=0.01 as described in section 2.3.2; ** Statistically 
significant difference at the P<0.01 level
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A final experiment was carried out to clarify effects for zoledronate 10'4 M. In 
experiment b.a6.2, tissue was sourced from 18 month-old heifers and treatment 
cultures were performed in serum supplemented medium for two days (Table 
3.2). Zoledronate 10'4M decreased cell viability in both basal and IL-1 a co­
treated cultures by 5.7% (P<0.001) and 3.5% (P=0.003) respectively (Fig. 3.6; 
Table 3.4). Again, no effects were seen with lower zoledronate concentrations. 
Table 3.4 summarises the observed effects on chondrocyte viability of the 
zoledronate concentrations tested across the four experiments.
3.5.2 Effects of zoledronate on chondrocyte proliferation and 
proteoglycan synthesis with and without IL-1 a co-treatment
Effects of IL-1 a on chondrocyte proliferation and proteoglycan synthesis
In controls, IL-1 a treatment reduced cell proliferation (measured by 3H-TdR 
incorporation) by 66.1% compared to basal culture (P<0.001). Consistent with 
this finding, cell numbers were also lower with IL-1 a as indicated by a 14.7% 
decrease in bead DNA content (P<0.001). IL-1 a also reduced proteoglycan 
synthesis (measured by 35S 04 incorporation) by 42.3% per culture well 
(P<0.001). When 35S 04 incorporation was normalised for DNA content in the 
beads, the effect of IL-1 a was still evident (24.5% reduction; P<0.001) indicating 
an action on chondrocyte proteoglycan synthesis independent of an effect on 
cell numbers.
Effects of zoledronate on chondrocyte proliferation and proteoglycan 
synthesis without IL-1 a co-treatment
ZoledronatelO-4 M reduced cell proliferation by 8.1% (P<0.001) and bead DNA 
content by14.7% (P<0.001) compared to control (Figs. 3.7 and 3.8). In addition, 
zoledronate 10'4 M inhibited proteoglycan synthesis by 29.5% per culture well 
(P<0.001; Fig. 3.9) and by 17.4% when values were normalised for DNA 
(P<0.001; Fig. 3.10). A 5% reduction in 35S 04 incorporation per culture well was 
seen with 10'5 M zoledronate (P=0.02; Fig. 3.9) but this finding was not
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interpreted to be statistically significant because the data set did not distribute 
normally and the P value was not highly significant. No effects were seen with 
any of the other zoledronate concentrations tested compared to control.
Fig. 3.7. Exp. b.a6.1: Effects of zoledronate (1.E-10 M to 1.E-4 M) with and without 
IL-1a co-treatment on the DNA content of chondrocytes cultured in alginate beads.
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Bovine articular chondrocytes cultured in alginate beads in the presence of treatments for two days prior to analysis of DNA content. 
Values for bead DNA content per culture well shown as means ± SD (n=6). *P<0.001 vs. zoledronate OM.
Fig. 3.8. Exp. b.a6.1: Effects of zoledronate (1.E-10 M to 1.E-4 M) with and without IL-1a 
co-treatment on the proliferation of chondrocytes cultured in alginate beads.
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Treatment
Bovine articular chondrocytes cultured in alginate beads inthe presence of treatments and 3H-TdR for two days. 
Chondrocyteproliferation assessed by amount of radioactive3H-TdR incorporated into DNA in beads at end of culture 
period. Values for radioactivity per culture well shown as means ±SD (n=6). Cpm= counts per minute *P<0.001 vs.
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Fig. 3.9. Exp. b.a6.1: Effects of zoledronate (1.E-10 M to 1.E-4 M) with and without IL-1a 
co-treatment on proteoglycan synthesis in chondrocytes cultured in alginate beads.
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. S  I  Bovine articular chondrocytes cultured in alginate beads in the presenceof treatments and 35S04 for two days. Chondrocyte proteoglycan
^  synthesis assessed by amount of radio act ive^SO* incorporated into proteoglycan in beads and medium at end of culture period. Values 
for radioactivity per culture well (beads + medium) shown as means ± SD (n=6). cprrt= counts per minute. *P=^).02 or **P<0.001vs. 
zoledronateOM. ***P=0.022 vs. zoledronateOM +IL-1n 10 ng/ml.
Fig. 3.10. Exp. b.a6.1: Effects of zoledronate (1.E-10 M to 1.E-4 M) with and without IL-1a 
co-treatment on proteoglycan synthesis (normalised for DNA content) in chondrocytes 
cultured in alginate beads.
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T reatm ent
Bovine articular chondrocytes cultured in alginate beads in the presence of treatments and 35S04for two days. Chondrocyte proteoglycan 
synthesis assessed by amount of radioactive^SOA incorporated into proteoglycan in beads and medium at end of culture period. Values 
for radioactivity per culture well (beads + medium) normalised for DNA content shown as means ± SD (n=6). cpm= counts per minute.
*P<0.001 vs.zoledronateOM. **P=O.025vs. zoledronateOM +IL-1a10 ng/ml.
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Effects of zoledronate on chondrocyte proliferation and proteoglycan 
synthesis with IL-1 a co-treatment
With IL-1 a co-treatment, no zoledronate treatment effects were observed on cell 
proliferation or bead DNA content (Figs. 3.7 and 3.8) compared to IL-1a-treated 
control. However, zoledronate 10'4M did reduce proteoglycan synthesis by 
8.0% per culture well (P=0.022; Fig. 3.9) or by 7.5% after normalising for DNA 
(P=0.025; Fig. 3.10).
3.6 Discussion
The aims behind the experiments described in this chapter were to determine 
whether zoledronate has adverse effects on chondrocytes and whether the 
bisphosphonate can stimulate chondrocyte proteoglycan synthesis. Treatment 
effects on chondrocyte viability, proliferation and proteoglycan synthesis were 
examined in bovine articular chondrocytes cultured in alginate beads with and 
without IL-1 a co-treatment as a stimulus for OA metabolic change.
Culture model
When chondrocytes isolated from bovine articular cartilage were cultured in 
alginate beads for up to two days with and without IL-1 a stimulation, the cells 
demonstrated good viability ranging from 92.1% to 98.2% (Table 3.3). In 
addition, the cells were shown to synthesise proteoglycan (as measured by 
35S 0 4 incorporation; Figs. 3.9 and 3.10), a phenotypic characteristic of 
chondrocytes, and proliferate (as measured by 3H-TdR incorporation; Fig. 3.8). 
These findings support the use of this model to investigate chondrocyte 
metabolism.
For the two-day culture period, IL-1a 10 ng/ml decreased cell viability in one out 
of three experiments (Table 3.3) and inhibited chondrocyte proliferation and 
proteoglycan synthesis in a single experiment (Figs. 3.7 to 3.10). These findings 
are consistent with previous reports of increased apoptosis, reduced cell 
proliferation and reduced proteoglycan synthesis following IL-1 a exposure in
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bovine articular chondrocytes (Badger et al. 1999; Schuerwegh et al. 2003). 
Such adverse effects on chondrocytes support the concept that the IL-1 a plays 
a regulatory role in chondrocyte metabolism and is involved in promoting 
articular cartilage degradation during the OA process.
Effects of zoledronate on chondrocyte viability, proliferation and 
proteoglycan synthesis
The effects of zoledronate on chondrocyte viability (zoledronate 10‘12 M to 
10'4 M), and chondrocyte proliferation and proteoglycan synthesis (zoledronate 
10'10 M to 10*4 M) have been evaluated under basal or IL-1 a co-treated 
conditions. Zoledronate 10 4 M consistently reduced cell viability under basal 
culture conditions (Figs. 3.1, 3.2, 3.5 and 3.6). With IL-1a co-treatment, 
zoledronate 10-4 M decreased chondrocyte viability in three out of four 
experiments (Figs. 3.1, 3.2, 3.5 and 3.6). The absolute reductions in % cell 
viability were small in size ranging from 2.8% to 10.5%.
In one of the four experiments, and only under basal culture conditions, 
zoledronate 10'6M treatment reduced chondrocyte viability by 4.6% (experiment 
b.a2; Fig. 3.1). Though this is an isolated finding, the significance level 
(P=0.002) indicates a genuine result. The lack of reproducibility may be due to 
an inter-experimental difference in the vulnerability of chondrocytes to toxicity 
arising from differences in methodology between experiments (see Table 3.2 for 
summary of methods). Adult bovine cartilage from the metacarpal articular 
surface of the MCP joint was used in all experiments, though other unknown 
characteristics of the tissue source may have been important for determining 
chondrocyte vulnerability in vitro (e.g. bovine breed, animal weight or history of 
joint injury). Alternatively, the lack of a pre-culture period to stabilise 
chondrocytes prior to commencing treatment in one of the four experiments 
(exp. b.a2 in which reduced chondrocyte viability was observed with 
zoledronate 10‘6 M) could have been important. Chondrocytes that are cultured 
in alginate demonstrate initial cell loss (van Susante et al. 1995), suggesting
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that chondrocytes that do not undergo initial pre-culture stabilisation may be 
more susceptible to toxic treatment effects.
Taken together the results from the four cell viability experiments indicate that 
zoledronate 10'4 M treatment is clearly adverse for the viability of bovine 
articular chondrocytes from the bovine MCP joint and this appears to be a 
biological effect across bovine animals of a similar age. These findings are 
consistent with reported effects of zoledronate on other cell types. At 
zoledronate concentrations 10'4 M and above, the bisphosphonate has been 
found to cause apoptosis of rabbit osteoclasts (Benford et al. 2001), human 
bone marrow stromal cells and human myeloma cells (Derenne et al. 1999). 
Furthermore clodronate, pamidronate and risedronate, all at the concentration 
of 10'3 M, have been shown to cause necrosis of bovine articular chondrocytes, 
(Van Offel et al. 2002). Thus, bisphosphonates as a class, at high 
concentrations, appear to reduce chondrocyte survival.
Zoledronate 10'4 M also inhibited chondrocyte proliferation under basal culture 
conditions (Figs. 3.7 and 3.8) and, with or without IL-1 a co-treatment, reduced 
proteoglycan synthesis (Figs. 3.9 and 3.10). The observed reductions in 
chondrocyte proliferation are consistent with previous reports which have found 
inhibitory effects of zoledronate on the proliferation of human foetal osteoblasts 
(zoledronate 10'5 M and 10'4 M) (Reinholz et al. 2000) and human myeloma 
cells (zoledronate 5x1 O'5 M to 10'4 M) (Derenne et al. 1999). Considering 
bisphosphonates as a class, the detrimental effects of zoledronate on 
chondrocyte proteoglycan synthesis are similar to reported inhibitory effects of 
etidronate and clodronate on canine cartilage proteoglycan synthesis (Palmoski 
and Brandt 1978) but discordant with a study that found a stimulatory effect of 
clodronate on rabbit chondrocyte proteoglycan synthesis (Guenther et al. 1979).
The mechanisms of action of the observed adverse effects of zoledronate on 
chondrocyte viability, proliferation and proteoglycan synthesis are unknown.
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Reduced levels of chondrocyte viability may occur via stimulation of cell 
apoptosis. Such an effect might occur via inhibition of FPP synthase in the 
mevalonate pathway, which is the probable mechanism behind induction of 
rabbit osteoclast apoptosis seen with zoledronate treatment (Benford et al. 
2001). Chelation of divalent cations by zoledronate is a possible mechanism for 
the inhibition of chondrocyte proteoglycan synthesis since calcium ions are 
stimulatory for proteoglycan synthesis in cartilage (Shulman and Opler 1974).
Overall, the results from the series of experiments described in this chapter 
indicate that zoledronate 1C4 M is detrimental for bovine articular chondrocytes 
from the MCP joint. This concentration was used to limit the upper range of 
subsequent experiments that evaluated the effects of the bisphosphonate on 
proteoglycan metabolism. The findings also have implications for the clinical 
use of zoledronate in that it would be advisable to avoid exposing cartilage to 
high concentrations of the bisphosphonate.
No information was found to support the hypothesis that zoledronate can 
enhance on cartilage proteoglycan metabolism during the OA process. 
Zoledronate treatments at concentrations 10'10 M through 10‘4 M were not 
observed to stimulate chondrocyte proteoglycan synthesis, nor demonstrate any 
protective effects on the inhibitory actions of IL-1 a. The negative findings 
suggest that if zoledronate can improve the retention of cartilage proteoglycan 
in OA, the mechanism may be through inhibition of proteoglycan degradation.
3.7 Conclusions
. Culture of bovine articular chondrocytes in alginate beads provides a model 
for studying cell metabolism in which chondrocytes remain viable, proliferate 
and synthesise proteoglycan. Addition of IL-1 a to the culture system 
produces adverse effects on chondrocyte proliferation and proteoglycan 
synthesis and, possibly, chondrocyte viability.
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. Zoledronate 10'4 M has detrimental effects on bovine articular chondrocyte 
viability, proliferation and proteoglycan synthesis. It would be advisable to 
avoid exposing cartilage to high concentrations of zoledronate during clinical 
use.
. Since adverse effects were observed, zoledronate 10'4 M was used as the 
upper limit of the concentration range to investigate in further in vitro studies 
of chondrocyte or cartilage metabolism. The lower end of this range, 
zoledronate 10‘10 M, was defined by zoledronate concentrations reported to 
have effects on cell or enzyme processes in vitro (Table 3.1).
. No evidence was demonstrated to support the hypothesis that zoledronate 
can conserve cartilage GAG content during the OA process through 
stimulating chondrocyte proteoglycan synthesis or preventing the inhibitory 
effect of IL-1 a on proteoglycan synthesis. An alternative mechanism of action 
for zoledronate that has yet to be investigated is an inhibitory effect on 
proteoglycan degradation in cartilage.
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Chapter 4. Effects of zoledronate on IL-1a-stimulated proteoglycan 
degradation in bovine articular cartilage explants
This chapter describes experiments that tested for effects of zoledronate on IL- 
1a-stimulated proteoglycan degradation in bovine cartilage explants.
4.1 Introduction
The investigations described in this chapter were performed to continue testing 
the hypothesis that zoledronate can modify cartilage metabolism to reduce the 
loss of cartilage GAG during the OA process. Results from investigations 
detailed in Chapter 3 do not indicate that zoledronate has a beneficial effect on 
the amount of proteoglycan synthesised by chondrocytes. In this chapter 
attention has turned towards examining for an effect on the other side of the 
metabolic balance: the degradation of proteoglycan in cartilage.
MMPs and aggrecanases are proteinases implicated in the degradation of 
aggrecan and type II collagen in OA cartilage (discussed in section 1.2.3.5) and 
there has been considerable interest in inhibiting the activities of these enzymes 
as a therapeutic strategy to prevent joint destruction in arthritic disorders 
including OA (Clark and Parker 2003; Elliott and Cawston 2001). At the 
biochemical level, studies have demonstrated that zoledronate and other 
bisphosphonates can inhibit the activities of various MMPs at bisphosphonate 
concentrations in the range 2x1 O'5 M to 10‘3 M (Heikkila et al. 2002; Konttinen et 
al. 1999; Teronen et al. 1997a; Teronen et al. 1997b; Teronen et al. 1999) 
(Table 1.9). In addition, since MMPs and aggrecanases share common 
inhibitors (Hughes et al. 1998), it is possible that bisphosphonates can also 
inhibit aggrecanase activity.
At the cell or tissue level, bisphosphonates other than zoledronate have been 
found to have effects on chondrocyte-mediated proteinase activity, though 
findings are conflicting as to the direction of effect. Pamidronate was observed
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to increase collagenase activity (Evequoz et al. 1985) and proteoglycan 
degradation (Couchman and Sheppeard 1986); clodronate to decrease 
collagenase activity (McGuire et al. 1982); tiludronate to reduce proteinase 
activity (Emonds-Alt et al. 1985); and etidronate to both increase collagenase 
activity (Evequoz et al. 1985) and decrease proteinase activity (Emonds-Alt et 
al. 1985; McGuire et al. 1982). The inhibitory effects on chondrocyte-mediated 
proteinase activity were observed at bisphosphonate concentrations in the 
range 10'5 M to 10'3 M (Table 1.9).
It is not known whether zoledronate can inhibit cartilage proteoglycan 
degradation at the tissue level. The principal investigations described in this 
chapter have sought this information in bovine articular cartilage explants 
stimulated with IL-1a to induce GAG release (model described in section 2.2.1).
4.2 Experimental hypothesis 
Zoledronate 10'10 M to 10*4 M reduces IL-1a-stimulated GAG release 
from bovine articular cartilage explants 
4.3 Experimental objectives
i) Culture bovine articular cartilage explants with and without zoledronate 
(10'1° M to 10*4 M) and with and without 10 ng/ml IL-1a
ii) Measure GAG content in explant and in medium
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4.4 Materials and methods
4.4.1 Tissue culture and treatments
Bovine cartilage explants prepared and pre-cultured as detailed in section 
2.3.1.1. Single explants were placed in individual wells of 24-well tissue culture 
plates (Orange Scientific NV/SA, Braine-l’Alleud, Belgium). One ml of serum- 
free DMEM supplemented with or without 10 ng/ml recombinant human IL-1 a 
(tebu-bio, Peterborough, UK) and various concentrations of zoledronate (2- 
[imidazol-1-yl]-hydroxy-ethylidene-1,1-bisphosphonic acid, disodium salt, 4.75 
hydrate; MW 401.6; donated by Novartis Pharma AG, Basel, Switzerland) was 
added to each well and explants were maintained in culture for four days. A 
four-day IL-1 a stimulation period was used based on previously described 
methods in studies of aggrecan catabolism (Caterson et al. 2000; Little et al. 
1999). At the end of the culture period, the cartilage explants (approx wet 
weight 10-15 mg) and conditioned medium were collected and stored 
separately at -20°C until biochemical analysis of GAG content.
Five experiments were performed to test for effects of zoledronate. For each 
separate experiment, cartilage was sourced from the metacarpal surfaces of a 
single MCP joint (Fig. 4.1). Tissue source characteristics and the zoledronate 
concentrations evaluated for the five experiments are detailed in Table 4.1.
During the course of the experiments, notable intra-experimental variability in 
cartilage GAG release was encountered (described more fully below). In order 
to define this variability a preliminary experiment was performed to examine the 
effect of topographical sampling on IL-1a-stimulated GAG release. The 
metacarpal articular surface was arbitrarily divided into three equal transverse 
bands (dorsal, central and palmar) and cartilage explants were sampled from 
these three regions (Fig. 4.1). Explants were cultured with and without IL-1 a 
10 ng/ml as described above.
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Metacarpal articular 
surfaces
Phalangeal articular 
surfaces
Fig. 4.1. Photograph showing the articular surfaces of a bovine metacarpophalangeal 
joint. Joint capsule and ligaments have been dissected to open joint and reveal articular 
surfaces. For experiments examining effects of zoledronate on cartilage, explant samples 
were taken only from the metacarpal surface. For an experiment investigating 
topographical differences in cartilage metabolism, the metacarpal articular surfaces of a 
single joint were arbitrarily divided into three equal transverse bands (dorsal, central and 
palmar) and separate pools of explant samples were taken from each of these regions.
Table 4.1. Summary of tissue source characteristics and zoledronate concentrations 
tested for experiments evaluating the effects of zoledronate on basal and IL-1a- 
stimulated GAG release in bovine articular cartilage explants
Exp.
Animal tissue 
source Number of replicates Zoledronate concentration tested (M)
Age Sex
b.el 18 months N/A n=2 10‘8 10‘7 10’6 10‘5 10'4
b.e2.b 16 months heifer n=6 10*9 10'8 10'7 10-6 10'5
b.e2.w 16 months heifer n=6 10'9 10'8 10’7 10'6 10'5
b.e3.2 20-24 months steer n=6 10'10 10'9 10'8 10'7 10‘6
b.e3.3 20-24 months steer n=6 10’10 10'9 10*8 10'7 10’6
Regions of metacarpal 
articular surfaces:
DORSAL
CENTRAL
PALMAR
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4.4.2 Biochemical analysis
GAG quantification
Post culture cartilage explants were digested with 125 pg/ml papain (Sigma- 
Aldrich, Poole, UK), 5 mM cysteine-HCI (BDH) and 5 mM sodium EDTA (BDH) 
in PBS adjusted to pH 6 with 1M NaOH (BDH) at 60°C for 12 h and then stored 
at -20°C. The GAG content of papain digests and medium was measured as 
sulphated glycosaminoglycan using the dimethylmethylene blue (DMMB; 
Sigma-Aldrich) colorimetric assay and chondroitin sulphate-C (Sigma-Aldrich) 
as the standard based on previously described methods (Farndale et al. 1986). 
Forty pi aliquots of standard in deionised distilled water or sample were placed 
in separate wells of 96 well flat bottom EIA microtitre plates (MP Biomedicals; 
Cambridge, Cambs, UK). A 250 pi aliquot of a solution containing 16 pg/ml 
DMMB in 1% (v/v) ethanol (BDH), 29.5 mM NaOH and 0.343% (v/v) formic acid 
(BDH) was added to each well and absorbance at 540 nm ( A 5 4 0 )  measured 
using a microplate reader (Bio-Rad model 3550; Bio-Rad Laboratories, Hemel 
Hempstead, Herts, UK). Reproducibility: intra-assay CV 0.37%; inter-assay CV 
1.96%. To exclude the possibility of an effect of zoledronate on this assay, A54o 
was measured on solutions containing 20 mcg/ml chondroitin sulphate-C and/or 
zoledronate 10'7 M to 10'4M. Zoledronate did not demonstrate an effect on A540. 
The amount of GAG release was expressed as a percentage and calculated as 
follows:
%GAG release = medium GAG content/ (medium GAG content + explant GAG content)
4.4.3 Statistical analyses
Statistical analyses were performed as described in section 2.3.2. For data 
relating to experiments evaluating zoledronate treatment, multiple comparisons 
between zoledronate-treated and untreated control were made with 
Dunnett’s t test. For the topographical sampling experiment multiple 
comparisons between sample regions were made using the Bonferroni test.
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4.5 Results
Effects of IL-1 a on GAG release (Table 4.2)
Control bovine articular cartilage explants released small amounts of GAG in 
basal culture (mean GAG release ranged from 5.9%to 15.1%). For IL-1a- 
stimulated controls, mean GAG release ranged from 36.9% to 62.9%. 
Differences in GAG release between IL-1a-treated controls and basal controls 
were significant at the P<0.001 level.
Table 4.2. GAG release from bovine articular cartilage explants with and without IL-1 a 
stimulation in controls.
Experiment Mean %GAG release from controls (SD) P value for difference 
between meansControl IL-1a-treated control
b.el 15.1 (1.1)* 36.9 (1.9)* N/A+
b.e2.b 11.5 (4.4)** 60.5(15.2)** P<0.001
b.e2.w 13.1 (3.9)** 62.9 (9.0)** P<0.001
b.e3.2 5.9 (0.9)** 46.1 (11.7)** P<0.001
b.e3.3 7.2 (0.9)** 59.8 (5.3)** P<0.001
*n=2. **n=6. +Statistical testing not performed since n=2.
Effects of zoledronate on GAG release with and without IL-1 a stimulation
The first experiment performed to evaluate effects of zoledronate was 
experiment b .e l. Though the experiment had been designed to be performed in 
triplicate (n=3), a technical issue meant that one set of samples was unavailable 
for GAG biochemical analysis. As only two observation were available for each 
treatment group (n=2) and the data also exhibited marked inhomogeneity of 
variance (Fig. 4.2), statistical comparisons were not performed.
In the four other experiments (Figs. 4.3 to 4.6), the effects of zoledronate at 
concentrations 10'10 M through to 10‘5 M were examined in the culture model.
No effects of the bisphosphonate were observed on either unstimulated or IL-
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1a-stimulated GAG release. The intra-experimental co-efficient of variation in 
IL-1a-stimulated GAG release, the main outcome measure of interest, was 
found to range from 8.9% to 25.4% in the four experiments (Table 4.3).
Table 4.3. Intra-experim ental variation in IL-1a- 
stimulated GAG release from bovine articular 
cartilage explants.
Experiment Co-efficient of variation (CV) for 
IL-1a-stim ulated GAG release
b.e2.b 25.1%
b.e2.w 14.3%
b.e3.2 25.4%
b.e3.3 8.9%
Mean CM 18.4%
Fig. 4.2. Exp. b .e l: Effects of zoledronate (1.E-8 M to 1.E-4 M) on basal and 
IL-1a-stimulated GAG release in bovine cartilage explants.
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Bovine articular cartilage explants cultured in the presence of treatments for four days. Values for °/<GAG release shown as means ± SD 
(n=2). Statistical comparisons of means not performed as n=2.
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Fig. 4.3. Exp. b.e2.b: Effects of zoledronate (1.E-9 M to 1.E-5 M) on basal and IL-1a- 
stimulated GAG release in bovine cartilage explants
1.E-09 1.E-06 1.E-05IE -08 IE -07
zoledronate (M)
1.E-09 j 1.E-08 j 1.E-07 | IE-06
zoledronate (M) + IL-1Q 10ng/ml
Treatment
Bovine articdar cartilage explants cultured in the presence of treatments for four days. Values for °/GAG release shown as means tS D  (n=6).
Fig. 4.4. Exp. b.e2.w: Effects of zoledronate (1.E-9 M to 1.E-5 M) on basal and IL-1a- 
stimulated GAG release in bovine cartilage explants.
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Bovine articular cartilage explants cultured in the presence of treatments for four days. Values for °/.GAG release shown as means ± SD (n=6).
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Fig. 4.5. Exp. b.e3.2: Effects of zoledronate (1.E-10 M to 1.E-6 M) on basal 
and IL-1a-stimulated GAG release in bovine cartilage explants.
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Bovine articular cartilage exp Ians cultured in the presence of treatments for four days. Values for °/<GAG release shown as means ± 
SO (n=6).
Fig. 4.6. Exp. b.e3.3: Effects of zoledronate (1.E-10 M to 1.E-6 M) on basal 
and IL-1a-stimulated GAG release in bovine cartilage explants.
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Bovine articular cartilage explants cultured in the presence of treatments for four days. Values for °/<GAG release shown as 
means ± SD (n=6).
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Variation in GAG release across the joint surface
The marked variation in GAG release of cartilage explants from a single 
articular surface prompted an experiment to examine whether the site of 
cartilage sampling could contribute to variability. In this experiment the rounded 
metacarpal articular surfaces of a single joint were arbitrarily visually divided 
into three equal transverse bands (dorsal, central and palmar; Fig. 4.1). The 
amounts of GAG released, with and without IL-1 a stimulation, from cartilage 
explants taken from each of the three joint regions were compared.
Combining the three regions, the mean %GAG release from explants was 
10.2% for unstimulated cultures and 55.7% with IL-1 a stimulation (P<0.001 for 
difference between means). In unstimulated culture there was no difference in 
explant GAG release between different regions (Fig. 4.7). IL-1a-stimulated GAG 
release from explants sampled from the central region (mean 62.5%) was 
greater than that for explants from the dorsal region (mean 53.3%; P=0.026) or 
palmar region (mean 51.3%; P=0.005). The stimulated GAG release for the 
latter two regions did not differ.
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Fig. 4.7. Exp. b.e3.1: Basal and IL-1a-stimulated GAG release 
from bovine cartilage explants sampled from dorsal, central 
and palmar regions of the metacarpal articular surfaces of a 
single MCP joint.
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Topographical site of explant sample
Bovine articular cartilage explants cultured for four days. Values for °/<GAG release shown as means ±SD (n=6). 
*P=0.026 vs. dorsal with IL-1a and P=0.005 vs. palmar with IL-1a
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4.6 Discussion
Effects of IL-1 a in the culture model
In the series of experiments, IL-1 a 10 ng/ml exposure consistently stimulated 
GAG release in cartilage explants compared to control cultures (Table 4.2). This 
catabolic response is consistent with previous reports (Caterson et al. 2000;
Little et al. 1999) and supports the use of the culture model to investigate 
cartilage proteoglycan degradation.
Effects of zoledronate on cartilage GAG release with and without IL-1 a 
stimulation
Zoledronate treatment at concentrations 10"10 M to 10'5 M did not demonstrate 
any beneficial effects on the amount of GAG released from cartilage in the 
absence or presence of IL-1 a stimulation. Since separate experiments utilised 
tissue sourced from different animals (Table 4.1), the negative finding is more 
likely to be biologically relevant. Thus, in this series of experiments, no 
information was demonstrated to support the hypothesis that zoledronate can 
modify cartilage metabolism to reduce the loss of cartilage GAG during the OA 
process.
Intra-experimental variation for the culture model
However, these results need to be interpreted in light of the marked variability in 
GAG release observed within experiments that could have limited sensitivity for 
detecting treatment effects (Figs. 4.2 to 4.6; Table 4.2). Across the four 
experiments in which n=6 per treatment group, the intra-experimental coefficient 
of variation for IL-1a-stimulated GAG release, the main outcome measure of 
interest, ranged from 8.9% to 25.4% (mean 18.4%). With these levels of 
variation, sample size calculations indicate that, in order to detect a 10% 
difference in GAG release between independent control and treatment groups 
(a=0.05) with 80% power, sample sizes of at least 13 (n=13) or up to 102 
(n=102) per treatment group would be needed. Clearly the experiments that
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have been performed were underpowered to find zoledronate treatment effects 
that produced 10% differences in IL-1a-stimulated GAG release.
One possible source for the observed variability was experimental technique. In 
initial experiments, relative inexperience with laboratory technique may have 
introduced between-sample variation. However, even towards the later stages 
of the project, intra-experimental variation remained notable (Figs. 4.5 and 4.6). 
Interestingly, the cutting of articular cartilage explants has been found to have 
metabolic effects such as the release basic fibroblastic growth factor (a 
proposed extracellular mechanotransducer involved in the regulation of tissue 
turnover) (Vincent et al. 2002; Vincent and Saklatvala 2006), the induction of IL- 
1 (Gruber et al. 2004) and also the stimulation of cell proliferation and matrix 
synthesis at the wound edge (Redman et al. 2004). Thus, differences in the way 
that cartilage explants were excised during tissue preparation may have 
contributed to between-sample variation. An alternative explanation is that, in a 
similar fashion to reported topographical differences in cartilage matrix 
composition across the joint surface (Bayliss et al. 1999; Bayliss et al. 2001; 
Brama et al. 2000), cartilage metabolism also exhibits topographical variation 
according to sample site.
Variation in IL-1a-stimulated GAG release across the joint surface
In a single preliminary experiment, cartilage was sampled from the metacarpal 
articular surface of a single bovine MCP joint. Explants from the central region 
of the metacarpal articular surface released more GAG in response to IL-1 a 
10 ng/ml compared to samples taken from either the dorsal or palmar region 
(Fig 4.7). This sampling effect on IL-1a-stimulated GAG release offers a partial 
explanation for the high variability that was observed previously.
The results suggest that different regions of the bovine MCP joint have different 
vulnerabilities to IL-1a-induced cartilage degradation. If these susceptibilities 
were to correlate with areas that commonly develop cartilage loss in OA, this 
would provide an explanation for the focal nature of cartilage loss that is often
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seen during the OA process. In support of this concept, GAG release in 
response to IL-1 p has been found to vary in cartilage from different anatomical 
locations on human OA knee joints (Barakat et al. 2002). However, another 
study that investigated susceptibilities of equine cartilage to various cytokines 
(including IL-1) in relation to regions of the joint with known high or low 
vulnerabilities to degeneration in OA did not observe regional differences in 
response to catabolic cytokines that could explain the localisation of focal 
cartilage degeneration in OA (Little et al. 2005).
How to test the general hypothesis further
Increasing the sample size would be one way to evaluate zoledronate for small 
10% sized treatment effects on GAG release. However, the metacarpal articular 
surfaces of a single MCP joint only yield approximately 80 cartilage explants 
which would be inadequate since, from sample size calculations (see above this 
section), up to 102 samples per treatment group would be needed. Ways to 
increase numbers include pooling samples from both metacarpal and 
phalangeal joint surfaces, pooling samples from other MCP joints (either from 
the same animal or another animal) or taking smaller and more numerous 
cartilage explants from the articular surface, though it is likely that variability will 
be increased with each of these techniques. Additional evaluation of these 
methods to determine feasibility and, in addition, reproducibility of GAG release 
would be required prior to use of the model to continue testing the general 
hypothesis.
An alternative approach is to use a culture model in which sources of metabolic 
variation are minimised. In the next chapter, experiments are described that 
further test the general hypothesis in the bovine chondrocyte/ alginate bead 
culture system, a model that demonstrates less inherent variability for IL-1a- 
stimulated GAG release than the bovine cartilage explant culture model.
4.7 Conclusions
• The culture of bovine articular cartilage explants with IL-1 a 10 ng/ml to 
stimulate GAG release provides an in vitro culture model for studying 
cartilage proteoglycan degradation.
• There is noticeable variability in IL-1a-stimulated GAG release from 
cartilage sampled from the metacarpal articular surfaces of the bovine 
MCP joint. This variability may be partly explained by regional differences 
in the susceptibility of cartilage to IL-1 a across the joint surface.
• Zoledronate treatment in the concentration range 10'10 M to 10'5 M was 
not observed to reduce IL-1a-stimulated GAG release from bovine 
articular cartilage explants. Thus, no evidence was found to support the 
hypothesis that zoledronate can modify cartilage metabolism to reduce 
the loss of cartilage GAG during the OA process.
• The studies were under-powered to investigate for small-sized effects 
(e.g. 10%) with zoledronate treatment. An alternative culture model, with 
less inherent variability, should be more suitable for this purpose.
Chapter 5. Effects of zoledronate on IL-1a-stimulated proteoglycan 
degradation in bovine articular chondrocytes cultured in alginate beads
This chapter describes experiments that tested for the effects of zoledronate on 
IL-1a-stimulated proteoglycan degradation in a chondrocyte-matrix culture 
model.
5.1 Introduction
In the experiments detailed in Chapter 4, zoledronate treatment (10"1° M to 
10‘5 M) was not seen to alter IL-1 a stimulated GAG release in bovine articular 
cartilage explants. However, a small-sized effect may have been missed since 
the studies were underpowered to detect 10% differences between treatment 
and control. One approach to pursuing the possibility of small-sized treatment 
effects is to use a culture model with less variability. In the cartilage explant 
culture model, possible sources for between-sample variability in 
IL-1a-stimulated GAG release include (i) topographical variation in the 
susceptibility of cartilage across an articular surface to the effects of IL-1 a and 
(ii) variation introduced during tissue processing when cartilage explants are cut 
(discussed in section 4.6).
The bovine chondrocyte/ alginate bead model (described in section 2.3.1.2) 
offers the potential to remove or average-out these sources of variation. Since 
this culture technique involves isolating chondrocytes from cartilage, the 
existing matrix with its attendant variability is removed from the culture system. 
Subsequent mixing of the cell suspension redistributes and averages out 
metabolic cellular differences. For the study of chondrocyte-matrix interactions, 
the chondrocytes can then be cultured in the alginate beads to grow a cartilage- 
like matrix (Hauselmann et al. 1996b; Petit et al. 1996). Variation in the matrix 
newly synthesised by chondrocytes is likely to be minimal since all the cells 
come from the same homogenised pool.
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The studies described in this chapter investigate the effects of zoledronate on 
IL-1a-stimulated proteoglycan degradation in the bovine chondrocyte/ alginate 
bead culture model. Initially, some experiments are described that were 
performed to validate the model by characterising how stimulus duration and 
IL-1 a concentration affect GAG release.
5.2 Experimental hypotheses
A. To validate the culture model
A1. The amount of GAG release from alginate beads containing a 
matrix established by bovine articular chondrocytes is 
dependent on the duration of stimulus with IL-1 a 10 ng/ml.
A2. The amount of GAG release from alginate beads containing a 
matrix established by bovine articular chondrocytes is 
dependent on the concentration of IL-1 a used as a stimulus.
B. To evaluate zoledronate treatment effects
Zoledronate 10*8 M to 10-4 M reduces IL-1a-stimulated GAG release 
from alginate beads containing a matrix established by bovine 
articular chondrocytes
5.3 Experimental objectives
i) Culture bovine articular chondrocytes in alginate beads to establish an 
extracellular matrix.
ii) Measure GAG release from alginate beads stimulated by IL-1 a 10 ng/ml 
as a function of time (one, two or five days). Select duration of IL-1 a
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stimulus to use in further experiments.
iii) Measure IL-1a-stimulated GAG release from alginate beads as a function 
of IL-1 a concentration (0.05 ng/ml to 20 ng/ml). Select concentrations of 
IL-1 a to use for further experiments.
iv) Measure IL-1a-stimulated GAG release with and without zoledronate 
treatment at concentrations 10‘8 M to 10'4 M in the culture model.
Note: Objective (iii) was undertaken late on in the studies. Prior to information 
on GAG release as a function of IL-1 a concentration being available for the 
model, IL-1 a 10 ng/ml was used as the stimulus for GAG release in experiments 
of objective (iv) based on the concentration of IL-1 a that was found to effectively 
stimulate GAG release in the cartilage explant model (section 4.5).
5.4 Materials and methods
5.4.1 Chondrocyte culture in alginate beads
Alginate beads containing isolated bovine chondrocytes were formed as 
detailed in Chapter 2, Materials and methods. Culture to establish 
extracellular matrix: Beads were cultured in 225 cm2 tissue culture flasks 
maintained in DMEM + 10% or 20% FCS for 21 to 42 days with medium 
changes three times a week. Tissue source characteristics for chondrocytes 
and differences in culture conditions between experiments are summarised in 
Tables 5.2 and 5.3. Treatment culture: After the matrix-establishing culture 
period beads were washed 3 times for 10 minutes each in serum-free DMEM. 
Six beads were placed in individual wells of 24-well tissue culture plates to 
which was added 1 ml of serum-free DMEM supplemented with or without IL-1 a 
and with or without zoledronate treatments. Concentrations of IL-1 a and 
zoledronate used in different experiments are detailed in Tables 5.2 and 5.3. 
Each well represented one replicate and treatment cultures were performed 
replicates of three to six. Beads were maintained in medium for 1, 2 or 5 days. 
At the end of the treatment culture period beads and medium were harvested
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and stored separately at -20°C until biochemical analysis. A typical time line for 
chondrocyte/ bead culture is shown in Table 5.1.
Tab le  5.1. Typical even t tim e  line fo r the bovine ch ondrocyte / a lg inate bead cu lture m odel used in 
experim ents d eta iled  in C hapter 5.
Day o f cu lture
-1 0 0-35 35-37 37
Event
Cartilage 
excised off joint 
surface and 
digested to 
release 
chondrocytes
Formation of 
alginate beads 
containing 
chondrocytes
Culture of beads in 
DMEM + 20%
FCS with medium 
change 3x a week 
to establish matrix
Treatment 
culture of beads 
in serum-free 
DMEM ± IL-a ± 
Zol
Beads and 
medium 
harvested for 
analysis of 
GAG content
DMEM= Dulbecco’s modified Eagle’s medium; FCS= foetal calf serum; Zol= zoledronate; 
GAG= glycosaminoglycan
5.4.2 Biochemical analysis 
GAG quantification
Alginate beads were disrupted and digested in 1ml of 55 mM sodium citrate 
(BDH), 150 mM sodium chloride (Sigma), 5 mM cysteine hydrochloride , 5 mM 
EDTA (BDH) and 0.56 units/ml papain (Sigma), incubated at 60°C for 24 h 
(Enobakhare et al. 1996). Bead digest and medium GAG content was quantified 
using the DMMB dye method as described in chapter 4, Materials and methods, 
but with the dye adjusted to pH 1.5 to minimise alginate-dye complex formation 
according to previously reported adaptations (Enobakhare et al. 1996). 
Reproducibility: mean intra-assay CV 0.38%; mean inter-assay CV 4.01%. 
Measured GAG release was expressed as percentage released according to 
the following formula:
%GAG release = medium GAG content/ (medium GAG content + bead GAG content)
Table 5.2. S um m ary of cell source characteristics and culture conditions fo r experim ents evaluating IL-1a-stim ulated GAG release as a function of 
IL-1 a  concentration or stim ulus duration in the bovine chondrocyte/ alg inate bead culture model.
Exp. Functionevaluated
C haracteristics of cell 
source
M atrix-establish ing  
culture period; % FCS  
used
Treatm ent cu lture conditions
Replicates IL-1 a  stim ulus (ng/m l) IL-1 a stim ulus  
duration
b.a3.1 Duration of IL-1 a stimulus
1x MCP joint from a single 
heifer aged 20 months 21 days; 10% FCS n=3
0, 10 1, 2 or 5 days
b.a6.5 Concentration of IL- 1a stimulus
7x MCP joints from 4 heifers 
aged 18 months 42 days; 20% FCS n=4
0, 2 , 10 or 20 2 days
b.a7.3 Concentration of IL- 1a stimulus
5x MCP joints from 
5 heifers; ages unknown 23 days; 20% FCS n=4
0, 0.5, 1,2, 10 or 20 2 days
b.a7.4 Concentration of IL- 1a stimulus
5x MCP joints from 
5 heifers*; ages unknown 25 days; 20% FCS n=4
0, 0.05, 0.2, 0.5, 2 or 10 2 days
Exp.= experiment; MCP= metacarpophalangeal; FCS= foetal calf serum; 'different joints to those used in Exp. b.a7.3
Table 5.3. S um m ary of cell source characteristics and culture conditions for experim ents evaluating the effects of zo ledronate treatm ent on IL-1a- 
stim ulated GAG release in the bovine chondrocyte/ a lg inate bead culture model.
Exp. Characteristics of cell source
M atrix-establishing  
culture period; % FCS  
used
Treatm ent culture (all treatm ent cultures perform ed over 2 days)
Replicates IL-1 a  (ng/m l) Zoledronate treatm ent concentrations tested (M)
b.a3.2 1x MCP joint from a single heifer aged 20 months 28 days; 10% FCS n=6 0, 10 10'8 10'7 5x1 O'7
b.a4.2 3x MCP joints from 2 bulls aged 13 months 22 days; 20% FCS n=6 0, 10 10'8 10‘7 10'6
b.a4.4 3x MCP joints from 2 bulls aged 13 months 29 days; 20% FCS n=6 0, 10 10'8 10'7 10'6
b.a5.3 2x MCP joints from 2 heifers aged 24 and 29 months 31 days; 20% FCS n=5 0, 10 10‘7 10'6 10'5 10‘4
b.a6.3 7x MCP joints from 4 heifers aged 18 months 35 days; 20% FCS n=6 0, 10 10'7 10'6 10'5 10’4
b.a7.6 5x MCP joints from 5 heifers*; ages unknown 32 days; 20% FCS n=3 or n=6 0, 0.05 10'7 10'6 10'5 10'4
Exp.= experiment; FCS= foetal calf serum; MCP= metacarpophalangeal
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5.4.3 Statistical analyses
Statistical analyses were performed as described in section 2.3.2. Comparisons 
of means between multiple groups were made using the Bonferroni test, except 
where comparisons were only between treatment groups and control in which 
case Dunnett’s test was used. As previously detailed (section 2.3.2), the alpha 
level was set at P=0.05 for an hypothesis that was tested once and at P=0.01 
for an hypotheses that was tested in multiple experiments.
A linear regression model was used to describe correlation between GAG 
release and IL-1 a concentration in experiments b.a7.3 (assumptions met for 
data normality, equality of variance and linearity).
5.5 Results
5.5.1 Culture model characteristics
Culture of bovine articular chondrocytes in alginate beads to establish 
extracellular matrix (Fig. 5.1)
Culture of chondrocytes in alginate beads increased bead GAG content as a 
function of time, though the rate of GAG accumulation appeared to differ 
between experiments. After approximately one month of culture, GAG content 
ranged from 118 pg to 347 pg GAG per six beads.
GAG release as a function of IL-1 a stimulus duration (Fig. 5.2)
Experiment b.a3.1 investigated basal and IL-1a-stimulated GAG release at 
various time points (one, two and five days). GAG was spontaneously released 
from the beads in basal culture, with similar amounts released for one-day and 
two-day culture (mean GAG release 29.1% and 26.3% respectively; P=0.609) 
but higher amounts at five days (mean GAG release 60.5%; P<0.001 vs. one- 
day or two-day culture).
Fig. 5.1. Matrix synthesis by bovine articular chondrocytes cultured in 
alginate beads: GAG content as a function of time. Results for six different 
experiments.
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Bovine articular chondrocytes cultured in alginate beads in serum supplemented medium (10%foetal calf serum used in exp. b.a3 
and 20%foetal calf serum used in all other exps.) Different animals were used to source chondrocytes between experiments. 
Culture period prior to assessment of bead GAG content varied between experiments and ranged from 21 days to 57 days. 
Values for bead GAG content shown as means ± SO ( M 3). Lines connecting data points are for illustrative purposes.
With IL-1 a treatment, the means for %GAG release after one-day, two-day or 
five-day culture were 37.4%, 52.6% and 82.5% respectively. At each time point 
IL-1 a stimulated GAG release compared to basal culture (significance levels for 
time points: one-day, P=0.027; two-day P<0.001; and five day P<0.001). 
IL-1a-stimulated GAG release increased as a function of stimulus duration (two 
days vs. one day: P<0.001; five days vs. two days: P<0.001). Since the largest 
difference in GAG release between basal and IL-1 a stimulated culture was 
observed at the 2-day time point, this stimulation period was selected for use in 
subsequent experiments.
GAG release as a function of IL-1 a concentration (Figs. 5.3, 5.4, 5.5 and 
5.6)
In the first of three experiments, mean GAG release with basal culture was 
19.9%. Compared to basal culture, IL-1 a 2 ng/ml, 10 ng/ml and 20 ng/ml 
stimulated GAG release (mean values for GAG release 72.9%, 67.6% and 
67.8% respectively, P<0.001 for all comparisons; Fig. 5.3). There was no 
difference in GAG release between IL-1 a 10 ng/ml and 20 ng/ml (P>0.999) but,
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interestingly, both of these IL-1 a concentrations were less stimulatory than 
IL-1 a 2 ng/ml (P=0.003 and P=0.002 respectively).
Fig. 5.2. Exp. b.a3.1. Basal and IL-1a-stimulated GAG release as a 
function of time in the bovine articular chondrocyte/alginate bead 
culture model.
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(t) ng/ml)
D ays o f  c u ltu re
Alginate beads containing bo vine articular chondrocytes and an established matrix cultured with and without IL-1a stimulation 
for 1day, 2 days or 5 days. Values for %3AG release from beads shown as means ± SD (n=3). Mean°/<GAG release higher with 
IL-Vi stimulation than without at all time points (day 1, P=0.022; day 2. P<0.00t day 5, P<0.001). Mean unstimulated °/<GAG 
release higher at day 5 vs. day 1(P<0.001) and day 5 vs. day 2 (P<0.001). Mean IL-1a-stimulated °/<GAG release increases as a 
function of time (day 2 vs. day 1, P<0.00tday 5 vs. day 2, P<0.001)
Fig. 5.3. Exp. b.a6.5. GAG release as a function of IL-1 a concentration (2 ng/ml to 20 ng/ml) 
in the bovine articular chondrocyte/ alginate bead culture model.
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Alginate beads containing bovine articular chondrocytes and an established matrix cultured with treatments for 2 days. 
Values for %GAG release from beads shown as means ±  SD (n=4) on chart above left. P values for differences in mean 
%GAG release between treatments shown in table above right.
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This unexpected finding led to a further experiment examining IL-1 a 
concentrations down to 0.5 ng/ml (Fig. 5.4). Again each of the IL-1 a 
concentrations tested caused an increase in GAG release compared to control 
(P<0.001 for all comparisons). Furthermore, in agreement with the previous 
experiment (b.a6.5), there appeared to be an inverse relationship between IL-1 a 
concentration and GAG release. For IL-1 a 0.5 ng/ml to 20 ng/ml, a simple linear 
regression analysis of logi0(IL-1a concentration) and %GAG release indicated a 
significant correlation (P<0.001; R2= 0.79; Fig. 5.5) described by the following 
equation:
% G AG  release= 51.3 -  (5.1 x log10(IL -1a  concentration))
Fig. 5.4. Exp. b.a7.3. GAG release as a function of IL-1a concentration 
(0.5 ng/ml to 20 ng/ml) in the bovine articular chondrocyte/alginate 
bead culture model.
60 r
a 20
IL-1a (ng/ml)
Treatment
Alginatebeads containing bovine articular chondrocytes and an established matrix cultured withtreatmentsfor 2 days. 
Values for %3AG release from beads shown as means ±SD (n=4).
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Fig. 5.5. Exp. b.a7.3. Linear regression model of GAG release as a function of 
log10 IL-1 a concentration (0.5 ng/ml to 20 ng/ml) in the bovine articular chondrocyte/ 
alginate bead culture model.
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Linear regression modelling of data from exp. b.a7.3. Beads containing bovine articular chondrocytes and an 
established matrix cultured with treatments for 2 days. Data points represent %GAG release from beads treated with 
various concentrations of IL-1 a.
A subsequent experiment evaluated IL-1 a concentrations down to 0.05 ng/ml 
(Fig. 5.6). All IL-1 a concentrations tested (0.05 ng/ml to 10 ng/ml) compared to 
control stimulated GAG release (P<0.001 for all comparisons). Graphically, 
there appeared to be a positive relationship between GAG release and IL-1 a 
concentration at the IL-1 a concentration range 0.05 ng/ml to 2 ng/ml (Fig.5.6). 
Less GAG release was stimulated by IL-1 a 0.05 ng/ml than by IL-1 a 0.5 ng/ml 
(P=0.041) or IL-1 a 2.0 ng/ml (P=0.009), though other comparisons between 
IL-1 a concentrations did not reveal any significant differences. Linear regression 
modelling was not performed since the data did not fulfil the linearity 
assumption (with or without log transformation).
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Fig. 5.6. Exp. b.a7.4. GAG release as a function of IL-1a concentration (0.05 ng/ml to 10 ng/ml) in the 
bovine articular chondrocyte/ alginate bead culture model.
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Beads containing bovine articular chondrocytes and an established matrix cultured with treatments for two days. Values for %GAG 
release from beads shown as means ± SD (n=4) on chart above left. P values for differences in mean %GAG release between 
treatments shown in table above right.
Intra-experimental and inter-experimental variation in GAG release
IL-1 a 10 ng/ml consistently stimulated GAG release from beads compared to 
basal culture across nine experiments (P<0.001 for comparisons in each 
experiment; Fig. 5.7). Intra-experimental CVs for unstimulated and IL-1 a- 
stimulated GAG release ranged from 3.8% to 21.5% (mean 9.1%) and 0.7% to 
13% (mean 3.6%) respectively. The inter-experiment CVs for unstimulated and 
IL-1a-stimulated GAG release were 52.6% and 26.5% respectively. Between- 
experiment differences for unstimulated or IL-1a-stimulated GAG release were 
found to be highly significant (P<0.001 for both measures). Possible 
explanations for this striking inter-experimental variation are discussed below.
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Fig. 5.7. Inter-experimental variation in basal and !L-1a-stimulated (10 ng/ml) 
GAG release in the bovine articular chondrocyte/alginate bead culture 
model. Results from nine separate experiments.
□  unstim ulated  
culture
■  culture with IL-1o 
(10 ng/m l)
b.a3.l* b.a3.2' b.a4.2* b.a4.4* b.a5.3’ b.a6.3* b.a6.5" b.a7.3** b.a7.4**
Experiment
Beads containing bovine articular chondrocytes and an established matrix cultured with and without IL-la X) ng/ml for 2 days. 
Values f or “/GAG release from beads shown as means ± SO (*n=6; **n=4).
Fig. 5.8. Basal and IL-1a-stimulated (0.05 ng/ml) 
GAG release in the bovine articular chondrocyte/ 
alginate bead culture model. Results from two 
separate experiments.
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□ unstimulated 
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■ culture with IL-ia 
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Experiment
Beads containing bovine articular chondrocytes and an established matrix cultured 
with and without IL- 1a 0.05 ng/ml for 2 days. Values for °/<GAG release from beads 
shown as means ±SD (numbers indicated on chart). *P<0.001 vs. unstimulated 
culture in exp. b.a7.4. **P=0.06 vs. unstimulated culture in exp. b.a7.6.
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In two experiments (b.a7.4 and b.a7.6), IL-1a 0.05 mg/ml was used to stimulate 
GAG release (Fig. 5.8). In experiment b.a7.4, IL-1 a 0.05 ng/ml significantly 
increased %GAG release compared to unstimulated culture (P<0.001).
However, the same concentration of IL-1 a was only associated with a trend for 
increased GAG release (P=0.06) in experiment b.a7.6. The intra-experimental 
CVs for IL-1a-stimulated GAG release for the two experiments were 19.2% 
(b.a7.4) and 42.2% (b.a7.6).
5.5.2 Effects of zoledronate on basal or IL-1a-stimulated GAG release
Investigations described in this chapter have examined the effects of 
zoledronate 10‘8 M to 10'4 M on basal or IL-la-stimulated GAG release in the 
bovine articular chondrocyte/ alginate bead culture model. Most experiments 
used IL-1 a at the concentration 10 ng/ml to stimulate GAG release. IL-1 a 0.05 
ng/ml was employed as the stimulus in a single later experiment.
Effects of zoledronate on basal GAG release- six experiments (Figs. 5.9 to 
5.14 and Table 5.4)
Compared to control, treatment with zoledronate 10’8 M to 10'4 M was not 
observed to effect basal GAG release. Trends for increases in basal GAG 
release were seen with zoledronate 10"7 M in one experiment out of six (b.a4.4; 
10.6% increase vs. control; P=0.034) and with zoledronate 10'4 M in one 
experiment out of three (b.a6.3; 9.6% increase vs. control; P=0.039).
Effects of zoledronate on GAG release stimulated by IL-1 a 10 ng/ml- five 
experiments (Figs. 5.9 to 5.13 and Table 5.5)
No effects on IL-1a-stimulated GAG release were seen with zoledronate 10'8 M 
to 10‘4 M. However, several trends that approached significance were apparent. 
In separate experiments increases in stimulated GAG release were found with 
zoledronate 10'6 M in one experiment of four (b.a4.4; 6.2% increase vs. control; 
P=0.011) and zoledronate 10‘5 M in one of two experiments (b.a6.3; 4.8% 
increase vs. control; P=0.012). Decreases in stimulated GAG release were seen
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with zoledronate 10'5 M (4% decrease vs. control; P=0.033) and zoledronate 
10'4 M (4.3% decrease vs. control; P=0.022) in one of two experiments (b.a5.3; 
both findings in the same experiment).
Effects of zoledronate on GAG release with IL-1 a 0.05 ng/ml co-treatment- 
single experiment (Fig. 5.14)
In one experiment IL-1 a 0.05 ng/ml was chosen as the stimulus since it had 
been previously shown that this concentration caused a sub-maximal stimulus 
of GAG release (Fig. 5.6) and it was considered that a gentler stimulus of GAG 
release might be more readily modulated by zoledronate. Unexpectedly, in 
controls, only a trend for increased GAG release was seen with IL-1 a 
0.05 ng/ml compared to no IL-1 a (P=0.06). In cultures co-treated with IL-1 a 
0.05 ng/ml, none of the zoledronate treatments tested (10'7 M to10'4 M) was 
observed to alter GAG release compared to control.
Fig. 5.9. Exp. b.a3.2. Effects of zoledronate (1.E-8 M to 5.E-7 M) on basal and 
IL-1a-stimulated (10 ng/ml) GAG release in the bovine articular 
chondrocyte/alginate bead culture model.
r 'T '
j
r i^
0 1.E-08 1.E-07 | 5.E-07 x 0 1.E-08 1.E-07 I 5.E-07
zoledronate (M ) x zoledronate (M ) + IL-1a 10 ng/ml
Treatment
Beads containing bovine articular chondrocytes and an established matrix cultured in the presence of treatments for two 
days. Values for °/(GAG release from beads shown as means ±SD (n=6).
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Fig. 5.10. Exp. b.a4.2. Effects of zoledronate (1.E-8 M to 1.E-6 M) on basal and 
IL-1a-stimulated (10 ng/ml) GAG release in the bovine articular 
chondrocyte/alginate bead culture model.
oto
S 40
zoledronate (M)
1.E-06
zoledronate (M ) + IL-1a 10 ng/ml
Treatment
Beads containing bovine articular chondrocytes and an established matrix cultured in the presence of treatments for two 
days. Values for °/<GAG release from beads shown as means ± SD (n=6).
Fig. 5.11. Exp. b.a4.4. Effects of zoledronate (1.E-8 M to 1.E-6 M) on basal and 
IL-1 a-stimulated (10 ng/ml) GAG release in the bovine articular chondrocyte/ 
alginate bead culture model.
O  30
zoledronate (M)
1.E-08 | 1.E-07
zoledronate (M ) + IL-ta 10 ng/ml
Treatment
Beads containing bovine articular chondrocytes and an established matrix cultured in the presence of treatments for two 
days. Values for °/<GAG release from beads shown as means ±SD (n=6).
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Fig. 5.12. Exp. b.a5.3. Effects of zoledronate (1.E-7 M to 1.E-4 M) on basal and 
IL-1a-stimulated (10 ng/ml) GAG release in the bovine articular chondrocyte/ 
alginate bead culture model.
0) 60
CO
2  50
1.E-040 IE -0 7  I 1.E-06 1.E-05 1.E-04 X 0 tE-07 ■ 1.E-06 1.E-05
zoledronate (M) X zoledronate (M )+IL-1a 10 ng/ml
Treatment
Beads containing bovine articular chondrocytes and an established matrix cultured in the presence of treat merits for two days. 
Values for °/fiAG release from beads shown as means ±SD (n=6).
Fig. 5.13. Exp. b.a6.3. Bfects of zoledronate (1.E-7 M to 1.E-4 M) on basal and 
IL-1a-stimulated (10 ng/ml) GAG release in the bovine articular chondrocyte/ 
alginate bead culture model.
_ _ .  _ —  l
1.E-07 1.E-06 1.E-05 1.E-04 X 0 ! 1E-07 1.E-06 ; IE -0 5  ' 1.E-04
zoledronate (M ) X zoledronate (M) +IL-1a 10 ng/ml
Treatment
Beads containing bovine articular chondrocytes and an established matrix cultured in the presence of treatments for two days. 
Values for °/<GAG release from beads shown as means ±SD (n=6).
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Fig. 5.14. Exp. b.a7.6. EJfects of zoledronate (1.E-7 M to 1.E-4 M) with and 
without IL-1a 0.05 ng/ml co-treatment on GAG release in the bovine 
articular chondrocyte/alginate bead culture model.
n=2L fl=3 n=3 r>=3
1.E-07 IE -06  IE -05 1.E-04 X 0 IE -07 1.E-06 IE -05
zoledronate (M ) X zoledronate (M ) +IL-1a 0.05 ng/ml
1.E-04
Treatment
Beads containing bovine articular chondrocytes and an established matrix cultured in the presence of treatments for two days. 
Values for °/£3AG release from beads shown as means ±SD (n=3 or n=6 as indicated on chart).
5.6 Discussion
Characteristics of the bovine articular chondrocyte/ alginate bead culture 
model
In vitro culture of bovine articular chondrocytes within alginate beads in serum- 
supplemented medium for periods ranging from 21 days to 42 days led to the 
GAG accumulation in the beads (Fig. 5.1). Synthesis of GAG is an indication 
that the chondrocyte phenotype was maintained in the culture model, consistent 
with previous detailed studies which have demonstrated that the cell and matrix 
characteristics of chondrocytes cultured in alginate beads closely resemble 
those of native articular cartilage (Almqvist et al. 2001; Chubinskaya et al. 2001; 
Guo et al. 1989; Hauselmann et al. 1992; Hauselmann et al. 1994; Hauselmann 
et al. 1996b; Petit et al. 1996), and supports the use of the culture system to 
investigate chondrocyte-matrix metabolism.
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Table 5.4. Results summary from six experiments for the effects of zoledronate (1.E-8 M to 1.E-4 M) on basal GAG release from alginate beads containing 
chondrocytes and an established matrix.
Exp.
Mean %GAG 
release for 
control
Difference (A) in mean %GAG release between zoledronate and control; and significance level of the difference*
Zoledronate treatment concentration (M)
10-8 10'7 5x1 O'7 10* 10* 10*
A P value A P value A P value A P value A P value A P value
b.a3.2 16.7 -.2 .995 -.3 .973 +.2 .990
b.a4.2 7.6 +.2 .782 +.3 .267 +.2 .619
b.a4.4 6.9 +.3 .499 +.7 .034 -.5 .203
b.a5.3 11.3 -.6 .589 -.3 .931 -1.3 .055 +.5 .715
b.a6.3 11.6 +.4 .725 -.1 .999 .0 >.999 +1.1 .039
b.a7.6 5.2 -.6 .388 .0 >.999 -.4 .730 -.5 .338
* Since multiple experiments were performed the alpha level to indicate a significant difference between means was set at P=0.01 as described in section 2.3.2
Table 5.5. Results summary from five experiments for the effects of zoledronate (1.E-8 M to 1.E-4 M) on IL-1a-stimulated (10 ng/ml) GAG release from alginate beads 
containing chondrocytes and an established matrix.
Exp.
Mean % GAG 
release for 
IL-1a-stimulated 
control
Difference (A) in mean IL-1a-stimulated %GAG release between zoledronate and control; 
and significance level of the difference*
Zoledronate treatment concentration (M)
10° 10" 5x10" 10" 10 s 10*
A P value A P value A P value A P value A P value A P value
b.a3.2 72.0 -.3 .970 -.6 .789 +.3 .967
b.a4.2 47.0 -.5 .904 +.9 .586 -.2 .985
b.a4.4 57.6 +1.5 .383 +1.4 .467 +3.6 .011
b.a5.3 64.8 +1.1 .610 -1.6 .288 -2.6 .033 -2.8 .022
b.a6.3 61.5 +1.1 .663 +.9 .814 +3.0 .012 -1.7 .284
* Since multiple experiments were performed the alpha level to indicate a significant difference between means was set at P=0.01 as described in section 2.3.2
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Subsequent culture of alginate beads containing chondrocytes and an 
established matrix with IL-1 a stimulated GAG release from the beads. IL-1 a 
10 ng/ml stimulated GAG release in a time-dependent fashion (Fig. 5.2), which 
is consistent with a previous study that found a similar relationship for IL-1 (3 
stimulation in the same culture system (Beekman et al. 1998). In the present 
studies, the greatest separation between basal and IL-1 a stimulated GAG 
release occurred with two-day culture (Fig. 5.2) leading to the selection of this 
stimulation period in all subsequent experiments. IL-1 a at the concentration of 
10 ng/ml was used in nearly all experiments and, consistently, this stimulus was 
found to increase GAG release (Fig. 5.7). These observed effects of IL-1 a 
10 ng/ml support its use in the model to investigate chondrocyte-mediated 
proteoglycan degradation.
Later on in the studies, GAG release as a function of IL-1 a concentration in the 
model was explored to examine the possibility that GAG release might saturate 
at higher IL-1 a concentrations. Across three experiments, the IL-1 a 
concentration range evaluated was 0.05 ng/ml to 20 ng/ml. Surprisingly, though 
all IL-1 a concentrations tested did stimulate GAG release, the highest cytokine 
concentrations did not produce maximal stimulatory effects (Figs. 5.3 to 5.6). It 
is possible that chondrocytes may become initially desensitised to IL-1 a at high 
ligand concentrations since human dermal fibroblasts, another type of 
connective tissue cell, have been found to transiently down-regulate IL-1 
receptors on exposure to IL-1 a 5 ng/ml (though receptor expression then up- 
regulated on longer-term exposure to the cytokine) (Akahoshi et al. 1988). 
Alternatively, there may be a mild cytotoxic effect at higher IL-1 a 
concentrations, as is suggested by one of the viability experiments described in 
Chapter 3 in which IL-1 a 10 ng/ml treatment caused a 3.1% reduction in 
chondrocyte viability (Table 3.3). Clarification of these possible mechanisms 
would require further study.
IL-1 a 0.05 ng/ml, which was the lowest IL-1 a concentration evaluated, also 
produced a sub-maximal stimulatory effect on GAG release (Figs. 5.6). Taken
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together, the results suggest a biphasic relationship: at lower IL-1 a 
concentrations the amounts of GAG release increase with cytokine 
concentration up to a peak beyond which higher IL-1 a concentrations are less 
stimulatory for GAG release.
For evaluating the effects of zoledronate on GAG release in the culture model, it 
was considered that a milder stimulus of proteoglycan degradation might be 
more readily modulated by the bisphosphonate. Thus, IL-1 a 0.05 ng/ml was 
selected as a sub-maximal stimulus for the culture model in one experiment that 
tested the general hypothesis. However, in this experiment, IL-1 a 0.05 ng/ml did 
not stimulate GAG release significantly and, in addition, between-sample 
variation for GAG release was high (CV=42.2% for GAG release with IL-1 a 0.05 
ng/ml). The level of variability was unexpected since the cell source was 
standardised between samples, and it is assumed that variability was 
introduced during execution of the experimental methods. Additional work is 
needed on the model to identify relatively low concentrations of IL-1 a that mildly 
stimulate GAG release and, in further experiments, particular attention should 
be given to meticulous experimental technique.
In terms of within-experiment reproducibility for GAG release stimulated by 
IL-1 a 10 ng/ml, the culture model performed well. The mean intra-experimental 
CV for this measure was 3.6%, comparing favourably with that seen in the 
cartilage explant model (mean CV 18.4%; Table 4.3). Thus, of the two culture 
models, the bovine articular chondrocyte/ alginate bead model possesses 
greater sensitivity for detecting treatment effects on GAG release stimulated by 
IL-1a 10 ng/ml.
Interestingly, a recurring theme seen in the chondrocyte/ alginate bead culture 
system was inter-experimental variation. Firstly, the rate of bead GAG 
accumulation during the matrix-establishing culture period appeared to differ 
strikingly between experiments (Fig. 5.1), even in the absence of formal 
statistical comparisons which were not performed because the time points for
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measuring GAG accumulation were not uniform across studies. Secondly, the 
amounts of GAG released from the beads (both basal and IL-1a-stimulated) 
varied widely between experiments (Figs. 5.7 and 5.8). Thirdly, the IL-1 a 
concentration that was found to cause maximal GAG release was not uniform 
(IL-1 a 2 ng/ml in two experiments and IL-1 a 0.5 ng/ml in the third). Fourthly, IL- 
1a 0.05 ng/ml increased GAG release in one experiment but only led to a trend 
for increased GAG release in another experiment (Fig. 5.8).
Variability between experiments could have arisen from biological differences in 
the chondrocytes and/or differences in culture technique. The use of 10% FCS 
to supplement the culture medium in one experiment (b.a3) may have led to a 
reduced rate of bead GAG accumulation compared other experiments in which 
20% FCS was used since FCS is a known stimulus of proteoglycan synthesis in 
bovine articular chondrocytes (van Susante et al. 2000). In addition, the culture 
duration during which matrix was established in the beads prior to IL-1 a 
stimulation was different between experiments (it ranged from 21 days to 42 
days). Previous studies indicate that aspects of chondrocyte metabolism, such 
as the rates of cell proliferation and GAG synthesis, can vary with culture 
duration (Akmal et al. 2006). Catabolic responses of chondrocytes might also 
change according to in vitro culture duration, which would offer some 
explanation for the observed inter-experimental variation in bead GAG release.
Alternatively, inter-experimental variation may have reflected inter-animal 
differences in chondrocyte proteoglycan metabolism, though the use of at least 
two animals to source chondrocytes in most experiments is likely to have 
somewhat averaged-out such differences between experiments (Tables 5.2 and 
5.3). Since older age has been found to be associated with decreased 
responsiveness of articular cartilage to the effects of IL-1 (Hauselmann et al. 
1996a; Little et al. 1999; MacDonald et al. 1992), the variation in animal age in 
the present study (known ages of animals ranged from 13 months to 29 
months) may have been significant for between-experiment differences.
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Investigating the marked variation in chondrocyte metabolism seen in the 
present studies should identify model parameters to be standardised in further 
experiments and, in addition, could provide further insight into the role of IL-1 in 
OA and improve understanding of OA aetio-pathogenesis. Effects of differences 
in culture technique could be examined in a standardised cell line. Biological 
differences could be explored using standardised methodology for the culture 
model whilst varying the cell source, for example examining the responsiveness 
to IL-1 a of chondrocytes from various regions of the articular surface defined 
according to susceptibility to cartilage degeneration.
Effects of zoledronate on chondrocyte-mediated proteoglycan 
degradation
In the studies, zoledronate treatments at concentrations ranging from 10‘8 M to 
10‘4 M were not observed to have effects on unstimulated GAG release or GAG 
release stimulated by IL-1 a 10 ng/ml in the bovine articular chondrocyte/ 
alginate bead culture model (Tables 5.4 and 5.5). At specific zoledronate 
concentrations, sporadic trends for treatment effects were seen (both increases 
and decreases with effect sizes ranging from 4% to 10.6% compared to 
control), but since no trends were reproduced between experiments, they are 
not considered to be significant. Taken together, the negative findings can be 
interpreted to be biologically relevant for bovine animals in general as 
chondrocytes were sourced from different animals between experiments.
In order to explore the possibility that zoledronate might only have a moderate 
modulatory effect on IL-1a-stimulated proteoglycan degradation, an attempt was 
made to investigate effects of the bisphosphonate in the culture model but with 
a milder stimulus of GAG release. However, as described above (this section), 
a mild stimulus was not successfully identified in the present studies and further 
work is needed on the model in order to pursue this line of investigation. 
Ultimately, finding positive though mild modulatory effects on proteoglycan 
degradation may translate to clinical disease modification if the effects are
157
sustained and, thereby, lead to increases in cartilage proteoglycan content over 
time.
Overall, no effects of zoledronate were found to support the general hypothesis. 
On the other hand, there were also no observable detrimental effects that would 
exclude zoledronate as a disease-modifying treatment for OA through an action 
on cartilage metabolism.
5.7 Conclusions
• Bovine articular chondrocytes that are cultured in alginate beads 
establish GAG in the beads. Subsequent exposure of these beads to 
IL-1 a 10 ng/ml stimulates GAG release with excellent between-sample 
reproducibility. Thus, the culture system provides an in vitro model of 
chondrocyte-matrix catabolism for sensitively investigating treatment 
effects on proteoglycan degradation.
• Generally, IL-1 a has stimulatory effects on GAG release in the model. 
GAG release as a function of IL-1 a concentration appears to be biphasic 
with positive correlation between GAG release and IL-1 a concentration at 
lower cytokine concentrations and negative correlation at higher IL-1 a 
concentrations.
• Between experiments, there were high levels of variation in the rate of 
GAG accumulation in alginate beads and the subsequent release of 
GAG from the beads (with and without IL-1 a stimulation). This inter- 
experimental variation could have arisen from biological differences in 
the chondrocytes and/or differences in culture technique. Further study of 
inter-animal variation in chondrocyte-mediated proteoglycan metabolism 
in the culture model could yield important insight into aetio-pathogenesis 
of cartilage degradation in OA.
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• Zoledronate treatments 10'8 M to 10'4 M were not observed to have 
effects on GAG release stimulated by IL-1 a 10 ng/ml from alginate beads 
containing matrix established by bovine articular chondrocytes. Thus, no 
evidence was found to support the hypothesis that the bisphosphonate 
can decrease the loss of cartilage glycosaminoglycan during the 
osteoarthritic process by reducing chondrocyte-mediated proteoglycan 
degradation.
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Chapter 6. General discussion
6.1 Aim of studies
The studies described in this thesis have explored the concept that zoledronate 
can alter the disease course in OA by testing the hypothesis that the 
bisphosphonate can modify cartilage metabolism to reduce the loss of cartilage 
proteoglycan during the OA disease process.
6.2 In vitro models employed in experiments
Effects of zoledronate on proteoglycan synthesis and degradation, that is both 
sides of the metabolic balance, were examined in vitro in models of chondrocyte 
and cartilage metabolism, in which IL-1 a was used to stimulate “OA-like” 
metabolic change. The two culture models employed, bovine articular cartilage 
explant culture model and bovine articular chondrocyte/ alginate bead culture 
model, were found to be effective for investigating effects on IL-1a-stimulated 
proteoglycan degradation (measured as tissue GAG release). In addition, the 
chondrocyte/ alginate bead model proved useful for evaluating effects of 
zoledronate on chondrocyte proteoglycan synthesis, as well as potential 
adverse effects on chondrocyte viability and proliferation.
In relation to the bovine cartilage explant culture model, an interesting 
observation was marked intra-joint variability in IL-1a-stimulated GAG release in 
cartilage. Heterogeneity in the biochemical composition of articular cartilage 
across the joint surface is well known. Previous reports indicate that GAG 
content (Brama et al. 2000), chondroitin sulphate sulphation pattern (Bayliss et 
al. 1999) and aggrecanase-generated aggrecan fragment distribution (Bayliss et 
al. 2001) differ according to the site sampled. In addition, susceptibility to IL-1 (3- 
stimulated GAG release has been found to vary in cartilage from different 
anatomical locations in the human OA knee joint (Barakat et al. 2002). Further 
work to examine if the susceptibility of articular cartilage to IL-1a-stimulated 
proteoglycan degradation relates to cartilage sites that develop OA change
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within a joint could provide additional insight into the mechanisms behind focal 
cartilage loss in OA.
The levels of intra-experimental variability in IL-1a-stimulated GAG release for 
the cartilage explant model posed a problem for experimental design.
Unfeasibly large sample numbers would have been required in the model to 
achieve adequate power to detect small-sized treatment effects (e.g. from 
sample size calculations: up to 102 samples per treatment group needed to 
detect a 10% effect size with 80% power). Another culture system, the 
chondrocyte/ alginate bead model which involved culturing a “cartilage-like” 
tissue in vitro, demonstrated much less between-sample variability within 
experiments and was also used to investigate the effects of zoledronate on IL- 
1a-stimulated GAG release. It is likely that the improved levels of variability 
resulted from standardisation of the cell source for samples; alginate beads for 
all samples within experiments were formed using the same homogenised pool 
of cells in which any topographical differences in chondrocyte metabolism would 
have been averaged out. In further studies, the model could be used to explore 
possible topographical variation in chondrocyte metabolism by examining 
response to IL-1 a in cells sourced from defined areas of an articular surface of a 
single joint.
In both culture models, marked inter-experimental variability was encountered 
for the amounts of tissue GAG released, an unexpected finding since sources 
for cartilage or chondrocytes were relatively standardised across experiments. 
The studies for this project were not designed to examine the basis for this 
variability but one possible explanation is metabolic variation between animals. 
Additional work to assess cartilage and chondrocyte proteoglycan metabolism 
in relation to animal characteristics (e.g. age, sex and weight) could provide 
new information on the link between aetiology and pathogenesis for cartilage 
proteoglycan loss in OA.
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6.3 Effects of zoledronate in the models of chondrocyte and cartilage 
metabolism
The usefulness of any potential treatment for OA with proposed effects on 
cartilage metabolism is in part defined by an absence of toxic effects on 
chondrocytes. Based on the assessment of effects on basic parameters of 
chondrocyte metabolism (i.e. cell viability, proliferation and proteoglycan 
synthesis), zoledronate concentrations <10'5 M appear safe. However, 
zoledronate 10‘4 M is clearly detrimental to bovine chondrocytes from the MCP 
joint. It would be advisable to avoid exposing cartilage to zoledronate 
concentrations > 10 4 M during clinical use, though pharmacokinetic data have 
yet to be reported on cartilage levels achieved with current dosing regimens. 
Furthermore, toxicity studies would need to be repeated using human 
chondrocytes in order to form firm conclusions.
Across the series of studies, no evidence was demonstrated to support the 
general hypothesis that zoledronate modifies cartilage metabolism to reduce the 
loss of cartilage glycosaminoglycan during the OA process. Specifically, no 
enhancing effects were observed with zoledronate 10'10 M to 10'4 M on 
proteoglycan synthesis in the chondrocyte/ alginate bead culture model and, 
furthermore, no modulating effects on proteoglycan degradation were seen with 
zoledronate 10"10 M to 10'5 M in the cartilage explant culture model or with 
zoledronate 10'8 M to 10’4 M in the chondrocyte/ alginate bead culture model.
Prior to performing the studies, it had been considered that inhibition of MMP or 
aggrecanase activity was a plausible biochemical mechanism for an inhibitory 
effect of zoledronate on proteoglycan degradation. However, proteinase 
inhibition requires high zoledronate concentrations, in the range 2.5x1 O'5 M to 
10'3 M (Heikkila et al. 2002; Teronen et al. 1999), and in the present studies 
only zoledronate treatment at concentrations <10'5 M appeared safe for bovine 
articular chondrocytes. Thus, at least for bovine articular cartilage, there is no 
therapeutic window for zoledronate to modulate proteoglycan degradation 
through proteinase inhibition.
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Overall, the negative findings for the general hypothesis may be interpreted in 
three ways: (i) the general hypothesis has not been adequately tested due to 
limitations of the experimental approach; (ii) the overall concept of zoledronate 
as a disease-modifying treatment in OA is valid but its activity arises from a 
mechanism of action other than a direct effect on cartilage proteoglycan 
metabolism; or (iii) zoledronate does not have OA disease-modifying properties.
6.4 Limitations of the studies
The present studies have looked for direct effects of zoledronate on cartilage or 
chondrocyte metabolism in vitro. Several limitations to the experimental 
approach are apparent.
Firstly, some characteristics of the in vitro culture systems that were employed 
in the experiments indicate that these models are less than accurate 
representations of in vivo metabolism:
a) Regulation of cartilage metabolism in vitro and in vivo: The 10 ng/ml 
concentration of IL-1 a employed in the models to stimulate proteoglycan 
degradation is nearly 100-fold higher than IL-1 levels (albeit IL-1 (3 rather 
than IL-1 a) seen in synovial fluid of knee OA joints (Westacott et al. 
1990). Furthermore, the use of a single cytokine to stimulate metabolism 
is simplistic compared to the in vivo setting, in which regulation of 
metabolism is governed by various other cytokines, biochemical factors 
and mechanical factors that, in addition, can interact with one another 
(discussed in section 1.2.3.6).
Several reports indicate that In vitro culture techniques introduce 
changes to metabolism in cartilage and chondrocytes. In vitro culture of 
cartilage explants or chondrocytes alters proteinase expression patterns, 
in comparison to those found in fresh cartilage tissue extracts (Bau et al.
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2002; Flannery et al. 1999).In addition, the cutting of articular cartilage 
releases tissue bound basic fibroblastic growth factor (Vincent et al.
2002) (a proposed extracellular mechanotransducer (Vincent and 
Saklatvala 2006)), increases cell proliferation and matrix synthesis at the 
wound edge (Redman et al. 2004), and induces IL-1 (Gruber et al. 2004). 
Furthermore, the initial removal of the peri-cellular matrix during 
chondrocyte isolation in the chondrocyte/ alginate bead culture model is 
likely alter cell metabolism since this domain of matrix is thought to be a 
transducer of biomechanical and biochemical signals (Guilak et al. 2006). 
However, a pre-culture period was employed to stabilise cartilage or 
chondrocytes prior to treatment culture in all but one of the experiments 
of the present studies and its use is likely to have minimised acute 
effects of tissue processing.
b) Differences in rate of change: The rate of matrix change observed in 
the in vitro models is more rapid than that in vivo. IL-1 a stimulation in 
vitro led to up to 62.9% of the proteoglycan being released from cartilage 
over a four-day culture period. In comparison, the proteoglycan content 
in OA cartilage from OA hips removed at arthroplasty has been reported 
to be 52% less than that in cartilage from normal control hips (Byers et 
al. 1977). Though effect sizes are similar, the time course for 
pathological change in the OA hips must have been over several years, 
implying that quantitatively small but sustained alterations to metabolism 
could be significant for cartilage proteoglycan loss in vivo.
Secondly, the specific use of young adult, healthy cartilage from the metacarpal 
articular surfaces of bovine MCP joints in the studies somewhat limits 
interpretation of the results. Cartilage composition and metabolism varies 
between species (Cawston et al. 1998; Hughes et al. 1998), in different joints 
(Eger et al. 2002) and in relation to age (Hardingham 2004). Thus, the negative 
findings from the present studies should be interpreted cautiously in the context 
of the heterogeneous nature of cartilage metabolism. In particular, the use of
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results derived from present studies to understand the mechanisms behind the 
reductions in cartilage degradation with zoledronate treatment seen in rabbits 
with experimentally-induced OA (Muehleman et al. 2002) is limited by the 
possibility of inter-species differences in cartilage metabolism.
Other study limitations relate to potential zoledronate treatment effects in the 
model that were not addressed. An attempt had been made to examine 
treatment effects on proteoglycan degradation stimulated by a milder stimulus 
(i.e. IL-1 a at the 0.05 ng/ml concentration rather than 10 ng/ml) but conclusions 
were not drawn because the culture model did not perform as expected. 
Preventative or delayed treatment effects also have yet to be examined. The 
maximum duration of zoledronate treatment in the present studies was four 
days and the bisphosphonate was added at the same time as the IL-1 a 
stimulus. In comparison, the zoledronate treatment period that led to reductions 
in cartilage degradation in the animal OA model commenced 24 hours before 
induction of cartilage damage and then continued for 28 days or 56 days prior to 
assessment (Muehleman et al. 2002), raising the possibility of preventative or 
delayed treatment effects. Furthermore, the inhibitory effects of etidronate and 
clodronate on mono-nuclear cell factor-stimulated collagenase production by 
chondrocytes have been found to be more pronounced when cells were pre­
treated with the bisphosphonates for several days than when they were added 
at the same time as the stimulating factor (McGuire et al. 1982), suggesting that 
bisphosphonates in general may have preventative or delayed effects on 
chondrocyte metabolism.
6.5 Zoledronate as a disease-modifying treatment in OA: possible 
mechanisms of action other than a direct effect on cartilage proteoglycan 
metabolism
An alternative target for zoledronate in cartilage is the metabolism of type II 
collagen. Observed reductions in urinary CTX-II in Paget’s disease patients 
treated with zoledronate (Garnero et al. 2001a) point toward an inhibitory effect
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on type II collagen degradation. As discussed above, zoledronate can inhibit 
MMP proteolytic activity, providing a biochemical mechanism, but there does 
not appear to be a therapeutic window for MMP inhibition in cartilage without 
adverse effects on chondrocytes.
Beyond cartilage, possible mechanisms of action for zoledronate as a disease- 
modifying treatment in OA include effects on any one of the other joint tissues 
involved in pathogenesis. In particular, subchondral bone is a plausible target 
and there has been considerable recent interest in the potential for agents with 
anti-resorptive effects on bone as therapies in OA (Abramson and Honig 2007; 
Burr 2004; Spector 2003). Numerous studies have reported positive effects with 
various bisphosphonates or calcitonin (another anti-resorptive) in animal OA 
models (Agnello et al. 2005; Doschak et al. 2004; Hayami et al. 2004; Manicourt 
et al. 1999; Meyer et al. 2001a; Meyer et al. 2001b; Muehleman et al. 2002; 
Papaioannou et al. 2007; Sondergaard et al. 2007). In addition, clinical trials 
have evaluated risedronate treatment in OA patients. Encouraging results were 
found in an initial study of 284 patients with knee OA (Spector et al. 2005) but a 
subsequent larger study of nearly 2500 knee OA patients did not find clinical 
improvements or reductions in joint-space narrowing with risedronate (Bingham, 
III et al. 2006). It has been suggested that the latter study was under-powered 
for primary outcome measures due to low numbers of OA patients 
demonstrating disease progression (Abramson and Honig 2007). An alternative 
explanation for the discrepant results for bisphosphonate efficacy between the 
human and animal studies is the difference in treatment timing in relation to the 
OA disease process. In many animals studies, anti-resorptive treatment 
commenced around the time that experimental OA was induced (Agnello et al. 
2005; Doschak et al. 2004; Hayami et al. 2004; Manicourt et al. 1999; Meyer et 
al. 2001a; Meyer et al. 2001b; Muehleman et al. 2002; Papaioannou et al. 2007; 
Sondergaard et al. 2007) whereas in the human study, the bisphosphonate was 
given to patients with established knee OA (Bingham, III et al. 2006). Thus, it 
may be that inhibiting bone resorption to alter OA pathogenesis may be only 
effective if inhibition occurs during the early stages of the OA process.
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It is interesting to speculate how reducing bone resorption might affect the OA 
disease process. In OA, articular surface deformity and limb malalignment are 
thought to arise partly from collapse of weakened sub-articular cancellous bone 
(Buckland-Wright 2004). Peri-articular bone loss, which is seen in the OA joint 
(Kannus et al. 1992; Karvonen et al. 1998; Leppala et al. 1999), could 
predispose to structural failure. Prevention of bone loss with anti-resorptive 
therapies may, therefore, ultimately result in improved mechanical 
characteristics of the OA joint. Reducing osteophyte formation, as has been 
observed for alendronate in an OA animal model (Hayami et al. 2004), is 
another way that inhibition of bone resorption could structurally modify the OA 
joint. However, this may not be ultimately beneficial because osteophytes may 
in fact improve joint stability (Pottenger et al. 1990).
An effect on proposed biochemical interactions between subchondral bone and 
articular cartilage is an alternative mechanistic explanation for a bone effect. 
Through biochemical interactions, abnormal osteoblasts from OA subchondral 
bone may be involved in promoting proteoglycan loss in adjacent articular 
cartilage (Sanchez et al. 2005; Westacott et al. 1997). If activation of abnormal 
osteoblasts occurs as part of the bone remodelling process, then inhibiting bone 
turnover in OA subchondral bone with anti-resorptive therapies may lead 
indirectly to improved proteoglycan retention in articular cartilage.
Lastly, increases in systemic BMD may have an effect on the OA process. High 
BMD has been reported as a risk factor for incident OA whereas low BMD is a 
risk factor for progressive disease in patients with established OA (Hart et al. 
2002; Zhang et al. 2000). If these risk factors prove to be causal in nature, then 
increasing BMD with anti-resorptive therapies would be expected to increase 
incident OA but reduce progressive OA.
A caveat to the hypothesis that inhibiting bone remodelling modulates the OA 
disease process is the finding that treatment efficacy for a range of 
bisphosphonates in the Duncan-Hartley guinea pig model of OA did not relate to
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the anti-resorptive potency of the bisphosphonates (Meyer et al. 2001a). 
Additional work is needed to examine the role of bone remodelling in OA and 
the efficacy of inhibiting bone turnover for modifying the disease process.
6.6 Is there a role for zoledronate as a disease-modifying treatment in OA?
Overall the findings from these present studies do not suggest a role for 
zoledronate as a disease-modifying treatment in OA through an effect on 
cartilage proteoglycan metabolism. However, as discussed above, there are 
limitations to the present studies and other mechanisms of action remain 
unexplored. Further work to address these issues may yet find evidence for a 
mechanism of action and, in addition, provide insight into the pathophysiological 
relationship between subchondral bone and articular cartilage in the OA joint.
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Chapter 7. General conclusions
. In vitro culture of bovine articular cartilage explants with and without IL-1 a 
10ng/ml stimulation provides a model for investigating cartilage proteoglycan 
degradation.
. In vitro culture of bovine articular chondrocytes in alginate beads provides a 
model for evaluating chondrocyte viability, proliferation and proteoglycan 
synthesis. In addition, following a period in culture to establish matrix in the 
alginate beads, subsequent culture of the beads with and without IL-1 a 10 
ng/ml provides a model for investigating chondrocyte-mediated proteoglycan 
degradation. Tissue GAG release is less variable in the chondrocyte/ alginate 
bead culture model than in the cartilage explant culture model. Thus, 
treatment effects on GAG release can be detected more sensitively in the 
former model.
. Zoledronate treatments at concentrations <1 O'5 M generally appear safe for 
bovine articular chondrocytes. However, zoledronate 10‘4 M has adverse 
effects on chondrocyte viability, proliferation and proteoglycan synthesis.
. No evidence was demonstrated that short-term treatment with zoledronate 
<10'4 M enhances chondrocyte proteoglycan synthesis or reduces IL-1 a- 
stimulated chondrocyte-mediated proteoglycan degradation. Thus, the results 
do not support the hypothesis that zoledronate has a role as a disease- 
modifying treatment in OA through an effect on cartilage to reduce the 
pathological loss of cartilage proteoglycan.
. Preventative or delayed zoledronate treatment effects on cartilage
proteoglycan metabolism remain unaddressed. In addition, it is possible that 
zoledronate can modify the OA disease process through effects on cartilage
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type II collagen metabolism or effects on another joint tissue, such 
subchondral bone.
Chapter 8. Further work
Optimising the models of cartilage or chondrocyte-matrix catabolism
Adjustments to parameters of the in vitro chondrocyte or cartilage culture 
systems used in these present studies could be made to improve their accuracy 
as models of in vivo metabolism. The OA disease process is slow and it can 
take many years before pathology becomes evident. The chronic nature to 
pathogenesis is seen clearly in patients with trauma to the knee causing injury 
to the anterior cruciate ligament or meniscus, in whom the first radiographic 
signs of OA appeared on average about 10 years after the injury (Roos et al. 
1995). It follows that even minor imbalances to degradation and repair in 
cartilage may be important for cartilage loss if they are sustained over long 
periods of time. Studies to characterise proteoglycan degradation as a function 
of time and IL-1 a concentration could be followed by the development of 
accurate in vitro models of in vivo cartilage metabolism in which GAG release 
stimulated by a gentle IL-1 a stimulus can be observed over long term culture.
In view of the marked inter-experimental variation in proteoglycan metabolism 
seen in the models of the present studies, future experiments should be 
performed with standardised cell / tissue sources (e.g. a single pool of cells or 
an immortalised chondrocyte cell line) and standardised culture techniques.
Additional testing of zoledronate for effects on cartilage proteoglycan 
metabolism
Further work should examine preventative and delayed treatment effects of 
zoledronate on cartilage proteoglycan synthesis and degradation since these 
have not been addressed in these present studies. In addition, subsequent 
experiments could use cartilage or chondrocytes from rabbits instead of a 
bovine source in the culture models. Findings from such experiments would be 
informative for understanding the mechanisms behind the beneficial effects of 
zoledronate treatment in rabbits with experimentally-induced OA (Muehleman et
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al. 2002) without being limited by inter-species differences in cartilage or 
chondrocyte metabolism.
Examining other mechanisms of action for zoledronate as a disease- 
modifying treatment in OA
Effects of zoledronate on cartilage type II collagen synthesis or degradation are 
unknown. In order to address this, an alternative culture model to those used in 
the present studies would be needed since little or no collagen degradation is 
induced by IL-1 in bovine articular cartilage explants (Caterson et al. 2000). One 
candidate model is the co-stimulation of collagen degradation in bovine nasal 
cartilage or human articular cartilage with IL-1 a and oncostatin M (Cawston et 
al. 1998).
More information about potential target tissues for zoledronate could be derived 
in animal OA models. Studies to reproduce the treatment effects previously 
demonstrated a rabbit OA model (Muehleman et al. 2002) could examine, in 
addition, the localisation of zoledronate within the joint. The absence of 
zoledronate in any particular joint tissue would exclude it from being a target 
tissue whereas the presence of the bisphosphonate would indicate a possible 
target tissue. These findings would be useful for directing further studies of 
target tissues to elucidate underlying metabolic mechanisms.
Overall, the continued search for disease-modifying treatments for OA may lead 
not only to the identification of clinically useful treatments but, if underlying 
mechanisms are known, also add to the understanding of OA pathogenesis.
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